0001530766 2025-01-01 2025-09-30 0001530766 2025-11-13 0001530766 2025-09-30 0001530766 2024-12-31 0001530766 us-gaap:RelatedPartyMember 2025-09-30 0001530766 us-gaap:RelatedPartyMember 2024-12-31 0001530766 STEX:SeriesCNinePercentageConvertiblePreferredStockMember 2025-09-30 0001530766 STEX:SeriesCNinePercentageConvertiblePreferredStockMember 2024-12-31 0001530766 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001530766 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001530766 us-gaap:SeriesBPreferredStockMember 2025-09-30 0001530766 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2025-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2025-09-30 0001530766 us-gaap:SeriesDPreferredStockMember 2024-12-31 0001530766 us-gaap:SeriesEPreferredStockMember 2025-09-30 0001530766 us-gaap:SeriesEPreferredStockMember 2024-12-31 0001530766 us-gaap:SeriesFPreferredStockMember 2025-09-30 0001530766 us-gaap:SeriesFPreferredStockMember 2024-12-31 0001530766 2025-07-01 2025-09-30 0001530766 2024-07-01 2024-09-30 0001530766 2024-01-01 2024-09-30 0001530766 us-gaap:CommonStockMember 2024-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001530766 us-gaap:RetainedEarningsMember 2024-12-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2024-12-31 0001530766 us-gaap:CommonStockMember 2025-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001530766 us-gaap:RetainedEarningsMember 2025-03-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-03-31 0001530766 2025-03-31 0001530766 us-gaap:CommonStockMember 2025-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001530766 us-gaap:RetainedEarningsMember 2025-06-30 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2025-06-30 0001530766 2025-06-30 0001530766 us-gaap:CommonStockMember 2023-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001530766 us-gaap:RetainedEarningsMember 2023-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2023-12-31 0001530766 2023-12-31 0001530766 us-gaap:CommonStockMember 2024-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001530766 us-gaap:RetainedEarningsMember 2024-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2024-03-31 0001530766 2024-03-31 0001530766 us-gaap:CommonStockMember 2024-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001530766 us-gaap:RetainedEarningsMember 2024-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-06-30 0001530766 2024-06-30 0001530766 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001530766 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001530766 2025-01-01 2025-03-31 0001530766 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001530766 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001530766 2025-04-01 2025-06-30 0001530766 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001530766 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001530766 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001530766 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001530766 2024-01-01 2024-03-31 0001530766 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001530766 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001530766 2024-04-01 2024-06-30 0001530766 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001530766 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001530766 us-gaap:CommonStockMember 2025-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001530766 us-gaap:RetainedEarningsMember 2025-09-30 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2025-09-30 0001530766 us-gaap:CommonStockMember 2024-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001530766 us-gaap:RetainedEarningsMember 2024-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-09-30 0001530766 2024-09-30 0001530766 STEX:ViralClearMember 2025-09-30 0001530766 STEX:ViralClearMember 2024-12-31 0001530766 STEX:BioSigAIMember 2025-09-30 0001530766 STEX:BioSigAIMember 2024-12-31 0001530766 us-gaap:TradeNamesMember 2025-09-30 0001530766 STEX:DevelopedTechnologyMember 2025-09-30 0001530766 STEX:LegalAndComplianceFrameWorkMember 2025-09-30 0001530766 us-gaap:PatentsMember 2025-09-30 0001530766 STEX:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001530766 STEX:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001530766 STEX:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001530766 STEX:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001530766 STEX:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001530766 STEX:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001530766 STEX:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001530766 country:US 2025-09-30 0001530766 country:CA 2025-09-30 0001530766 2024-01-01 2024-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001530766 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001530766 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001530766 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0001530766 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001530766 STEX:ExchangeableSharesMember 2025-01-01 2025-09-30 0001530766 STEX:ExchangeableSharesMember 2024-01-01 2024-09-30 0001530766 us-gaap:ComputerEquipmentMember 2025-09-30 0001530766 us-gaap:ComputerEquipmentMember 2024-12-31 0001530766 us-gaap:FurnitureAndFixturesMember 2025-09-30 0001530766 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001530766 STEX:TestingAndDemoEquipmentMember 2025-09-30 0001530766 STEX:TestingAndDemoEquipmentMember 2024-12-31 0001530766 us-gaap:LeaseholdImprovementsMember 2025-09-30 0001530766 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001530766 us-gaap:TradeNamesMember 2024-12-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2025-09-30 0001530766 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001530766 STEX:LegalAndComplianceFrameWorkMember 2024-12-31 0001530766 us-gaap:PatentsMember 2024-12-31 0001530766 2022-01-01 2022-12-31 0001530766 2022-12-31 0001530766 STEX:ContractAssetsCurrentMember 2024-12-31 0001530766 STEX:ContractAssetsCurrentMember 2025-01-01 2025-09-30 0001530766 STEX:ContractAssetsCurrentMember 2025-09-30 0001530766 STEX:ContractAssetsNoncurrentMember 2024-12-31 0001530766 STEX:ContractAssetsNoncurrentMember 2025-01-01 2025-09-30 0001530766 STEX:ContractAssetsNoncurrentMember 2025-09-30 0001530766 STEX:ContractAssetsCurrentMember 2023-12-31 0001530766 STEX:ContractAssetsCurrentMember 2024-01-01 2024-09-30 0001530766 STEX:ContractAssetsCurrentMember 2024-09-30 0001530766 STEX:ContractAssetsNoncurrentMember 2023-12-31 0001530766 STEX:ContractAssetsNoncurrentMember 2024-01-01 2024-09-30 0001530766 STEX:ContractAssetsNoncurrentMember 2024-09-30 0001530766 STEX:PremiumFinanceAgreementMember 2025-08-27 0001530766 STEX:PremiumFinanceAgreementMember 2025-08-27 2025-08-27 0001530766 us-gaap:ConvertiblePreferredStockMember 2025-09-30 0001530766 us-gaap:ConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001530766 2025-09-05 0001530766 2024-01-31 2024-01-31 0001530766 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001530766 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember us-gaap:WarrantMember 2025-01-01 2025-09-30 0001530766 2025-05-02 2025-05-02 0001530766 STEX:EndicottManagementPartnersLLCMember 2025-05-02 2025-05-02 0001530766 srt:ChiefExecutiveOfficerMember 2025-05-02 2025-05-02 0001530766 us-gaap:InvestorMember 2024-01-12 2024-01-12 0001530766 us-gaap:InvestorMember 2024-01-12 0001530766 us-gaap:InvestorMember 2024-05-01 2024-05-01 0001530766 us-gaap:InvestorMember 2024-05-01 0001530766 us-gaap:InvestorMember 2024-05-29 2024-05-29 0001530766 us-gaap:InvestorMember 2024-05-29 0001530766 STEX:PurchaseAgreementMember 2025-05-29 0001530766 STEX:PurchaseAgreementMember 2025-03-05 2025-03-05 0001530766 STEX:PurchaseAgreementMember 2025-03-05 0001530766 srt:MaximumMember STEX:PurchaseAgreementMember 2025-03-05 2025-03-05 0001530766 STEX:UnderwritingAgreementMember 2025-08-13 2025-08-13 0001530766 STEX:UnderwritingAgreementMember 2025-08-13 0001530766 us-gaap:InvestorMember 2024-12-18 0001530766 STEX:SalesAgreementMember STEX:H.CWainwrightAndCoLLCMember 2024-12-18 2024-12-18 0001530766 STEX:MarketOfferingAgreementMember 2025-01-01 2025-09-30 0001530766 srt:MaximumMember STEX:MarketOfferingAgreementMember 2025-01-01 2025-09-30 0001530766 srt:MinimumMember STEX:MarketOfferingAgreementMember 2025-01-01 2025-09-30 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-05 2025-09-05 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-04 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-05 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-30 0001530766 us-gaap:InvestorMember us-gaap:WarrantMember 2025-09-30 0001530766 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001530766 us-gaap:WarrantMember 2025-09-30 0001530766 STEX:MitchellWilliamsMember 2025-01-01 2025-09-30 0001530766 STEX:MitchellWilliamsMember 2025-09-30 0001530766 STEX:KeyConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2025-09-30 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandNineteenLongTermIncentivePlanMember 2025-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-01-01 2025-09-30 0001530766 STEX:BioSigAISciencesIncMember 2025-01-01 2025-09-30 0001530766 STEX:OptionsUnder999Member 2025-01-01 2025-09-30 0001530766 STEX:OptionsUnder999Member 2025-09-30 0001530766 STEX:Options1000To1999Member 2025-01-01 2025-09-30 0001530766 STEX:Options1000To1999Member 2025-09-30 0001530766 STEX:Options2000To4999Member 2025-01-01 2025-09-30 0001530766 STEX:Options2000To4999Member 2025-09-30 0001530766 STEX:Options5000To6999Member 2025-01-01 2025-09-30 0001530766 STEX:Options5000To6999Member 2025-09-30 0001530766 us-gaap:MeasurementInputSharePriceMember 2025-09-30 0001530766 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0001530766 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0001530766 us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0001530766 us-gaap:MeasurementInputExpectedTermMember 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt03000Member 2025-09-30 0001530766 STEX:WarrantsAt03000Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt09547Member 2025-09-30 0001530766 STEX:WarrantsAt09547Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt17800Member 2025-09-30 0001530766 STEX:WarrantsAt17800Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt23875Member 2025-09-30 0001530766 STEX:WarrantsAt23875Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt33640Member 2025-09-30 0001530766 STEX:WarrantsAt33640Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt40660Member 2025-09-30 0001530766 STEX:WarrantsAt40660Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt44550Member 2025-09-30 0001530766 STEX:WarrantsAt44550Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt44660Member 2025-09-30 0001530766 STEX:WarrantsAt44660Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt46626Member 2025-09-30 0001530766 STEX:WarrantsAt46626Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt49252Member 2025-09-30 0001530766 STEX:WarrantsAt49252Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt49290Member 2025-09-30 0001530766 STEX:WarrantsAt49290Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt51358Member 2025-09-30 0001530766 STEX:WarrantsAt51358Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt71810Member 2025-09-30 0001530766 STEX:WarrantsAt71810Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt75020Member 2025-09-30 0001530766 STEX:WarrantsAt75020Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt79630Member 2025-09-30 0001530766 STEX:WarrantsAt79630Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt90000Member 2025-09-30 0001530766 STEX:WarrantsAt90000Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt95960Member 2025-09-30 0001530766 STEX:WarrantsAt95960Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt100992Member 2025-09-30 0001530766 STEX:WarrantsAt100992Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt102600Member 2025-09-30 0001530766 STEX:WarrantsAt102600Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt104678Member 2025-09-30 0001530766 STEX:WarrantsAt104678Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt113000Member 2025-09-30 0001530766 STEX:WarrantsAt113000Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt132800Member 2025-09-30 0001530766 STEX:WarrantsAt132800Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt480000Member 2025-09-30 0001530766 STEX:WarrantsAt480000Member 2025-01-01 2025-09-30 0001530766 STEX:WarrantsAt616000Member 2025-09-30 0001530766 STEX:WarrantsAt616000Member 2025-01-01 2025-09-30 0001530766 STEX:RangeOneMember STEX:ViralClearPharmaceuticalsIncMember 2025-09-30 0001530766 STEX:RangeOneMember STEX:ViralClearPharmaceuticalsIncMember 2025-01-01 2025-09-30 0001530766 STEX:BioSigAISciencesIncMember 2025-09-30 0001530766 STEX:BioSigAISciencesIncMember 2025-01-01 2025-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2024-12-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2025-01-01 2025-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2025-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-07-01 2025-09-30 0001530766 STEX:BioSigAISciencesIncMember 2025-07-01 2025-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-07-01 2024-09-30 0001530766 STEX:BioSigAISciencesIncMember 2024-07-01 2024-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-01-01 2025-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-09-30 0001530766 STEX:BioSigAISciencesIncMember 2024-01-01 2024-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-12-31 0001530766 STEX:BioSigAISciencesIncMember 2024-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-09-30 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2023-12-31 0001530766 STEX:BioSigAISciencesIncMember 2023-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 STEX:BioSigAISciencesIncMember 2024-09-30 0001530766 srt:MinimumMember STEX:TwentyTwentySeventeenKnowHowLicenseAgreementMember 2017-03-15 2017-03-15 0001530766 srt:MaximumMember STEX:TwentyTwentySeventeenKnowHowLicenseAgreementMember 2017-03-15 2017-03-15 0001530766 STEX:TwentyTwentySeventeenKnowHowLicenseAgreementMember 2025-09-30 0001530766 STEX:TwentyTwentySeventeenKnowHowLicenseAgreementMember 2024-12-31 0001530766 STEX:EPSoftwareAgreementMember 2019-11-20 0001530766 STEX:EPSoftwareAgreementMember 2025-09-30 0001530766 STEX:EPSoftwareAgreementMember 2024-12-31 0001530766 STEX:ToolsAgreementMember 2019-11-20 0001530766 STEX:ToolsAgreementMember 2021-09-01 2021-09-30 0001530766 STEX:ToolsAgreementMember 2025-09-30 0001530766 STEX:ToolsAgreementMember 2024-12-31 0001530766 STEX:ViralClearPatentAgreementMember 2019-11-20 0001530766 STEX:ViralClearPatentAgreementMember 2021-09-01 2021-09-30 0001530766 STEX:ViralClearPatentAgreementMember 2025-09-30 0001530766 STEX:ViralClearPatentAgreementMember 2024-12-31 0001530766 STEX:FirstCountryMember STEX:TrekTherapeuticsMember 2020-03-24 2020-03-24 0001530766 STEX:SecondCountryMember STEX:TrekTherapeuticsMember 2020-03-24 2020-03-24 0001530766 STEX:TrekTherapeuticsMember 2020-03-24 2020-03-24 0001530766 STEX:TrekTherapeuticsMember 2025-09-30 0001530766 STEX:TrekTherapeuticsMember 2024-12-31 0001530766 srt:MaximumMember STEX:MonetaryMetalsAndCoMember 2025-01-01 2025-09-30 0001530766 srt:MinimumMember STEX:MonetaryMetalsAndCoMember 2025-01-01 2025-09-30 0001530766 STEX:TriViewCapitalLtdMember 2025-06-01 0001530766 STEX:TriViewCapitalLtdMember 2025-06-01 2025-06-01 0001530766 STEX:TriViewCapitalLtdMember 2025-06-01 0001530766 STEX:SeniorSecuredConvertibleDebenturesMember 2025-07-07 0001530766 STEX:TwoSecuredConvertibleDebenturesMember 2025-07-07 0001530766 STEX:TwoSecuredConvertibleDebenturesMember 2025-07-07 2025-07-07 0001530766 STEX:StandbyEquityPurchaseAgreementMember 2025-07-07 2025-07-07 0001530766 STEX:InvestorsMember STEX:StandbyEquityPurchaseAgreementMember 2025-07-07 0001530766 STEX:InvestorsMember us-gaap:CommonStockMember STEX:StandbyEquityPurchaseAgreementMember 2025-07-07 0001530766 STEX:StandbyEquityPurchaseAgreementMember 2025-07-07 0001530766 STEX:SubscriptionAgreementMember 2025-02-28 0001530766 STEX:SubscriptionAgreementMember 2025-02-28 2025-02-28 0001530766 2025-05-27 2025-05-27 0001530766 STEX:SharePurchaseAgreementMember 2025-05-23 2025-05-23 0001530766 2024-02-22 2024-02-22 0001530766 STEX:SettlementAgreementMember 2025-01-01 2025-09-30 0001530766 STEX:SettlementAgreementMember 2024-01-01 2024-12-31 0001530766 STEX:StreamexExchangeCorporationMember 2025-05-28 2025-05-28 0001530766 STEX:SharePurchaseAgreementMember 2025-05-28 2025-05-28 0001530766 STEX:SharePurchaseAgreementMember 2025-05-28 0001530766 STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-05-27 0001530766 STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-05-28 0001530766 2025-05-27 0001530766 2025-05-28 0001530766 2025-05-28 2025-05-28 0001530766 STEX:StreamexExchangeCorporationMember 2025-01-01 2025-09-30 0001530766 us-gaap:TradeNamesMember 2025-05-28 0001530766 us-gaap:TechnologyBasedIntangibleAssetsMember 2025-05-28 0001530766 STEX:SecuritizationPlatformMember 2025-05-28 0001530766 STEX:BlockchainIntegrationMember 2025-05-28 0001530766 STEX:LegalAndComplianceFrameWorkMember 2025-05-28 0001530766 STEX:StreamexExchangeCorporationMember 2024-07-01 2024-09-30 0001530766 STEX:StreamexExchangeCorporationMember 2024-01-01 2024-09-30 0001530766 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:TradeNamesMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember STEX:DevelopedTechnologyMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember STEX:LegalAndComplianceFrameWorkMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member STEX:TradeNameMember STEX:RoyaltyRateMember STEX:ReliefFromRoyaltyMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:TradeNameMember STEX:RevenueGrowthRateMember STEX:ReliefFromRoyaltyMethodMember 2025-01-01 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:TradeNameMember STEX:DiscountRateMember STEX:ReliefFromRoyaltyMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:TradeNameMember STEX:IncomeTaxRateMember STEX:ReliefFromRoyaltyMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:TradeNameMember STEX:TaxAmortizationPeriodMember STEX:ReliefFromRoyaltyMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:RoyaltyRateMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:RevenueGrowthRateMember STEX:MultiPeriodExcessEarningsMethodMember 2025-01-01 2025-09-30 0001530766 srt:MinimumMember us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:RevenueGrowthRatesMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 srt:MaximumMember us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:RevenueGrowthRatesMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 srt:MinimumMember us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:ContributoryAssetsChargeMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 srt:MaximumMember us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:ContributoryAssetsChargeMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:ObsoleceMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:EBITMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:DiscountRateMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:IncomeTaxRateMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:DevelopedTechnologyMember STEX:TaxAmortizationPeriodMember STEX:MultiPeriodExcessEarningsMethodMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:LegalAndComplianceFrameWorkMember STEX:ReplacementCostGrowthRateMember STEX:CostApproachMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:LegalAndComplianceFrameWorkMember STEX:CapExRatesMember STEX:CostApproachMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:LegalAndComplianceFrameWorkMember STEX:ContributoryAssetsChargeMember STEX:CostApproachMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:LegalAndComplianceFrameWorkMember STEX:AfterTaxRateOfReturnMember STEX:CostApproachMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member STEX:LegalAndComplianceFrameWorkMember STEX:UsefulLifeMember STEX:CostApproachMember 2025-09-30 0001530766 STEX:DiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 0001530766 STEX:TerminalGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 0001530766 STEX:CapitalizationRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 0001530766 STEX:RevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 2025-05-28 0001530766 srt:MinimumMember STEX:ExpenseRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 0001530766 srt:MaximumMember STEX:ExpenseRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 0001530766 STEX:CapitalExpenditureRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 0001530766 STEX:IncomeTaxRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-05-28 0001530766 STEX:DiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-09-30 0001530766 STEX:TerminalGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-09-30 0001530766 STEX:CapitalizationRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-09-30 0001530766 STEX:RevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-01-01 2025-09-30 0001530766 srt:MinimumMember STEX:ExpenseRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-09-30 0001530766 srt:MaximumMember STEX:ExpenseRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-09-30 0001530766 STEX:CapitalExpenditureRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-09-30 0001530766 STEX:IncomeTaxRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member 2025-05-27 0001530766 us-gaap:FairValueInputsLevel3Member 2025-05-28 2025-09-30 0001530766 us-gaap:FairValueInputsLevel3Member 2025-09-30 0001530766 STEX:TriViewCapitalLtdMember 2025-09-30 0001530766 STEX:TriViewCapitalLtdMember 2025-09-30 0001530766 us-gaap:CorporateMember 2025-07-01 2025-09-30 0001530766 us-gaap:CorporateMember 2024-07-01 2024-09-30 0001530766 us-gaap:CorporateMember 2025-01-01 2025-09-30 0001530766 us-gaap:CorporateMember 2024-01-01 2024-09-30 0001530766 STEX:HenryMcPhieMember us-gaap:RelatedPartyMember 2025-09-30 0001530766 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001530766 STEX:MrAmatoMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0001530766 STEX:SeniorSecuredConvertibleDebenturesMember us-gaap:SubsequentEventMember 2025-10-24 2025-10-24 0001530766 STEX:FirstClosingMember STEX:SeniorSecuredConvertibleDebenturesMember us-gaap:SubsequentEventMember 2025-10-24 2025-10-24 0001530766 STEX:SecondClosingMember STEX:SeniorSecuredConvertibleDebenturesMember us-gaap:SubsequentEventMember 2025-10-24 2025-10-24 0001530766 STEX:SeniorSecuredConvertibleDebenturesMember us-gaap:SubsequentEventMember 2025-11-04 0001530766 STEX:SeniorSecuredConvertibleDebenturesMember us-gaap:SubsequentEventMember 2025-11-04 2025-11-04 0001530766 us-gaap:SubsequentEventMember STEX:StreamexExchangeProposalMember 2025-11-04 2025-11-04 0001530766 STEX:ConsultantsMember us-gaap:SubsequentEventMember 2025-10-01 2025-10-31 0001530766 STEX:ConsultantsOneMember us-gaap:SubsequentEventMember 2025-11-01 2025-11-30 0001530766 STEX:ConsultantsOneMember us-gaap:SubsequentEventMember 2025-10-01 2025-10-31 0001530766 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2025-10-06 2025-10-06 0001530766 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2025-12-06 2025-12-06 0001530766 STEX:ConsultantsTwoMember us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2025-10-06 2025-10-06 0001530766 STEX:ConsultantsTwoMember us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2025-12-06 2025-12-06 0001530766 STEX:ConsultantsFourMember us-gaap:SubsequentEventMember 2025-10-01 2025-10-01 iso4217:USD shares iso4217:USD shares pure STEX:Integer iso4217:CAD false Q3 --12-31 0001530766

10-Q true 2025-09-30 2025 false 001-38659 STREAMEX CORP. DE 26-4333375 2431 Aloma Avenue Suite 243 Winter Park FL 32792 (203) 409-5444 Common Stock, par value $0.001 per share STEX NASDAQ Yes Yes Non-accelerated Filer true false false 39540603 0.001

11045000

142000

109000

39000

11000

13000

3897000

80000

14992000

344000

38000

85000

96000

4000

142000

44000

45410000

269000

69888000

115522000

498000

130514000

842000

499000

19000

9771000

2052000

115712000

117000

110000

102000

125600000

2264000

11735000

137335000

2264000

0.001

1000000

4200

105

105000

117000

110000

105000

0.001

1000000

200

600

4200

1400

1000

200000

0.001

500000000

35462204

17239096

36000

17000

287905000

253784000

-787000

-294113000

-255345000

-6959000

-1544000

33000

17000

-6926000

-1527000

130514000

842000

27000

6000

156000

31000

736000

4619000

2763000

27365000

10559000

253000

1488000

31000

2065000

158000

6113000

2950000

29461000

11706000

-6113000

-2950000

-29461000

-11679000

-10000

3000

-8000

10214000 10214000 1021000 196000 2409000

-12000

15000

-40000

38000

-10236000

1036000

-10055000

2439000

-16349000

-1914000

-39516000

-9240000

-765000

-15584000

-1914000

-38751000

-9240000

16000

-9000

-15584000

-1914000

-38767000

-9231000

2000

7000

24000

157000

-15586000

-1940000

-38774000

-9395000

-0.47

-0.12

-1.42

-0.72

33352004

16200928

27343190

13002868

-15584000

-1914000

-38751000

-9240000

2325000

787000

-17909000

-1914000

-39538000

-9240000

16000

-9000

-17909000

-1914000

-39554000

-9231000

17239096

17000

253784000

-255345000

17000

-1527000

1438542

2000

1960000

1962000

48996

225001

112000

4403166

4000

3878000

3882000

758514 1000 817000 818000 135000 189000 189000

2000

-2812000

12000

-2800000

24248315

24000

260738000

-258157000

29000

2634000

3758380

4000

5278000

5282000

818827

1000

-1000

-272399

2240012

2000

7330000

7332000

2000

1538000 1538000

-20372000

4000

-20368000

30793135

31000

273343000

-278529000

1538000

33000

-3584000

40000

155000

776920

1000

-1000

842000

3852149 4000 13568000 13572000

2000

-2325000 -2325000 -2325000 -2325000

-15584000

35462204

36000

287905000

-294113000

-787000

33000

-6926000

9040043

9000

241988000

-245015000

26000

-2992000

1862744

2000

1249000

1251000

260720

1040000

1500

-190000

133000 133000 133000 133000

2000

-3402000

-13000

-3415000

11165007

11000

244085000

-248417000

13000

-4308000

278000

420000

434782

1000

635000

636000

348624

509000

1570683 2000 2532000 2534000 75000 122000 122000

1238750

1000

4011000

4012000

3000

-3915000

4000

-3911000

15110846

15000

252311000

-252332000

17000

11000

15110846

15000

252311000

-252332000

17000

11000

1506250

2000

1515000

1517000

24000 24000 24000 24000

2000

-1914000

16617096

17000

253824000

-254246000

17000

-388000

16617096

17000

253824000

-254246000

17000

-388000

-38751000

-9240000

2065000

158000

196000

96000

275000

10214000 -7274000

8286000

7010000

-765000

-109000 -2409000

253000

57000

-77000

-25000

-5000

13000

2033000

-93000

-7000

6399000

-4953000

-102000

-307000

-7416000

-4284000

144000

-365000

221000

3882000

14390000

176000

500000

4209000

18096000

4709000

2000

10903000

425000

142000

190000

11045000

615000

105498000 117982000 12850000 189000 122000 7000 7000 1628000 125000 46000

157000

509000

<p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z6V2k9vc1nV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 1 – NATURE OF OPERATIONS Business and organization Streamex Corp. formerly known as BioSig Technologies, Inc. (“Streamex,” “we,” “us,” or the “Company”) is a technology company focused on building digital tools and platforms that facilitate commodity trading and finance. On May 28, 2025, we acquired Streamex Exchange Corporation (“Streamex Exchange”), a software development company based in Vancouver, BC. In connection with this strategic expansion, on September 10, 2025, we changed our corporate name from BioSig Technologies, Inc. to Streamex Corp., and effective September 12, 2025 our common stock began trading on the Nasdaq Stock Market under the ticker “STEX” (formerly “BSGM”). On May 28, 2025, the Company completed the acquisition of Streamex Exchange, pursuant to the Share Purchase Agreement dated as of May 23, 2025 (the “Merger Agreement”) and amended on May 27, 2025 under the First Amendment to Share Purchase Agreement (the “Amendment”) by and among the Company, BioSig Technologies, Inc., a Delaware corporation, BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (“ExchangeCo”), 1540875 B.C. Ltd., a company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (“Callco”), each shareholder of Streamex Exchange (each, a “Shareholder” and, collectively, the “Shareholders”), and 1540873 B.C. Ltd., a company organized under the laws of the Province of British Columbia, as trustee (the “Trustee”) of the trust formed pursuant to the exchange rights agreement to be entered into between the Company, ExchangeCo, Callco, and the Trustee (the “Exchange Rights Agreement”), the board of directors of the Company and Streamex Exchange. Streamex Exchange is a software development company based in Vancouver, BC. The Company focuses on building advanced digital tools and platforms that facilitates commodity trading and finance. The Company continues to evaluate opportunities for its subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig AI Sciences, Inc. (“BioSig AI”). As of September 30, 2025 and December 31, 2024, the Company held majority interests of approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ViralClearMember_zAGaJIH9cpl8" title="Equity method investment, ownership percentage">69.7% and <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ViralClearMember_zYwJ0gPohl7h" title="Equity method investment, ownership percentage">69.08% in ViralClear, respectively. As of September 30, 2025 and December 31, 2024, the Company held majority interests of approximately<span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioSigAIMember_zV8UflwbOwg1" title="Equity method investment, ownership percentage"> <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioSigAIMember_zxMba0kUVRU3" title="Equity method investment, ownership percentage">84.5% in BioSig AI.

0.697

0.6908

0.845

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of September 30, 2025, the Company had cash of $11 million and working capital deficit of $111 million. During the nine months ended September 30, 2025, the Company used net cash in operating activities of $7.4 million. These balances create a liquidity concern, which in turn raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s primary source of operating funds since inception has been cash proceeds from sale of equity securities and issuance of debt. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company will require additional financing to fund future operations. Further, although the Company began commercial operations, there is no assurance that the Company will be able to generate sufficient cash flow to fund operations. In addition, there can be no assurance that the Company’s ongoing development of its technology platforms will be successfully completed or that future enhancements will achieve market adoption. Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

11000000

111000000

-7400000

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024, which are included with the Company’s Annual Report on Form 10-K filed with the United States Securities Exchange Commission (“SEC”) on April 15, 2025. Furthermore, the Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the years ended December 31, 2024 and 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC. Since the date of those audited consolidated financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below. The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the Company’s financial position, results of operations, and cash flows. The December 31, 2024, consolidated balance sheet was derived from audited financial statements, but does not include all U.S. GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex and its majority owned subsidiaries, ViralClear and BioSig AI and wholly owned subsidiaries, Streamex Exchange, ExchangeCo, Callco, Streamex Capital LLC, Streamex Tokenization Holdco SPV LLC, and Streamex Gold SPV LLC herein collectively referred to as the “Company” or “STEX”. All significant intercompany accounts and transactions have been eliminated in consolidation. Segment Reporting The Company determines its operating and reportable segments in accordance with ASC 280, Segment Reporting, based on the financial information regularly reviewed by the Chief Operating Decision Maker (“CODM”) for purposes of performance assessment and resource allocation. As of September 30, 2025, the CODM evaluates the Company’s financial performance and allocates resources on a consolidated basis. The Company manages its operations as one integrated business and does not prepare or review discrete financial information for individual business units or subsidiaries. Accordingly, the Company has concluded that it operates as a single reportable segment. Management will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at a further disaggregated level. Use of Estimates The Company prepares its unaudited condensed consolidated financial statements in conformity with U.S. GAAP which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Business Acquisition The Company recognizes and measures identifiable tangible and intangible assets acquired and liabilities assumed as of the acquisition date at fair value. Fair value measurements require extensive use of estimates and assumptions, including estimates of future cash flows to be generated by the acquired assets. The operating results of the acquired business are included in our unaudited condensed consolidated financial statements beginning on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Acquisition-related costs are expensed as incurred. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Intangible Assets The Company intangible assets consist of trade name, developed technology, legal and compliance framework and patents. Trade name was recognized based on its distinct branding and expected contribution to future revenues. Developed technology was recognized for its proprietary protocols and systems enabling tokenization of real-world assets and its integration with decentralized finance platforms. Legal and compliance framework was recognized based on the cost to recreate the regulatory and legal infrastructure necessary for operations. Trade name was assigned a useful life of <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zhegBMFgIW41" title="Useful life of intangible assets">10 years, developed technology was assigned a useful life of <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedTechnologyMember_zrKbRGdGN4u8" title="Useful life of intangible assets">8 years and legal and compliance framework was assigned a useful life of <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zLDlSaG181ta" title="Useful life of intangible assets">7 years. The amortization of the intangible asset is computed using the straight-line method. The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized patent costs are amortized to expense over the lesser of the legal patent term or the estimated life of the product of <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvcQ62Ofqg5b" title="Useful life of intangible assets">20 years. The Company evaluates its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Such indicators may include adverse changes in market conditions, legal or regulatory developments, or underperformance relative to expectations. If indicators are present, the Company performs a recoverability test by comparing the asset’s carrying amount to the undiscounted future cash flows expected to result from its use and eventual disposition. If the carrying amount is not recoverable, an impairment loss is recognized for the excess of the carrying amount over the asset’s fair value. Goodwill Goodwill represents the excess of the cost of an acquired business over the fair value assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include, but not limited to, significant adverse changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than it’s carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value. During the nine months ended September 30, 2025, the Company recorded goodwill in connection with a business acquisition. In evaluating whether a triggering event occurred during the period, the Company performed a qualitative assessment consistent with the guidance in U.S. GAAP. This assessment considered the totality of events and circumstances, including the existence of substantial doubt to continue as a going concern, and concluded that it is not more likely than not (i.e., less than a 50% likelihood) that the fair value of the reporting unit is below its carrying amount. Based on this assessment, no impairment charges related to goodwill were recorded for the periods presented. Derivative Liability The Exchangeable Shares issued by ExchangeCo in connection with the Acquisition are classified as derivative liabilities under ASC 815 – Derivatives and Hedging. Although legally issued by a Canadian subsidiary, the Exchangeable Shares are exchangeable into the Company’s common stock and include economic rights that are substantially similar to the Company’s common stock, including rights to dividends, liquidation preferences, and voting (via a Special Voting Preferred Stock held by a trustee). The right to exchange Exchangeable Shares into the Company’s common stock is not itself subject to shareholder approval. However, the exercise of certain rights—specifically, the ability to exchange into more than 19.99% of the Company’s outstanding common stock (the “NASDAQ 19.99% limitation”) and the receipt of special voting rights—are contingent upon shareholder approval. As a result, until shareholder approval is obtained and the 19.99% limitation is lifted, the instrument contains exercise contingencies that preclude equity classification under ASC 815-40. The NASDAQ 19.99% limitation is an exercise contingency that restricts the number of the Company’s common shares that can be issued upon exchange prior to shareholder approval. In addition, the Exchange Ratio is subject to adjustment from 1.00 to 1.25 of the Company’s common shares for each Exchangeable Share if shareholder approval is not obtained within six months of issuance. These features, taken together, result in the instrument not qualifying for the ASC 815-10-15-74 scope exception and require classification as a level 3 liability under ASC 815-40. Accordingly, the Exchangeable Shares are initially recognized as a derivative liability at fair value, measured at $105.5 million as of the acquisition date, and are remeasured at fair value through earnings each reporting period for as long as the exercise contingencies—including both the NASDAQ 19.99% limitation and shareholder approval—remain in place. As of September 30, 2025, these contingencies have not been resolved; therefore, the Exchangeable Shares continue to be classified as a liability. On November 4, 2025 the Company received shareholder approval. As a result, the conversion cap was removed, and Streamex Exchange shareholders may now convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. Revenue and Accounts Receivable The Company had one customer which accounts for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zrFQPy5GUJ51">96% of our revenue in the nine months ended September 30, 2024. As of September 30, 2025 and December 31, 2024, the Company had no customers and three customers representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWyT1dQFXgr4" title="Concentration risk, percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRyiOzAgINn2" title="Concentration risk, percentage">43.6%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zi9UFdr4gdQ5" title="Concentration risk, percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLyvrZSDPVn7" title="Concentration risk, percentage">39.9% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOkQ9T2Py8W9" title="Concentration risk, percentage"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFHQcAsatiee" title="Concentration risk, percentage">12% of the outstanding accounts receivable, respectively. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Allowance for Credit losses The Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for credit losses for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the customer and the status of any open or unresolved issues with the customer preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for credit losses was $109 and $0 as of September 30, 2025 and December 31, 2024, respectively. The Company believes that its reserve is adequate, however results may differ in future periods. For the nine months ended September 30, 2025 and 2024, bad debt expense totaled $109 and $0, respectively. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash. The Company places its cash with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. As of September 30, 2025 and December 31, 2024, deposits in excess of FDIC limits were $10.4 million and nil, respectively. In addition, as of September 30, 2025, the Company held $0.4 million in cash deposits with a Canadian financial institution that are not insured by the FDIC. Foreign Currency Translations and Transactions The Company translates the financial statements of foreign subsidiaries whose functional currency is the local currency into U.S. dollars in accordance with ASC 830, Foreign Currency Matters. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, while revenues and expenses are translated at average exchange rates for the reporting period. Translation adjustments resulting from the conversion of foreign currency financial statements are recorded in “Accumulated Other Comprehensive Loss”, a separate component of stockholders’ equity (deficit). Foreign currency transactions denominated in a currency other than the functional currency are remeasured at the exchange rate in effect on the transaction date. Monetary assets and liabilities are remeasured at period-end exchange rates, and resulting gains or losses are recognized in “Other income (expense), net” in the unaudited condensed consolidated statement of operations. The majority of the Company’s transactions are settled in U.S. dollars. The Company does not currently engage in foreign currency hedging activities. Concentration of Assets As of September 30, 2025, the Company’s consolidated assets totaled approximately $130.5 million, of which approximately 11.36% ($14.8 million) were located in the United States and 88.64% ($115.7 million) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($115.0 million), cash ($432 thousand), sales tax receivable ($39 thousand), amounts due from a related party ($11 thousand), prepaid expenses ($27 thousand), and investments ($142 thousand). The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. For periods in which the Company reports net income and has outstanding convertible preferred stock, diluted earnings per share is calculated using the if-converted method, as required by ASC 260-10. This method assumes conversion of the preferred shares into common stock at the beginning of the period (or at issuance, if later), and includes the resulting common shares in the denominator of diluted EPS, while adjusting the numerator to exclude preferred dividends. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable. The two-class method would only be used if participating securities were present. The computation of basic and diluted loss per share as of September 30, 2025 and 2024 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGIdPlNofRCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20250101__20250930_zhSsdehBYlMc" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20240101__20240930_zz7BIeBFkZp8" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zcXZn0LXxNhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Redeemable series C convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">352,171</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">618,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNmZxT2C38u9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,515,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWuQetoOYMb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,951,068</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zrr6vVXjDVq1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units to acquire common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,965,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExchangeableSharesMember_zWbrAUxEjZK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exchangeable Shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">109,070,057</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zJTfhM0Up5F9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">115,572,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,049,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are anticipated to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A valuation allowance is established when it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. Based on the weight of available evidence, the Company maintains a full valuation allowance against its U.S. deferred tax assets. Deferred tax liabilities have been recorded for taxable temporary differences related to intangible assets acquired in connection with the Company’s foreign subsidiary. These deferred tax liabilities are initially measured in the local currency and translated into U.S. dollars at the applicable exchange rate. Subsequent changes in the deferred tax liability due to amortization of the related intangible assets are recognized in income tax expense (benefit), while changes due to currency translation are recorded in accumulated other comprehensive income (loss). The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. No such amounts were recorded for the periods presented. For the nine months ended September 30, 2025, the Company recorded an income tax benefit of $765,000, compared to $0 in the prior-year periods. The benefit resulted from the reversal of a deferred tax liability associated with the amortization of identifiable intangible assets acquired in the Company’s Canadian subsidiary. The benefit recognized in the current period reflects the impact of this measurement period adjustment and was recorded retrospectively as of the acquisition date. No comparable benefit was recorded in the prior-year periods as the acquisition and related tax effects did not exist at that time. Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about our effective tax rate reconciliation as well as information on income taxes paid. The guidance will first be effective in our annual disclosures for the year ending December 31, 2025, and should be applied on a prospective basis with the option to apply retrospectively. Early adoption is permitted. The Company is in the process of assessing the impact of ASU 2023-09 on our disclosures. In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. ASU 2024-03 will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s consolidated financial statements. In March 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2025-02 “Liabilities (405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 122” (“ASU 2025-02”), which amends the Accounting Standards Codification to remove the text of SEC Staff Accounting Bulletin (“SAB”) 121 “Accounting for Obligations to Safeguard Crypto- Assets an Entity Holds for its Platform Users” as it has been rescinded by the issuance of SAB 122. ASU 2025-02 is effective immediately and is not expected to have an impact on the Company’s financial statements. In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements. In July, 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-05. In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024, which are included with the Company’s Annual Report on Form 10-K filed with the United States Securities Exchange Commission (“SEC”) on April 15, 2025. Furthermore, the Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the years ended December 31, 2024 and 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC. Since the date of those audited consolidated financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below. The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the Company’s financial position, results of operations, and cash flows. The December 31, 2024, consolidated balance sheet was derived from audited financial statements, but does not include all U.S. GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year.

Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex and its majority owned subsidiaries, ViralClear and BioSig AI and wholly owned subsidiaries, Streamex Exchange, ExchangeCo, Callco, Streamex Capital LLC, Streamex Tokenization Holdco SPV LLC, and Streamex Gold SPV LLC herein collectively referred to as the “Company” or “STEX”. All significant intercompany accounts and transactions have been eliminated in consolidation.

Segment Reporting The Company determines its operating and reportable segments in accordance with ASC 280, Segment Reporting, based on the financial information regularly reviewed by the Chief Operating Decision Maker (“CODM”) for purposes of performance assessment and resource allocation. As of September 30, 2025, the CODM evaluates the Company’s financial performance and allocates resources on a consolidated basis. The Company manages its operations as one integrated business and does not prepare or review discrete financial information for individual business units or subsidiaries. Accordingly, the Company has concluded that it operates as a single reportable segment. Management will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at a further disaggregated level.

Use of Estimates The Company prepares its unaudited condensed consolidated financial statements in conformity with U.S. GAAP which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Business Acquisition The Company recognizes and measures identifiable tangible and intangible assets acquired and liabilities assumed as of the acquisition date at fair value. Fair value measurements require extensive use of estimates and assumptions, including estimates of future cash flows to be generated by the acquired assets. The operating results of the acquired business are included in our unaudited condensed consolidated financial statements beginning on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Acquisition-related costs are expensed as incurred. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

Intangible Assets The Company intangible assets consist of trade name, developed technology, legal and compliance framework and patents. Trade name was recognized based on its distinct branding and expected contribution to future revenues. Developed technology was recognized for its proprietary protocols and systems enabling tokenization of real-world assets and its integration with decentralized finance platforms. Legal and compliance framework was recognized based on the cost to recreate the regulatory and legal infrastructure necessary for operations. Trade name was assigned a useful life of <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zhegBMFgIW41" title="Useful life of intangible assets">10 years, developed technology was assigned a useful life of <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedTechnologyMember_zrKbRGdGN4u8" title="Useful life of intangible assets">8 years and legal and compliance framework was assigned a useful life of <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zLDlSaG181ta" title="Useful life of intangible assets">7 years. The amortization of the intangible asset is computed using the straight-line method. The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized patent costs are amortized to expense over the lesser of the legal patent term or the estimated life of the product of <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvcQ62Ofqg5b" title="Useful life of intangible assets">20 years. The Company evaluates its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Such indicators may include adverse changes in market conditions, legal or regulatory developments, or underperformance relative to expectations. If indicators are present, the Company performs a recoverability test by comparing the asset’s carrying amount to the undiscounted future cash flows expected to result from its use and eventual disposition. If the carrying amount is not recoverable, an impairment loss is recognized for the excess of the carrying amount over the asset’s fair value.

P10Y

P8Y

P7Y

P20Y

Goodwill Goodwill represents the excess of the cost of an acquired business over the fair value assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include, but not limited to, significant adverse changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than it’s carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value. During the nine months ended September 30, 2025, the Company recorded goodwill in connection with a business acquisition. In evaluating whether a triggering event occurred during the period, the Company performed a qualitative assessment consistent with the guidance in U.S. GAAP. This assessment considered the totality of events and circumstances, including the existence of substantial doubt to continue as a going concern, and concluded that it is not more likely than not (i.e., less than a 50% likelihood) that the fair value of the reporting unit is below its carrying amount. Based on this assessment, no impairment charges related to goodwill were recorded for the periods presented.

Derivative Liability The Exchangeable Shares issued by ExchangeCo in connection with the Acquisition are classified as derivative liabilities under ASC 815 – Derivatives and Hedging. Although legally issued by a Canadian subsidiary, the Exchangeable Shares are exchangeable into the Company’s common stock and include economic rights that are substantially similar to the Company’s common stock, including rights to dividends, liquidation preferences, and voting (via a Special Voting Preferred Stock held by a trustee). The right to exchange Exchangeable Shares into the Company’s common stock is not itself subject to shareholder approval. However, the exercise of certain rights—specifically, the ability to exchange into more than 19.99% of the Company’s outstanding common stock (the “NASDAQ 19.99% limitation”) and the receipt of special voting rights—are contingent upon shareholder approval. As a result, until shareholder approval is obtained and the 19.99% limitation is lifted, the instrument contains exercise contingencies that preclude equity classification under ASC 815-40. The NASDAQ 19.99% limitation is an exercise contingency that restricts the number of the Company’s common shares that can be issued upon exchange prior to shareholder approval. In addition, the Exchange Ratio is subject to adjustment from 1.00 to 1.25 of the Company’s common shares for each Exchangeable Share if shareholder approval is not obtained within six months of issuance. These features, taken together, result in the instrument not qualifying for the ASC 815-10-15-74 scope exception and require classification as a level 3 liability under ASC 815-40. Accordingly, the Exchangeable Shares are initially recognized as a derivative liability at fair value, measured at $105.5 million as of the acquisition date, and are remeasured at fair value through earnings each reporting period for as long as the exercise contingencies—including both the NASDAQ 19.99% limitation and shareholder approval—remain in place. As of September 30, 2025, these contingencies have not been resolved; therefore, the Exchangeable Shares continue to be classified as a liability. On November 4, 2025 the Company received shareholder approval. As a result, the conversion cap was removed, and Streamex Exchange shareholders may now convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity.

105500000

Revenue and Accounts Receivable The Company had one customer which accounts for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zrFQPy5GUJ51">96% of our revenue in the nine months ended September 30, 2024. As of September 30, 2025 and December 31, 2024, the Company had no customers and three customers representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWyT1dQFXgr4" title="Concentration risk, percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRyiOzAgINn2" title="Concentration risk, percentage">43.6%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zi9UFdr4gdQ5" title="Concentration risk, percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLyvrZSDPVn7" title="Concentration risk, percentage">39.9% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOkQ9T2Py8W9" title="Concentration risk, percentage"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFHQcAsatiee" title="Concentration risk, percentage">12% of the outstanding accounts receivable, respectively. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

0.96

0.436

0.399

0.12

Allowance for Credit losses The Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for credit losses for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the customer and the status of any open or unresolved issues with the customer preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for credit losses was $109 and $0 as of September 30, 2025 and December 31, 2024, respectively. The Company believes that its reserve is adequate, however results may differ in future periods. For the nine months ended September 30, 2025 and 2024, bad debt expense totaled $109 and $0, respectively.

109000

Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash. The Company places its cash with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. As of September 30, 2025 and December 31, 2024, deposits in excess of FDIC limits were $10.4 million and nil, respectively. In addition, as of September 30, 2025, the Company held $0.4 million in cash deposits with a Canadian financial institution that are not insured by the FDIC.

10400000

400000

Foreign Currency Translations and Transactions The Company translates the financial statements of foreign subsidiaries whose functional currency is the local currency into U.S. dollars in accordance with ASC 830, Foreign Currency Matters. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, while revenues and expenses are translated at average exchange rates for the reporting period. Translation adjustments resulting from the conversion of foreign currency financial statements are recorded in “Accumulated Other Comprehensive Loss”, a separate component of stockholders’ equity (deficit). Foreign currency transactions denominated in a currency other than the functional currency are remeasured at the exchange rate in effect on the transaction date. Monetary assets and liabilities are remeasured at period-end exchange rates, and resulting gains or losses are recognized in “Other income (expense), net” in the unaudited condensed consolidated statement of operations. The majority of the Company’s transactions are settled in U.S. dollars. The Company does not currently engage in foreign currency hedging activities.

Concentration of Assets As of September 30, 2025, the Company’s consolidated assets totaled approximately $130.5 million, of which approximately 11.36% ($14.8 million) were located in the United States and 88.64% ($115.7 million) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($115.0 million), cash ($432 thousand), sales tax receivable ($39 thousand), amounts due from a related party ($11 thousand), prepaid expenses ($27 thousand), and investments ($142 thousand). The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations.

130500000

0.1136

14800000

0.8864

115700000

115000000.0

432000

39000

11000

27000

142000

Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. For periods in which the Company reports net income and has outstanding convertible preferred stock, diluted earnings per share is calculated using the if-converted method, as required by ASC 260-10. This method assumes conversion of the preferred shares into common stock at the beginning of the period (or at issuance, if later), and includes the resulting common shares in the denominator of diluted EPS, while adjusting the numerator to exclude preferred dividends. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable. The two-class method would only be used if participating securities were present. The computation of basic and diluted loss per share as of September 30, 2025 and 2024 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGIdPlNofRCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20250101__20250930_zhSsdehBYlMc" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20240101__20240930_zz7BIeBFkZp8" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zcXZn0LXxNhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Redeemable series C convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">352,171</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">618,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNmZxT2C38u9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,515,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWuQetoOYMb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,951,068</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zrr6vVXjDVq1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units to acquire common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,965,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExchangeableSharesMember_zWbrAUxEjZK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exchangeable Shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">109,070,057</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zJTfhM0Up5F9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">115,572,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,049,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zGIdPlNofRCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20250101__20250930_zhSsdehBYlMc" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20240101__20240930_zz7BIeBFkZp8" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zcXZn0LXxNhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Redeemable series C convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">352,171</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">618,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNmZxT2C38u9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,515,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWuQetoOYMb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,951,068</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zrr6vVXjDVq1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units to acquire common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,965,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExchangeableSharesMember_zWbrAUxEjZK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exchangeable Shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">109,070,057</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zJTfhM0Up5F9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">115,572,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,049,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

352171

618060

2736000

2515200

2414647

4951068

1000000

1965000

109070057

115572875

10049328

Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are anticipated to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A valuation allowance is established when it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. Based on the weight of available evidence, the Company maintains a full valuation allowance against its U.S. deferred tax assets. Deferred tax liabilities have been recorded for taxable temporary differences related to intangible assets acquired in connection with the Company’s foreign subsidiary. These deferred tax liabilities are initially measured in the local currency and translated into U.S. dollars at the applicable exchange rate. Subsequent changes in the deferred tax liability due to amortization of the related intangible assets are recognized in income tax expense (benefit), while changes due to currency translation are recorded in accumulated other comprehensive income (loss). The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. No such amounts were recorded for the periods presented. For the nine months ended September 30, 2025, the Company recorded an income tax benefit of $765,000, compared to $0 in the prior-year periods. The benefit resulted from the reversal of a deferred tax liability associated with the amortization of identifiable intangible assets acquired in the Company’s Canadian subsidiary. The benefit recognized in the current period reflects the impact of this measurement period adjustment and was recorded retrospectively as of the acquisition date. No comparable benefit was recorded in the prior-year periods as the acquisition and related tax effects did not exist at that time.

-765000

Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about our effective tax rate reconciliation as well as information on income taxes paid. The guidance will first be effective in our annual disclosures for the year ending December 31, 2025, and should be applied on a prospective basis with the option to apply retrospectively. Early adoption is permitted. The Company is in the process of assessing the impact of ASU 2023-09 on our disclosures. In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. ASU 2024-03 will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s consolidated financial statements. In March 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2025-02 “Liabilities (405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 122” (“ASU 2025-02”), which amends the Accounting Standards Codification to remove the text of SEC Staff Accounting Bulletin (“SAB”) 121 “Accounting for Obligations to Safeguard Crypto- Assets an Entity Holds for its Platform Users” as it has been rescinded by the issuance of SAB 122. ASU 2025-02 is effective immediately and is not expected to have an impact on the Company’s financial statements. In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements. In July, 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-05. In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.

NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment as of September 30, 2025 and December 31, 2024 is summarized as follows: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_490_20250930_zrmD8ogKvUUh" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49F_20241231_z29MyUsxz3Gf" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">December 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLqRvZs5Jt8a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 60%; padding-right: 0pt; padding-bottom: 0pt">Computer equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z2gX6j7Ev0Xa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Furniture and fixtures</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">109</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">109</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingAndDemoEquipmentMember_zoDtihB5jbYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Testing/Demo equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">312</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">312</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zBYYKP7XI5lb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Leasehold improvements</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">84</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">84</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzbNh_zRVedWmJv8n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">1,036</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">1,036</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzbNh_zi3AsSw5751h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Less accumulated depreciation</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(998</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(951</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzbNh_zENREoVimVve" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Property and equipment, net</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">38</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">85</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> As of September 30, 2025, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived assets. During the nine months ended September 30, 2024, the Company re-assessed it carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts exceeded the estimated undiscounted future cash flows. Accordingly, the Company recorded no impairment charges to current operations during the three and nine months ended September 30, 2025. Impairment charges totaled $0 and $253 during the three and nine months ended September 30, 2024. Depreciation expenses were $15 and $27 for the three months ended September 30, 2025 and 2024, respectively. Depreciation expenses were $48 and $144 for the nine months ended September 30, 2025 and 2024, respectively.

Property and equipment as of September 30, 2025 and December 31, 2024 is summarized as follows: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_490_20250930_zrmD8ogKvUUh" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49F_20241231_z29MyUsxz3Gf" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">December 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zLqRvZs5Jt8a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 60%; padding-right: 0pt; padding-bottom: 0pt">Computer equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z2gX6j7Ev0Xa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Furniture and fixtures</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">109</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">109</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingAndDemoEquipmentMember_zoDtihB5jbYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Testing/Demo equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">312</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">312</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zBYYKP7XI5lb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Leasehold improvements</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">84</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">84</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzbNh_zRVedWmJv8n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">1,036</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">1,036</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzbNh_zi3AsSw5751h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Less accumulated depreciation</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(998</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(951</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzbNh_zENREoVimVve" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Property and equipment, net</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">38</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">85</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table>

531000

109000

312000

84000

1036000

998000

951000

38000

85000

253000

15000

27000

48000

144000

NOTE 5 – GOODWILL AND INTANGIBLE ASSETS Goodwill The following table shows the changes in the carrying amount of goodwill for the period: SCHEDULE OF CARRYING AMOUNT OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Goodwill as of December 31, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_98E_eus-gaap--Goodwill_iS_pn3n3_c20250101__20250930_z2kHywVU1ma6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Goodwill, beginning">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 78%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Acquisition1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_98C_eus-gaap--GoodwillAcquiredDuringPeriod_pn3n3_c20250101__20250930_fMQ_____zMbP0KETsH1d" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 18%; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Acquisition">70,435</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Impairment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td id="xdx_986_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20250101__20250930_zXKiDXQMbUwl" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: right; padding-right: 0pt" title="Impairment">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Foreign currency translation adjustment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_98E_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_c20250101__20250930_zl4jtmukjpeh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Foreign currency translation adjustment">(547</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Goodwill as of September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td id="xdx_983_eus-gaap--Goodwill_iE_pn3n3_c20250101__20250930_zMEEbKWYxx3g" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Goodwill, ending">69,888</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Related to the acquisition of the Streamex Exchange. See Note 13 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.</td></tr> </table> During the nine months ended September 30, 2025, the Company evaluated the existence of any indicators of impairment in accordance with ASC 350, Intangibles—Goodwill and Other. While substantial doubt to continue as a going concern was considered as part of the qualitative analysis, it did not, in isolation or in combination with other factors, rise to the level of a triggering event requiring a quantitative impairment test. Based on the assessment, there was no goodwill impairment recognized in the period ended September 30, 2025. Intangible Assets Intangible assets consist of trade name, developed technology, legal and compliance framework, and patents, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined. The Company continues to assess potential triggering events related to the value of its intangible assets and concluded that there was no triggering events that require a quantitative impairment test during the nine months ended September 30, 2025. The following summarizes the Company’s intangible assets as of September 30, 2025 and December 31, 2024: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_491_20250930_zW6wAK39tePf" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49F_20241231_zivRaWomzkpf" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">December 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zq045hX9QP3l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Trade name1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,100</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zCJB23EjRQa7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Developed technology1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">40,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zDvo5a2wEPze" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Legal and compliance framework1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">2,400</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbOO76YrXuf8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Patents</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">380</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">380</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzACZ_zv1GyBwHKo4a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">47,880</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">380</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40B_ecustom--FiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment_iNI_di_zDuKVueL7zul" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt">Foreign currency translation adjustment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt">(369</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzACZ_zVMgwoLMBQe5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Accumulated amortization</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(2,101</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(111</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzACZ_z78ygrBlmdnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify">Intangible assets, net</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">45,410</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">269</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.</td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Amortization expenses were $1.5 million and $2.0 million for the three and nine months ended September 30, 2025, respectively. Amortization expenses were $5 thousand and $14 thousand for the three and nine months ended September 30, 2024, respectively. <p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOwerm5N7rS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Expected future amortization expense of intangible assets as of September 30, 2025, is as follows: SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_498_20250930_zEEEOYMAgcN3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzgFe_zKl3QBvFj0Y2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 78%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Remainder of 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 18%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">1,457</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzgFe_zNXYgN9YPvsb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2026</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzgFe_zrkshH9ZThc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2027</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzgFe_zGy7KAmlGGHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2028</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzgFe_ztUGGrMFCAwb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2029</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzgFe_z6cx2vltmfOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Thereafter</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">20,649</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzgFe_zdsGuaAeqWr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">45,410</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table>

SCHEDULE OF CARRYING AMOUNT OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Goodwill as of December 31, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_98E_eus-gaap--Goodwill_iS_pn3n3_c20250101__20250930_z2kHywVU1ma6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Goodwill, beginning">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 78%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Acquisition1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_98C_eus-gaap--GoodwillAcquiredDuringPeriod_pn3n3_c20250101__20250930_fMQ_____zMbP0KETsH1d" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 18%; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Acquisition">70,435</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Impairment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td id="xdx_986_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20250101__20250930_zXKiDXQMbUwl" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: right; padding-right: 0pt" title="Impairment">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Foreign currency translation adjustment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_98E_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_c20250101__20250930_zl4jtmukjpeh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Foreign currency translation adjustment">(547</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Goodwill as of September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td id="xdx_983_eus-gaap--Goodwill_iE_pn3n3_c20250101__20250930_zMEEbKWYxx3g" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt" title="Goodwill, ending">69,888</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Related to the acquisition of the Streamex Exchange. See Note 13 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.</td></tr> </table>

70435000

-547000

69888000

The following summarizes the Company’s intangible assets as of September 30, 2025 and December 31, 2024: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_491_20250930_zW6wAK39tePf" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49F_20241231_zivRaWomzkpf" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">December 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zq045hX9QP3l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Trade name1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,100</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zCJB23EjRQa7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Developed technology1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">40,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zDvo5a2wEPze" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Legal and compliance framework1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">2,400</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbOO76YrXuf8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Patents</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">380</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">380</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzACZ_zv1GyBwHKo4a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">47,880</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">380</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40B_ecustom--FiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment_iNI_di_zDuKVueL7zul" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt">Foreign currency translation adjustment</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt">(369</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzACZ_zVMgwoLMBQe5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Accumulated amortization</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(2,101</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(111</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzACZ_z78ygrBlmdnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify">Intangible assets, net</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">45,410</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">269</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.</td></tr> </table>

5100000

40000000

2400000

380000

47880000

380000

369000

2101000

111000

45410000

269000

1500000

2000000.0

5000

14000

<p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOwerm5N7rS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Expected future amortization expense of intangible assets as of September 30, 2025, is as follows: SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td id="xdx_498_20250930_zEEEOYMAgcN3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzgFe_zKl3QBvFj0Y2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 78%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Remainder of 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 18%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">1,457</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzgFe_zNXYgN9YPvsb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2026</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzgFe_zrkshH9ZThc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2027</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzgFe_zGy7KAmlGGHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2028</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzgFe_ztUGGrMFCAwb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">2029</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">5,826</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzgFe_z6cx2vltmfOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Thereafter</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">20,649</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzgFe_zdsGuaAeqWr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">45,410</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table>

1457000

5826000

20649000

45410000

NOTE 6 – RIGHT TO USE ASSETS AND LEASE LIABILITY As of September 30, 2025 and December 31, 2024, the Company had one operating lease with payments of $15 per month, that expired on July 31, 2025. Right to use assets is summarized below: SCHEDULE OF RIGHT TO USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250930_zcMUUCdjFQR3" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20241231_zrUMgaAkOmLd" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; width: 60%; padding-bottom: 1pt"> </td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-weight: bold; text-align: center">(000’s)</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: center"></td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-weight: bold; text-align: center">(000’s)</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: center"></td></tr> <tr id="xdx_40A_ecustom--OperatingLeaseRightToUseAssetsGross_iI_pn3n3_zLFh1C88TMX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right to use asset</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">502</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">502</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--OperatingLeaseRightToUseAssetAccumulatedDepreciation_iNI_pn3n3_di_zHGuw7hR2NAl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(502</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(406</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pn3n3_zJlvQtCiN2N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right to use assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three months ended September 30, 2025 and 2024, the Company recorded $64 and $37 as lease expense to current period operations, respectively. During the nine months ended September 30, 2025 and 2024, the Company recorded $160 and $203 as lease expense to current period operations, respectively. Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_493_20250930_zFKotSIXNcRc" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_497_20241231_z3FSiK9MSVBe" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">December 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zY3ethQXLTV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 60%; padding-right: 0pt; padding-bottom: 0pt">Total lease liability</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">102</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zlCOc8ShMU5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Less: short term portion</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(102</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iTI_pn3n3_zQcJ8xiVHQpj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Long term portion</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table>

15000

expired on July 31, 2025

Right to use assets is summarized below: SCHEDULE OF RIGHT TO USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250930_zcMUUCdjFQR3" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20241231_zrUMgaAkOmLd" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; width: 60%; padding-bottom: 1pt"> </td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-weight: bold; text-align: center">(000’s)</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: center"></td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-weight: bold; text-align: center">(000’s)</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: center"></td></tr> <tr id="xdx_40A_ecustom--OperatingLeaseRightToUseAssetsGross_iI_pn3n3_zLFh1C88TMX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right to use asset</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">502</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">502</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--OperatingLeaseRightToUseAssetAccumulatedDepreciation_iNI_pn3n3_di_zHGuw7hR2NAl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(502</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(406</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pn3n3_zJlvQtCiN2N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right to use assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 502000 502000 502000 406000

96000

64000

37000

160000

203000

Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_493_20250930_zFKotSIXNcRc" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_497_20241231_z3FSiK9MSVBe" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">December 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zY3ethQXLTV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 60%; padding-right: 0pt; padding-bottom: 0pt">Total lease liability</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">102</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zlCOc8ShMU5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Less: short term portion</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(102</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iTI_pn3n3_zQcJ8xiVHQpj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Long term portion</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table>

102000

NOTE 7 – LEASE RECEIVABLES In 2022, the Company entered into two leases for our PURE EP™ Platform at a rate of $4,333 per month each. The term of the leases is for 30 months with an option provided to extend for an additional one year. The leases also have an option to purchase at the end of the lease at the fair market value. The Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception. The discount rate utilized was the contract explicit rate of 2% per annum. Both leases reached the end of their contractual terms during 2025, and no extension or purchase options were exercised. As of September 30, 2025, the Company has no remaining lease receivables related to these agreements. A reconciliation of lease receivables with customers for the nine months ended September 30, 2025 and 2024 are presented below: SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS Nine months ended September 30, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unguaranteed</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Recognized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Invoiced to</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Residual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">31-Dec-24</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">in Revenue</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Customer</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Earned</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">Contract asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20250101__20250930_zNvbG9E3cBtd" style="width: 8%; text-align: right" title="Balance">17</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930_zjWpcoqEg3gf" style="width: 8%; text-align: right" title="Recognized in Revenue"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20250101__20250930_zDoowOzDXYsj" style="width: 8%; text-align: right" title="Invoiced to Customer"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20250101__20250930_zgLjlajgxbj9" style="width: 8%; text-align: right" title="Interest Earned">(17</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20250930_zaKFnU6K7PI9" style="width: 8%; text-align: right" title="Unguaranteed Residual Assets"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20250101__20250930_zbK8C6gdOSva" style="width: 8%; text-align: right" title="Balance"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_di_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zFB5MVNQTvif" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">(13</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zQMOg71L3pk2" style="border-bottom: Black 1pt solid; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zhdfrI2Vh95f" style="border-bottom: Black 1pt solid; text-align: right" title="Invoiced to Customer">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zTL038vNb9Fe" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Earned">13</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_di_c20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zGNnN6t87BPe" style="border-bottom: Black 1pt solid; text-align: right" title="Unguaranteed Residual Assets">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_di_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zubC1H8NeuSh" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Noncurrent portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zkfnTUyc0LI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zIp4Ad8JO1Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zl8jHnr361Rk" style="border-bottom: Black 2.5pt double; text-align: right" title="Invoiced to Customer">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zoayoviZpQC2" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest Earned">(4</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z6IgSPR0sHvk" style="border-bottom: Black 2.5pt double; text-align: right" title="Unguaranteed Residual Assets">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z9J95Ufq0K2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Nine months ended September 30, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Recognized in</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Invoiced to</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">Unguaranteed Residual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Balance at September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">31-Dec-23</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Revenue</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Customer</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Earned</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Contract asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20240101__20240930_zhss58kBc5Q9" style="width: 6%; text-align: right" title="Balance">120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20240101__20240930_zqp8ubgL4nhb" style="width: 6%; text-align: right" title="Recognized in Revenue">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20240101__20240930_zCIb1oXX9xga" style="width: 6%; text-align: right" title="Invoiced to Customer">(81</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20240101__20240930_zRM0uCpQEP3h" style="width: 6%; text-align: right" title="Interest Earned">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20240930_ze01hxAj31vb" style="width: 6%; text-align: right" title="Unguaranteed Residual Assets">4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20240101__20240930_zHOdOM0OOosd" style="width: 6%; text-align: right" title="Balance">43</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_di_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zk71ubG3ov9b" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">(103</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zVqJ7SyH7cfi" style="border-bottom: Black 1pt solid; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_z4kZBoNxVlwk" style="border-bottom: Black 1pt solid; text-align: right" title="Invoiced to Customer">66</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zCZhjspcYUW3" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Earned">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_di_c20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zfsrxI3eP9xd" style="border-bottom: Black 1pt solid; text-align: right" title="Unguaranteed Residual Assets">(2</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_di_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_ziJn3ItYB7ig" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">(39</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Noncurrent portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zAcmw85WoCzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z4gzEbchPa66" style="border-bottom: Black 2.5pt double; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zJqfdWdLMLM7" style="border-bottom: Black 2.5pt double; text-align: right" title="Invoiced to Customer">(15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zsYaj9vNsFub" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest Earned">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z1zXcrWbWQ29" style="border-bottom: Black 2.5pt double; text-align: right" title="Unguaranteed Residual Assets">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zgGeD1vL6RSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4333

P30M

P1Y

0.02

A reconciliation of lease receivables with customers for the nine months ended September 30, 2025 and 2024 are presented below: SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS Nine months ended September 30, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unguaranteed</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Recognized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Invoiced to</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Residual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">31-Dec-24</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">in Revenue</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Customer</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Earned</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">Contract asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20250101__20250930_zNvbG9E3cBtd" style="width: 8%; text-align: right" title="Balance">17</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930_zjWpcoqEg3gf" style="width: 8%; text-align: right" title="Recognized in Revenue"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20250101__20250930_zDoowOzDXYsj" style="width: 8%; text-align: right" title="Invoiced to Customer"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20250101__20250930_zgLjlajgxbj9" style="width: 8%; text-align: right" title="Interest Earned">(17</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20250930_zaKFnU6K7PI9" style="width: 8%; text-align: right" title="Unguaranteed Residual Assets"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20250101__20250930_zbK8C6gdOSva" style="width: 8%; text-align: right" title="Balance"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_di_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zFB5MVNQTvif" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">(13</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zQMOg71L3pk2" style="border-bottom: Black 1pt solid; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zhdfrI2Vh95f" style="border-bottom: Black 1pt solid; text-align: right" title="Invoiced to Customer">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zTL038vNb9Fe" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Earned">13</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_di_c20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zGNnN6t87BPe" style="border-bottom: Black 1pt solid; text-align: right" title="Unguaranteed Residual Assets">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_di_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zubC1H8NeuSh" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Noncurrent portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zkfnTUyc0LI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zIp4Ad8JO1Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zl8jHnr361Rk" style="border-bottom: Black 2.5pt double; text-align: right" title="Invoiced to Customer">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zoayoviZpQC2" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest Earned">(4</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z6IgSPR0sHvk" style="border-bottom: Black 2.5pt double; text-align: right" title="Unguaranteed Residual Assets">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20250101__20250930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z9J95Ufq0K2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Nine months ended September 30, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Recognized in</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Invoiced to</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">Unguaranteed Residual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Balance at September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">31-Dec-23</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Revenue</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Customer</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Earned</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Contract asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20240101__20240930_zhss58kBc5Q9" style="width: 6%; text-align: right" title="Balance">120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20240101__20240930_zqp8ubgL4nhb" style="width: 6%; text-align: right" title="Recognized in Revenue">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20240101__20240930_zCIb1oXX9xga" style="width: 6%; text-align: right" title="Invoiced to Customer">(81</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20240101__20240930_zRM0uCpQEP3h" style="width: 6%; text-align: right" title="Interest Earned">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20240930_ze01hxAj31vb" style="width: 6%; text-align: right" title="Unguaranteed Residual Assets">4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20240101__20240930_zHOdOM0OOosd" style="width: 6%; text-align: right" title="Balance">43</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_di_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zk71ubG3ov9b" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">(103</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zVqJ7SyH7cfi" style="border-bottom: Black 1pt solid; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_z4kZBoNxVlwk" style="border-bottom: Black 1pt solid; text-align: right" title="Invoiced to Customer">66</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zCZhjspcYUW3" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Earned">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_di_c20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_zfsrxI3eP9xd" style="border-bottom: Black 1pt solid; text-align: right" title="Unguaranteed Residual Assets">(2</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_di_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsCurrentMember_ziJn3ItYB7ig" style="border-bottom: Black 1pt solid; text-align: right" title="Balance">(39</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Noncurrent portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iS_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zAcmw85WoCzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z4gzEbchPa66" style="border-bottom: Black 2.5pt double; text-align: right" title="Recognized in Revenue">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SalesTypeLeaseInvoicedToCustomer_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zJqfdWdLMLM7" style="border-bottom: Black 2.5pt double; text-align: right" title="Invoiced to Customer">(15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SalesTypeLeaseInterestIncomeLeaseReceivableS_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zsYaj9vNsFub" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest Earned">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--SalesTypeLeaseUnguaranteedResidualAsset_iI_pn3n3_c20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_z1zXcrWbWQ29" style="border-bottom: Black 2.5pt double; text-align: right" title="Unguaranteed Residual Assets">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SalesTypeLeaseNetInvestmentInLease_iE_pn3n3_c20240101__20240930__us-gaap--SaleLeasebackTransactionDescriptionAxis__custom--ContractAssetsNoncurrentMember_zgGeD1vL6RSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

17000

-17000

13000

4000

-4000

120000

-81000

4000

43000

103000

66000

2000

39000

17000

-15000

2000

4000

NOTE 8 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses as of September 30, 2025 and December 31, 2024 consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20250930_zS05kFcKHja1" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20241231_ziU8W48YVYgd" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maAPAALzKpF_zUsIEZiUOnWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-left: 0pt">Accrued accounting and legal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">391</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedReimbursementsCurrent_iI_pn3n3_maAPAALzKpF_zakorhwGJnRg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued reimbursements and travel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedConsultingCurrent_iI_pn3n3_maAPAALzKpF_zsOLbLmCzdi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued consulting</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccruedFindersFees_iI_pn3n3_maAPAALzKpF_zntjzY7BO8R" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued finders fee</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maAPAALzKpF_zPXgjB9RgAq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">351</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedMarketingCostsCurrent_iI_pn3n3_maAPAALzKpF_zSULKITsmMke" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedOfficeExpenseAndOtherExpense_iI_pn3n3_maAPAALzKpF_zWPyaIwngBIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued office and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">439</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedInsurancePremiumFinancing_iI_pn3n3_maAPAALzKpF_zilycxBhF1A1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued insurance premium financing(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,452</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--AccruedSettlementExpense_iI_pn3n3_maAPAALzKpF_zKR7XsGzencc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued settlement expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">494</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maAPAALzKpF_z7uwBjWzyF7k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Accrued payroll</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">795</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">186</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzKpF_z8KmvAPUKxC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,052</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zaVKU4miDrag" title="Total Premium">2,172,622, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--AccountsPayableOtherCurrent_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zKY02D5qulD4" title="Paid as down payment">544,242 was paid as a down payment and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zprBBpL3EYIe" title="Paid as down payment">1,628,380 was financed. The agreement includes a finance charge of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PaymentsToAcquireFinanceReceivables_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zhqK3hg863X3" title="Paid as down payment">51,172, resulting in total payments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zAw4fpwpTgxc">1,679,552, payable in nine monthly installments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_ecustom--AccountsPayableMonthlyInstallments_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zXOvFpui4ina" title="Accounts payable, monthly installments">186,617 through May 2026 at an annual percentage rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_ecustom--AnnualPercentageRate_iI_pid_dp_uPure_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_ztvcliscPcR1" title="Annual percentage rate">7.48%.</td></tr></table> The financing obligation is secured by unearned premiums under the financed policies. As of September 30, 2025, the Company recorded prepaid insurance of approximately $1.99 million and AFCO loan payable of approximately $1.45 million. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

Accounts payable and accrued expenses as of September 30, 2025 and December 31, 2024 consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20250930_zS05kFcKHja1" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20241231_ziU8W48YVYgd" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maAPAALzKpF_zUsIEZiUOnWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-left: 0pt">Accrued accounting and legal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">391</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedReimbursementsCurrent_iI_pn3n3_maAPAALzKpF_zakorhwGJnRg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued reimbursements and travel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedConsultingCurrent_iI_pn3n3_maAPAALzKpF_zsOLbLmCzdi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued consulting</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccruedFindersFees_iI_pn3n3_maAPAALzKpF_zntjzY7BO8R" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued finders fee</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maAPAALzKpF_zPXgjB9RgAq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">351</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedMarketingCostsCurrent_iI_pn3n3_maAPAALzKpF_zSULKITsmMke" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedOfficeExpenseAndOtherExpense_iI_pn3n3_maAPAALzKpF_zWPyaIwngBIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued office and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">439</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedInsurancePremiumFinancing_iI_pn3n3_maAPAALzKpF_zilycxBhF1A1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Accrued insurance premium financing(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,452</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--AccruedSettlementExpense_iI_pn3n3_maAPAALzKpF_zKR7XsGzencc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Accrued settlement expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">494</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maAPAALzKpF_z7uwBjWzyF7k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Accrued payroll</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">795</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">186</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzKpF_z8KmvAPUKxC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,052</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zaVKU4miDrag" title="Total Premium">2,172,622, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--AccountsPayableOtherCurrent_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zKY02D5qulD4" title="Paid as down payment">544,242 was paid as a down payment and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zprBBpL3EYIe" title="Paid as down payment">1,628,380 was financed. The agreement includes a finance charge of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PaymentsToAcquireFinanceReceivables_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zhqK3hg863X3" title="Paid as down payment">51,172, resulting in total payments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zAw4fpwpTgxc">1,679,552, payable in nine monthly installments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_ecustom--AccountsPayableMonthlyInstallments_iI_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zXOvFpui4ina" title="Accounts payable, monthly installments">186,617 through May 2026 at an annual percentage rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_ecustom--AnnualPercentageRate_iI_pid_dp_uPure_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_ztvcliscPcR1" title="Annual percentage rate">7.48%.</td></tr></table>

1062000

391000

7000 188000 171000 6026000 168000 351000

13000

80000 439000 1452000 494000

795000

186000

9771000

2052000

2172622000

544242000

1628380000

51172000

1679552000

186617000 0.0748

1990000

1450000

NOTE 9 – STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of September 30, 2025 and December 31, 2024, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock and 200,000 shares of Series F Preferred Stock. As of September 30, 2025 and December 31, 2024, there were no issued or outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock. Series C Preferred Stock Series C Preferred Stock (“Series C”) issued and outstanding totaled <span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJM5fta5xiW3" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zPFeW9kaf9pi" title="Preferred stock, shares outstanding">105 shares as of September 30, 2025, and December 31, 2024. As of September 30, 2025, and December 31, 2024, the Company has accrued $117,111 and $110,042 dividends payable on the Series C, respectively. As of September 30, 2025, and December 31, 2024, the cumulative dividend per share payable on the Series C was approximately $1,115 and $1,048, respectively. Each share of Series C is convertible at the holder’s option into shares of common stock at a conversion price of $0.3197 per share, based on the stated value of $1,000 per preferred share. As of September 30, 2025, the outstanding Series C shares were convertible into an aggregate of 352,171 shares of common stock, which includes <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zFKZGtsR31Ee" title="Shares issued for services">23,738 shares issuable for accrued dividends at a conversion rate of $4.9989 per share. The Series C is subject to full ratchet anti-dilution price protection upon issuance of equity or equity-linked securities at an effective price below $0.3197 per share, as well as customary anti-dilution adjustments for stock splits and similar events. The Series C ranks senior to common stock and all other equity securities with respect to dividends and liquidation. In the event of liquidation, holders are entitled to receive the stated value plus accrued but unpaid dividends and any other amounts due. The Series C becomes redeemable at a premium or subject to an increased dividend rate of 18% upon the occurrence of certain events, including but not limited to: <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">failure to deliver common stock upon conversion within specified timeframes,</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">failure to pay cash amounts due upon such failure,</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">insufficient authorized shares to honor conversions,</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">uncured material breaches of agreements related to the Series C,</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">a change of control transaction,</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">bankruptcy or insolvency, or</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">an unstayed judgment exceeding $100,000 for more than 45 days.</td></tr></table> Common stock On September 5, 2025, the Company’s shareholders approved an amendment to the Company’s articles of incorporation that increased the amount of common stock authorized for issuance to 500,000,000 with a par value of $0.001 per share. The Company is authorized to issue 500,000,000 shares of $0.001 par value common stock. As of September 30, 2025 and December 31, 2024, the Company had 35,462,204 and 17,239,096 shares issued and outstanding, respectively. On January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February 2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option awards, exercise prices and per share data have been adjusted in these unaudited condensed consolidated financial statements, on a retroactive basis, to reflect the reverse stock split for all periods presented. Authorized common and preferred stock was not adjusted because of the reverse stock split. During the nine months ended September 30, 2024, the Company issued an aggregate of 75,000 shares of common stock for the forgiveness of accounts payable at a fair value of $<span id="xdx_90A_ecustom--SettlementAndExtinguishmentOfAccountsPayable_pn5n6_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zGdW4O2d7Cih" title="Settlement and extinguishment of accounts payable">0.1 million. During the nine months ended September 30, 2024, the Company issued an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXimjp6MK5nk" title="Number of shares issued">2,140,744 shares of common stock for services at a fair value of $1.7 million. During the nine months ended September 30, 2024, the Company issued an aggregate of 2,322,747 shares of common stock for vested restricted stock units. During the nine months ended September 30, 2025, the Company issued an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJuconLOvEd3" title="Number of shares issued">5,236,922 shares of common stock for services at a fair value of $7.4 million. During the nine months ended September 30, 2025, the Company issued an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_uShares_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXiEuhMnHTz7" title="Number of shares issued">1,644,743 shares of common stock in exchange for<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_uShares_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWPLGpKoYhIb" title="Number of shares exercised"> 2,357,377 warrants cashless exercised. During the nine months ended September 30, 2025, the Company issued an aggregate of 135,000 restricted stock units for shares of its common stock for the settlement and extinguishment of accounts payable at a fair value of $<span id="xdx_90E_ecustom--SettlementAndExtinguishmentOfAccountsPayable_pn5n6_c20250101__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzRrP3cbTuCc" title="Settlement and extinguishment of accounts payable">0.2 million. During the nine months ended September 30, 2025, the Company issued an aggregate of 2,465,013 shares of common stock for vested restricted stock units. On May 2, 2025, the Company cancelled an aggregate of 272,399 shares of its common stock, consisting of 158,096 shares returned by the Company’s former Chief Executive Officer, Kenneth Londoner, and 114,303 shares returned by Endicott Management Partners LLC, an entity affiliated with Mr. Londoner. All cancelled shares were surrendered to the Company and retired, resulting in a reduction to the total number of issued and outstanding shares. Exchangeable Shares The Exchangeable Shares issued by ExchangeCo in connection with the Acquisition are classified as derivative liabilities under ASC 815 – Derivatives and Hedging. Although legally issued by a Canadian subsidiary, the Exchangeable Shares are exchangeable into the Company’s common stock and include economic rights that are substantially similar to the Company’s common stock, including rights to dividends, liquidation preferences, and voting (via a Special Voting Preferred Stock held by a trustee), these rights are contingent upon stockholder approval. The right to exchange Exchangeable Shares into the Company’s common stock is not itself subject to shareholder approval. However, the exercise of certain rights—specifically, the ability to exchange into more than 19.99% of the Company’s outstanding common stock (the “NASDAQ 19.99% limitation”) and the receipt of special voting rights—are contingent upon shareholder approval. As a result, until shareholder approval is obtained and the 19.99% limitation is lifted, the instrument contains exercise contingencies that preclude equity classification under ASC 815-40. The NASDAQ 19.99% limitation is an exercise contingency that restricts the number of the Company’s common shares that can be issued upon exchange prior to shareholder approval. In addition, the Exchange Ratio is subject to adjustment from 1.00 to 1.25 the Company’s common shares for each Exchangeable Share if shareholder approval is not obtained within six months of issuance. These features, taken together, result in the instrument not qualifying for the ASC 815-10-15-74 scope exception and require classification as a liability. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) The Exchangeable Shares were initially recognized as a derivative liability at fair value, measured at $105.5 million as of the acquisition date. They are remeasured at fair value through earnings each reporting period for as long as the exercise contingencies—including the NASDAQ 19.99% limitation and the requirement for shareholder approval—remain unresolved. As of September 30, 2025, shareholder approval has not been obtained and the contingencies remain in place; therefore, the Exchangeable Shares continue to be classified as a liability. On November 4, 2025 the Company received shareholder approval. As a result, the conversion cap was removed, and Streamex Exchange shareholders may now convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. Sale of common stock. On January 12, 2024, the Company entered into a securities purchase agreement with certain accredited and institutional investors, pursuant to which the Company sold to the investors an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240112__20240112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z8J3WxYy0lT" title="Sold to investors">260,720 shares of the Company’s common stock and warrants to purchase up to 130,363 shares of common stock, at a purchase price of $3.989 per share and a warrant to purchase one-half of a share. The warrants have an exercise price of $3.364 per share, will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance. The gross proceeds from this offering were $1,040,000. On May 1, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company sold to the investors an aggregate of 783,406 shares of the Company’s common stock and warrants to purchase up to 391,703 shares of common stock, at a purchase price of $1.4605 per share and a warrant to purchase one-half of a share. The warrants have an exercise price of $1.398 per share, will become exercisable six months after the date of issuance, and will expire five and one-half years following the date of issuance. The gross proceeds from this offering were approximately $1,144,000, including $634,999 in cash and $509,165 representing conversion of the principal balance of and accrued interest on the previously issued related party note payable. The note was not convertible by its terms, but the holder has agreed to convert it into shares of common stock and warrants under the Purchase Agreement. On May 29, 2024, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to sell and issue to the investors (i) in a registered direct offering, 1,570,683 shares of Common Stock, par value $0.001 per share of the Company at a price of $1.91 per share and (ii) in a concurrent private placement, common stock purchase warrants to purchase up to an aggregate of 1,570,683 shares of Common Stock, at an exercise price of $1.78 per share of Common Stock. In connections with the Offering, the Company issued 109,948 warrants to its placement agent. On March 5, 2025, the Company entered into a securities purchase agreement with certain accredited investors pursuant to which the Company sold to the Investors an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250305__20250305__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zi8lAu4cGmO2" title="Stock issued during period, shares, new issues">758,514 shares Common Stock at a purchase price of $1.07974 per share, and warrants to purchase up to<span id="xdx_904_ecustom--ClassOfWarrantOrRightsGranted_pid_c20250305__20250305__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zyoVMgN2PJka" title="Class of warrant or rights granted"> 758,514 shares of Common Stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250305__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ze6puQBEYgO" title="Exercise price, warrants">0.95474 per share, that will become exercisable six months after the date of issuance and will expire three and one-half years following the date of issuance, in exchange for aggregate consideration of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250305__20250305__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjdEXwKbdZxg" title="Proceeds from issuance or sale of equity">0.8 million On August 13, 2025, the Company entered into an underwriting agreement with certain accredited investors pursuant to which the Company sold an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250813__20250813__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zssKiEclK2Mi" title="Stock issued during period, shares, new issues">3,852,149 shares of its common stock at a public offering price of $3.90 per share. The offering closed on August 15, 2025, resulting in gross proceeds of approximately $15.0 million. The Company incurred transaction costs of approximately $1.45 million, including underwriting discounts, commissions, and other offering expenses, resulting in net proceeds of approximately $13.6 million. ATM Sales Agreement 2024 On December 18, 2024, the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent or principal (the “Agent”), pursuant to which the Company may offer and sell, from time to time in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), the Company’s common stock, par value $0.001 per share (“common stock”), through or to the Agent (the “ATM Offering”). The Sales Agreement, among other things, provides for the issuance and sale of up to an aggregate of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241218__20241218__dei--LegalEntityAxis__custom--H.CWainwrightAndCoLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zLY8NXcp7i7h" title="Value of common stock sold">8,500,000 of shares of the Company’s common stock. The Shares are being offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-276298) and an accompanying prospectus filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on December 28, 2023, as amended on January 5, 2024 and December 9, 2024, and declared effective by the SEC on December 17, 2024 (the “Registration Statement”) and pursuant to a prospectus supplement dated December 18, 2024. During the nine months ended September 30, 2025, the Company sold an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_z9uaEw6OvOIk" title="Stock issued during period, shares, new issues">4,403,166 shares through the Company’s at the market offering agreement for gross proceeds of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember__srt--RangeAxis__srt--MaximumMember_zFWIx8Z04LZ5" title="Stock issued during period, shares, new issues">4,019,063, or $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember__srt--RangeAxis__srt--MinimumMember_znqRuM2lNRX8" title="Stock issued during period, shares, new issues">3,882,420 net of fees of $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_zkxl9gof4Phf" title="Sale of stock, consideration received on transaction">136,643. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

1000000

0.001

200

600

4200

1400

1000

200000

105

117111

110042

1115 1048

1000

352171

23738

4.9989

0.3197 100000000

500000000

0.001

500000000

0.001

35462204

17239096

1-for-10 reverse stock split

75000

100000

2140744

1700000

2322747

5236922

7400000

1644743

2357377

135000

200000

2465013

272399 158096 114303

105500000

260720

130363

3.989

3.364

1040000

783406

391703

1.4605

1.398

1144000

634999

509165

1570683

0.001

1.91

1570683

1.78

109948

758514

1.07974

758514

0.95474

800000

3852149

3.90

15000000.0

1450000

13600000

0.001

8500000

4403166

4019063

3882420

136643

NOTE 10 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Streamex Corp. 2023 Long-Term Incentive Plan Stockholders approved the Third Amendment to the Company’s 2023 Long-Term Incentive Plan (the “Incentive Plan Amendment”) on September 5, 2025, increasing the total number of shares authorized for issuance under the plan by <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250905__20250905__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zrEJXmVpgIBf" title="Shares issued">10,359,211 shares, from <span id="xdx_903_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250904__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zx9RUyTIm6Db" title="Shares authorized">4,376,595 shares to <span id="xdx_90A_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250905__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zSdyUNmbmbRd" title="Shares authorized">14,735,806 shares. As of September 30, 2025, there were <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zFzmRatreKPh" title="Common stock, capital shares reserved for future issuance">11,219,081 shares available under the 2023 Long-Term Incentive Plan. Options Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options using the based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRpyOXv1tq5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information related to stock options as of September 30, 2025: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">$</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">Under <span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_z3rnKWwIcF46" title="Options Outstanding, Exercise Price">9.99</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zjrOtrl7Yozi" style="width: 12%; text-align: right" title="Number of Options Outstanding">2,715,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zrDla8voqEu" style="width: 12%; text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">9.0</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zXN416IM50h1" style="width: 12%; text-align: right" title="Number of Options Outstanding Options Exercisable">2,715,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zagcuBdS3Kfe" title="Options Outstanding, Exercise Price">10.00-<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zWKi70iNhJl3" title="Options Outstanding, Exercise Price">19.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zfOH3vWMh1Sf" style="text-align: right" title="Number of Options Outstanding">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_z6NH8WZ88qQ8" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">7.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zpPZFRUeskLl" style="text-align: right" title="Number of Options Outstanding Options Exercisable">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zZ0GWWIeGbji" title="Options Outstanding, Exercise Price">20.00-<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zAbO9TBfvnTc" title="Options Outstanding, Exercise Price">49.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zbjAwDNCvy63" style="text-align: right" title="Number of Options Outstanding">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_z9fAZIgIdOF8" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">3.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zFA9ydtiyGB9" style="text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z3w5gituqITi" title="Options Outstanding, Exercise Price">50.00-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zne5L39ebQuk" title="Options Outstanding, Exercise Price">69.99</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zY3PS3uvzEIh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z3QyC8ujp4ja" style="padding-bottom: 1pt; text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">4.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zjBhEnb9vSAk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930_zv2h3yKtU6q9" style="text-align: right" title="Number of Options Outstanding">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zuulg1LN9425" title="Number of Options Outstanding Weighted Average Remaining Life">9.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930_zGtARZlfvqEe" style="text-align: right" title="Number of Options Outstanding Options Exercisable">2,736,000</td><td style="text-align: left"> </td></tr> </table> A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2025 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Remaining Contractual Term</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zphJLCiG26Tb" style="width: 12%; text-align: right" title="Outstanding shares">2,515,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20250101__20250930_zriaYMbF7qOf" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding">0.96</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zsqgr55vLlv1" style="width: 12%; text-align: right" title="Weighted-Average Remaining Contractual Term">9.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20250930_zyZPdj5du1sk" style="width: 12%; text-align: right" title="Outstanding Aggregate Intrinsic Value">2,501,040</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930_zPnPS6Z5e3ah" style="text-align: right" title="Issued">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zjTmKRHEBRK9" style="text-align: right" title="Weighted Average Exercise Price Issued">0.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zeZMfqSjEDi1" style="text-align: right" title="Weighted-Average Remaining Contractual Term, Issued">9.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeited/expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20250930_zW8Jlf6nTLK2" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited/expired">(29,200</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zYAVUH3LV6s" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited/expired">17.34</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zbilsVAuKqck" style="text-align: right" title="Outstanding shares">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20250101__20250930_zHfcWnF9chh6" style="text-align: right" title="Weighted Average Exercise Price Outstanding">0.78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zSHOBzxYJ84k" style="text-align: right" title="Weighted-Average Remaining Contractual Term">9.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20250930_zZTtuANk19Tf" style="text-align: right" title="Outstanding Aggregate Intrinsic Value">14,040,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zwwxtExWkhy8" style="text-align: right" title="Outstanding shares Exercisable">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zhmKNo6axA0e" style="text-align: right" title="Weighted Average Exercise Price Exercisable">0.78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20250101__20250930_zBqbW6BGrGp8" style="text-align: right" title="Weighted-Average Remaining Contractual Term">9.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20250930_z0q0nWqBRoS5" style="text-align: right" title="Outstanding Exercisable Aggregate Intrinsic Value">14,040,120</td><td style="text-align: left"> </td></tr> </table> The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of the Company of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zkMnsoKdZ8fa" title="Exercise price">5.76 as of September 30, 2025, which would have been received by the option holders had those option holders exercised their options as of that date. The fair value of all options vesting during the three and nine months ended September 30, 2025 of $0 and $1,076,015, respectively, was charged to current period operations. The fair value of all options vesting during the three and nine months ended September 30, 2024 of $498,445 and $655,863, respectively, was charged to current period operations. As of September 30, 2025, there was no unrecognized compensation expense related to stock options. On May 23, 2025, in connection with the Company’s acquisition of Streamex Exchange, the Company entered into an amendment to the Executive Employment Agreement with Anthony Amato, its former Chief Executive Officer. Pursuant to the amendment, all previously granted equity awards to Mr. Amato—including vested and unvested stock options—were accelerated and deemed fully vested and nonforfeitable as of May 28, 2025. In addition, the post-resignation exercise period for all vested options was extended to the later of the original expiration date or 36 months following the transaction closing. As a result of this modification, the Company recognized incremental stock-based compensation expense of $0 and $450,820 during the three and nine months ended September 30, 2025, which is included in the total expense disclosed above. No unrecognized compensation expense remains related to Mr. Amato’s equity awards as of September 30, 2025. <p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzLnGrTG40y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the nine months ended September 30, 2025, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted: SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assumption</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Weighted average grant date fair value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDHt4jHNgFu4" title="Derivative liability">0.80</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z1sKhKftfMn3" title="Derivative liability">122.43</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1KXfGilH25e" title="Derivative liability">4.32</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zl8pn7EUXXJf" title="Derivative liability">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeTermOfContract_dtY_c20250101__20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zSL53aLjuyyd" title="Derivative liability, measurement input, expected life">10.0</td><td style="text-align: left"> </td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Warrants <p id="xdx_892_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_zWrghcwcDW02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of September 30, 2025: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zO56bI8EQoif" style="width: 30%; text-align: right" title="Exercise price">0.3000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zJGF5rCHORGg" style="width: 30%; text-align: right" title="Number Outstanding">11,982</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_989_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_z7pzl1puXCjf" style="width: 32%; text-align: center; padding-left: 0pt" title="Expiration date">Nov-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zAkvbZOPNeT3" style="text-align: right" title="Exercise price">0.9547</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zISl91NZKu24" style="text-align: right" title="Number Outstanding">665,900</td><td style="text-align: left"> </td><td> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zKuAZ1vMoax" style="text-align: center; padding-left: 0pt" title="Expiration date">Sep-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_zjc140hKvUgd" style="text-align: right" title="Exercise price">1.7800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_zVEHQsRSL8Ze" style="text-align: right" title="Number Outstanding">523,561</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_zfcnNTRm7EGf" style="text-align: center; padding-left: 0pt" title="Expiration date">May-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt23875Member_zVWZ2K7Peoui" style="text-align: right" title="Exercise price">2.3875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt23875Member_zAKObytDKdNk" style="text-align: right" title="Number Outstanding">106,237</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt23875Member_zlcJEXNLCyo3" style="text-align: center; padding-left: 0pt" title="Expiration date">May-29</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zaundhH0sCdd" style="text-align: right" title="Exercise price">3.3640</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zWj5ly9OIOz8" style="text-align: right" title="Number Outstanding">117,828</td><td style="text-align: left"> </td><td> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_z6CJ0DKCIPad" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zRskGC9YaKvl" style="text-align: right" title="Exercise price">4.0660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_z4jJIDIVkRsk" style="text-align: right" title="Number Outstanding">25,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zaRhYD9YdDRg" style="text-align: center; padding-left: 0pt" title="Expiration date">Nov-32</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zGwrelWMOXsb" style="text-align: right" title="Exercise price">4.4550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zM9qkB4dUDJ5" style="text-align: right" title="Number Outstanding">107,483</td><td style="text-align: left"> </td><td> </td> <td id="xdx_982_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zTugMyHN1UDe" style="text-align: center; padding-left: 0pt" title="Expiration date">Jun-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zFjPCcl1nWkb" style="text-align: right" title="Exercise price">4.4660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zxFIVepwqnba" style="text-align: right" title="Number Outstanding">48,980</td><td style="text-align: left"> </td><td> </td> <td id="xdx_980_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_znjnAMCpvkjk" style="text-align: center; padding-left: 0pt" title="Expiration date">Nov-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_z3HkmvQXyDah" style="text-align: right" title="Exercise price">4.6626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zG02gYfz0szl" style="text-align: right" title="Number Outstanding">5,580</td><td style="text-align: left"> </td><td> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zhPZJSVz0fO1" style="text-align: center; padding-left: 0pt" title="Expiration date">Apr-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zGmVWnZawpMf" style="text-align: right" title="Exercise price">4.9252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zERPnZypLkDf" style="text-align: right" title="Number Outstanding">49,550</td><td style="text-align: left"> </td><td> </td> <td id="xdx_989_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zwGoyf8mVusd" style="text-align: center; padding-left: 0pt" title="Expiration date">Mar-29</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zqcOKzaDjYK1" style="text-align: right" title="Exercise price">4.9290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zDHFNWpsjb3e" style="text-align: right" title="Number Outstanding">71,593</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zZMxUR7bkS33" style="text-align: center; padding-left: 0pt" title="Expiration date">Mar-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zsZntc7uOkX6" style="text-align: right" title="Exercise price">5.1358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zYtPxHs3Izgb" style="text-align: right" title="Number Outstanding">99,243</td><td style="text-align: left"> </td><td> </td> <td id="xdx_987_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zGFt4ZX5V676" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zGqi3vY0DxQh" style="text-align: right" title="Exercise price">7.1810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zOO7DPz8P5v6" style="text-align: right" title="Number Outstanding">83,270</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zfFrk5hpA073" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_z9vO2KoGJSj" style="text-align: right" title="Exercise price">7.5020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zcTT2SBcGrA3" style="text-align: right" title="Number Outstanding">9,846</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zX4guVcJJMjg" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zJCsBuj1f1Ih" style="text-align: right" title="Exercise price">7.9630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zbfgzbkVJqNb" style="text-align: right" title="Number Outstanding">21,369</td><td style="text-align: left"> </td><td> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_ziORY5TRQ9Sf" style="text-align: center; padding-left: 0pt" title="Expiration date">Aug-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zvmECEOd3J8c" style="text-align: right" title="Exercise price">9.0000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zguQ2IoXXjZf" style="text-align: right" title="Number Outstanding">21,709</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zRPyLJHr8fzd" style="text-align: center; padding-left: 0pt" title="Expiration date">Jun-27</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_z12BomgLPtr8" style="text-align: right" title="Exercise price">9.5960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zeMc6x43r84j" style="text-align: right" title="Number Outstanding">84,390</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98C_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zCBcGxZK2ZN5" style="text-align: center; padding-left: 0pt" title="Expiration date">Jan-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zzHktr3QNqZ2" style="text-align: right" title="Exercise price">10.0992</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zgj4IrjWR62c" style="text-align: right" title="Number Outstanding">19,118</td><td style="text-align: left"> </td><td> </td> <td id="xdx_986_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zHYhteUpzfdl" style="text-align: center; padding-left: 0pt" title="Expiration date">Aug-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zTylGPqg6cu2" style="text-align: right" title="Exercise price">10.2600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zkN8Fe8NrIg4" style="text-align: right" title="Number Outstanding">51,705</td><td style="text-align: left"> </td><td> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zWpdw2DcM3Ca" style="text-align: center; padding-left: 0pt" title="Expiration date">Sep-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_z2zNI2zEch0k" style="text-align: right" title="Exercise price">10.4678</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zT1GvHRFCQ9" style="text-align: right" title="Number Outstanding">84,296</td><td style="text-align: left"> </td><td> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zPxcEZ8Sb6Z6" style="text-align: center; padding-left: 0pt" title="Expiration date">Sep-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zpDOcVdA4A3g" style="text-align: right" title="Exercise price">11.3000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zBV65b2A1Sbb" style="text-align: right" title="Number Outstanding">40,417</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98D_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zfNGpFguQY9d" style="text-align: center; padding-left: 0pt" title="Expiration date">Oct-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zmnX0WLTvS66" style="text-align: right" title="Exercise price">13.2800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zWS4XdCDMfya" style="text-align: right" title="Number Outstanding">96,198</td><td style="text-align: left"> </td><td> </td> <td id="xdx_986_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zD62lvvcE32c" style="text-align: center; padding-left: 0pt" title="Expiration date">Nov-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zBGvlKV3NCTc" style="text-align: right" title="Exercise price">48.0000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zNjNeTRzIXWg" style="text-align: right" title="Number Outstanding">12,500</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98B_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zbyrz74Wicoe" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-26</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_z977ZdxrB7L2" style="padding-bottom: 1pt; text-align: right" title="Exercise price">61.6000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zQzKpeMIH1Qg" style="border-bottom: Black 1pt solid; text-align: right" title="Number Outstanding">56,892</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zCLVkuVXygy4" style="text-align: center; padding-bottom: 1pt; padding-left: 0pt" title="Expiration date">Nov-27</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zRHwf9Ookvbd" style="text-align: right" title="Number outstanding">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="padding-left: 0pt"> </td></tr> </table> During the nine months ended September 30, 2025, the Company issued warrants to purchase an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrLUsUp3Lcte" title="Warrants to purchase shares">758,514 shares of its common stock to investors at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdhMxHfRDjNc" title="Warrants outstanding exercise price">0.9547 per share. During the nine months ended September 30, 2025, the Company issued <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN9n7MgpjQh2" title="Shares of its common stock, warrants">1,644,743 shares of its common stock upon cashless exercise of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqDKE4pgSV64" title="Warrants to purchase common stock">2,357,377 warrants to purchase shares of common stock, pursuant to the formula set forth in such warrants. A summary of the warrant activity for nine months ended September 30, 2025 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Remaining Contractual Term</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20250101__20250930_z66w5wUaI9G9" style="width: 12%; text-align: right" title="Outstanding shares">4,899,716</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20250101__20250930_zQU93NuwhI2c" style="width: 12%; text-align: right" title="Weighted-Average Exercise Price,beginning">4.88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> 3.5</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightsOutstandingIntrinsicValue_iS_c20250101__20250930_zooOrGrJxzik" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value">405,018</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantsOrRightIssued_pid_c20250101__20250930_zHksGGBUu58" style="text-align: right" title="Issued">758,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_pid_uUSDPShares_c20250101__20250930_z83lZ6Kjlrjj" style="text-align: right" title="Weighted-Average Exercise Price Issued">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantsOrRightForfeited_iN_pid_di_c20250101__20250930_zzAraWgrToP3" style="text-align: right" title="Forfeited/expired">(886,206</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zTQ54fXam302" style="text-align: right" title="Weighted Average Exercise Price Forfeited/expired">41.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredIntrinsicValue_c20250101__20250930_zWdyhNlK32Ul" style="text-align: right" title="Outstanding Aggregate Intrinsic Value, Forfeited/expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantsOrRightExpried_pid_c20250101__20250930_zHkLAhfTkDNl" style="border-bottom: Black 1pt solid; text-align: right" title="Exercised">(2,357,377</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_pid_uUSDPShares_c20250101__20250930_zFYymc1uEqW2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Expired">2.41</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue_c20250101__20250930_zeGt7Juan3Da" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding Aggregate Intrinsic Value, Exercised">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20250101__20250930_zZw95xKxQhA3" style="text-align: right" title="Outstanding shares">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,404,542</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightsVestedAndExpectedToVestOutstanding_iE_pid_c20250101__20250930_zecUf0QoUQd3" style="text-align: right" title="Warrants Vested and expected to vest, Shares">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding_iE_pid_uUSDPShares_c20250101__20250930_zoKBxKa2qV2c" style="text-align: right" title="Weighted-Average Exercise Price Vested and expected to vest">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930_ztehXGauDhBl" title="Weighted-Average Remaining Contractual Term Vested and expected to ves">3.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightsVestedAndExpectedToVestOutstandingIntrinsicValue_iI_c20250930_zuShBAysSdWe" style="text-align: right" title="Warrants Vested and expected to vest, Aggregate Intrinsic Value">6,404,542</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightsExercisable_iE_pid_c20250101__20250930_zb3bcrdoAVCb" style="text-align: right" title="Warrants Exercisable, Shares">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable_iE_pid_uUSDPShares_c20250101__20250930_z4PmjgRkjKV" style="text-align: right" title="Weighted-Average Exercise Price Exercisable">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightsExercisableIntrinsicValue_iI_c20250930_zzQn1XTWn7d" style="text-align: right" title="Warrants Exercisable, Aggregate Intrinsic Value">6,404,542</td><td style="text-align: left"> </td></tr> </table> The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $5.76 as of September 30, 2025, which would have been received by the warrant holders had those warrants holders exercised their options as of that date. Restricted Stock Units The following table summarizes the restricted stock activity for the nine months ended September 30, 2025: SCHEDULE OF RESTRICTED STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Restricted shares issued as of January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzf0dxvEfYU7" style="width: 16%; text-align: right" title="Restricted shares issued, beginning balance">1,385,839</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmuAYevFCZ09" style="text-align: right" title="Granted">7,515,267</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxvlVYCEU5ob" style="text-align: right" title="Vested and issued">(7,836,943</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWwu40Ia1wlf" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">(64,163</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbHYujNCPGd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested restricted shares, ending balance">1,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested restricted shares as of September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5yRBAHt3wzd" style="text-align: right" title="Vested restricted shares">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Unvested restricted shares as of September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1OLphmdh3Ii" style="text-align: right" title="Unvested restricted shares">1,000,000</td><td style="text-align: left"> </td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) During the nine months ended September 30, 2025, the Company granted an aggregate of 7,380,267 restricted stock units (“RSUs”) for shares of its commons stock to various key consultants and employees for services rendered. These RSUs were granted at fair value on the grant date. Included in this total are <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250930__srt--TitleOfIndividualAxis__custom--MitchellWilliamsMember_zYTUnGUqdNCe" title="Restricted common stock">1,000,000 RSUs granted to Mitchell Williams, the Company’s Chief Investment Officer, with a grant-date fair value of approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn5n6_c20250101__20250930__srt--TitleOfIndividualAxis__custom--MitchellWilliamsMember_z0SG5UZcjeZb" title="Restricted common stock, value">5.0 million. Also, included in this total are 40,000 RSUs granted to a third-party consultant for services for the period beginning in September through December 2025, with a grant-date fair value of approximately $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn3n3_c20250101__20250930__srt--TitleOfIndividualAxis__custom--MitchellWilliamsMember_zgjdDppEDiEh" title="Restricted common stock, value">155 thousand. As of September 30, 2025, approximately $125 thousand is included in prepaid expenses and vendor deposits on the accompanying condensed consolidated balance sheet. Mr. Williams RSUs vest over an 18-month period, with one-third vesting on April 24, 2026 and the remaining two-thirds vesting in five substantially equal quarterly installments thereafter, subject to continued service. During the nine months ended September 30, 2025, the Company issued an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250101__20250930__srt--TitleOfIndividualAxis__custom--KeyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkfdcqEEOsd4" title="Services, shares">135,000 RSUs for shares of its common stock for the settlement of accounts payable at a fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20250101__20250930__srt--TitleOfIndividualAxis__custom--KeyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYiQTmhUep5d" title="Services, value">0.2 million. Stock based compensation expense related to RSU grants was $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pn4n6_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPY1l8rzGsBk" title="Share-based payment arrangement, noncash expense">14.66 million and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn4n6_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jlNyCdcNx7" title="Share-based payment arrangement, noncash expense">4.59 million for the nine months ended September 30, 2025 and 2024, respectively. Stock based compensation expense related to RSU grants was $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pn4n6_c20250701__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPB0ksMJGiTe" title="Share-based payment arrangement, noncash expense">0.87 million and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn4n6_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK9bJ7RN2Prj" title="Share-based payment arrangement, noncash expense">1.02 million for the three months ended September 30, 2025 and 2024, respectively. As of September 30, 2025, the stock-based compensation relating to RSUs of $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn4n6_c20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziq4NOkalkz" title="Restricted stock, unamortized">4.03 million remains unamortized and a remaining weighted average life of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAmNyhT7hYYi" title="Restricted stock, emaining weighted average life">1.22 years. ViralClear Pharmaceuticals, Inc. 2019 Long-Term Incentive Plan There are <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250930__us-gaap--PlanNameAxis__custom--TwoThousandNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsXhXwiRMadf" title="Shares remaining">2,915,071 shares remaining available for future issuance of awards under the terms of the ViralClear Plan. Warrants (ViralClear) <p id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zhacXJP4cC5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the warrant activity for nine months ended September 30, 2025 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zZgXUKocqBYb" style="width: 12%; text-align: right" title="Outstanding shares">480,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zRez5gA8NO36" style="width: 12%; text-align: right" title="Weighted-Average Exercise Price,beginning">5.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z4b0KQ7r8J3f" style="width: 12%; text-align: right" title="Weighted-Average Remaining Contractual Term, Outstanding">2.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited/expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantsOrRightForfeited_iN_pid_di_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zLTdavE0Ei85" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited/expired">(6,575</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExpired_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zit5vraR65d4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited/expired">10.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zdiWWEQC9qjl" style="text-align: right" title="Outstanding shares">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding_iE_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z5R348bqgSX8" title="Weighted-Average Exercise Price ending">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zFZMzepnz5Rj" title="Weighted-Average Remaining Contractual Term, Outstanding">2.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightsExercisable_iE_pid_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zRwh3EpsX4nh" style="text-align: right" title="Warrants Exercisable, Shares">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable_iE_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zzCLp5ZT7E67" style="text-align: right" title="Weighted-Average Exercise Price Exercisable">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--WarrantsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zKgNXlXZ8Qal" title="Weighted-Average Remaining Contractual Term Exercisable">2.1</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_896_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zsHUEgzFHahh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information related to warrants (ViralClear) at September 30, 2025: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--AwardTypeAxis__custom--RangeOneMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zN5X8hzRBHVa" style="width: 30%; text-align: right" title="Exercise price">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__custom--RangeOneMember_z6dcmdh42L7" style="width: 30%; text-align: right" title="Number Outstanding">473,772</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_c20250101__20250930__us-gaap--AwardTypeAxis__custom--RangeOneMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zK1H3pyDgggd" style="width: 32%; text-align: center" title="Expiration date">November 2027</td></tr> </table> Restricted stock units (ViralClear) <p id="xdx_897_eus-gaap--NonvestedRestrictedStockSharesActivityTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zNhOHwyyCvK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the restricted stock activity for the nine months ended September 30, 2025: SCHEDULE OF RESTRICTED STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%">Restricted shares outstanding at January 1, 2025:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zG2vnkOIcTWl" style="width: 12%; text-align: right" title="Restricted shares issued, beginning balance">678,679</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zbeFbusdlvla" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total restricted shares outstanding at September 30, 2025:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zCyLdimZFVw1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted shares issued, ending balance">678,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested restricted shares as of September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zHvbyyhtGqe8" style="text-align: right" title="Vested restricted shares">678,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Unvested restricted shares as of September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zihQFXmvzyVg" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested restricted shares">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnvestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zhZnoobhKkY6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">678,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> BioSig AI Sciences, Inc. Warrants (BioSig AI) <p id="xdx_891_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--BioSigAISciencesIncMember_zGzRQZtapVr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at September 30, 2025: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zQmpUgZStKH8" style="width: 30%; text-align: right" title="Exercise price">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zzNwjgxFYjYh" style="width: 30%; text-align: right" title="Number Outstanding">130,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_988_ecustom--WarrantsExpirationDateDescription_c20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zBAFbXK7BB9k" style="width: 32%; text-align: right" title="Expiration date">June-July 2028</td></tr> </table>

10359211

4376595

14735806

11219081

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRpyOXv1tq5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information related to stock options as of September 30, 2025: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">$</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">Under <span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_z3rnKWwIcF46" title="Options Outstanding, Exercise Price">9.99</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zjrOtrl7Yozi" style="width: 12%; text-align: right" title="Number of Options Outstanding">2,715,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zrDla8voqEu" style="width: 12%; text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">9.0</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zXN416IM50h1" style="width: 12%; text-align: right" title="Number of Options Outstanding Options Exercisable">2,715,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zagcuBdS3Kfe" title="Options Outstanding, Exercise Price">10.00-<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zWKi70iNhJl3" title="Options Outstanding, Exercise Price">19.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zfOH3vWMh1Sf" style="text-align: right" title="Number of Options Outstanding">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_z6NH8WZ88qQ8" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">7.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zpPZFRUeskLl" style="text-align: right" title="Number of Options Outstanding Options Exercisable">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zZ0GWWIeGbji" title="Options Outstanding, Exercise Price">20.00-<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zAbO9TBfvnTc" title="Options Outstanding, Exercise Price">49.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zbjAwDNCvy63" style="text-align: right" title="Number of Options Outstanding">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_z9fAZIgIdOF8" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">3.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zFA9ydtiyGB9" style="text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z3w5gituqITi" title="Options Outstanding, Exercise Price">50.00-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zne5L39ebQuk" title="Options Outstanding, Exercise Price">69.99</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zY3PS3uvzEIh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z3QyC8ujp4ja" style="padding-bottom: 1pt; text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">4.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zjBhEnb9vSAk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930_zv2h3yKtU6q9" style="text-align: right" title="Number of Options Outstanding">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zuulg1LN9425" title="Number of Options Outstanding Weighted Average Remaining Life">9.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20250930_zGtARZlfvqEe" style="text-align: right" title="Number of Options Outstanding Options Exercisable">2,736,000</td><td style="text-align: left"> </td></tr> </table>

9.99

2715000

P9Y

2715000

10.00

19.99

15000

P7Y7M6D

15000

20.00

49.99

3000

P3Y6M

3000

50.00

69.99

3000

P4Y3M18D

3000

2736000

P9Y

2736000

A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2025 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Remaining Contractual Term</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zphJLCiG26Tb" style="width: 12%; text-align: right" title="Outstanding shares">2,515,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20250101__20250930_zriaYMbF7qOf" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding">0.96</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zsqgr55vLlv1" style="width: 12%; text-align: right" title="Weighted-Average Remaining Contractual Term">9.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20250930_zyZPdj5du1sk" style="width: 12%; text-align: right" title="Outstanding Aggregate Intrinsic Value">2,501,040</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930_zPnPS6Z5e3ah" style="text-align: right" title="Issued">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zjTmKRHEBRK9" style="text-align: right" title="Weighted Average Exercise Price Issued">0.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zeZMfqSjEDi1" style="text-align: right" title="Weighted-Average Remaining Contractual Term, Issued">9.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeited/expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20250930_zW8Jlf6nTLK2" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited/expired">(29,200</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zYAVUH3LV6s" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited/expired">17.34</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zbilsVAuKqck" style="text-align: right" title="Outstanding shares">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20250101__20250930_zHfcWnF9chh6" style="text-align: right" title="Weighted Average Exercise Price Outstanding">0.78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zSHOBzxYJ84k" style="text-align: right" title="Weighted-Average Remaining Contractual Term">9.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20250930_zZTtuANk19Tf" style="text-align: right" title="Outstanding Aggregate Intrinsic Value">14,040,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zwwxtExWkhy8" style="text-align: right" title="Outstanding shares Exercisable">2,736,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zhmKNo6axA0e" style="text-align: right" title="Weighted Average Exercise Price Exercisable">0.78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20250101__20250930_zBqbW6BGrGp8" style="text-align: right" title="Weighted-Average Remaining Contractual Term">9.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20250930_z0q0nWqBRoS5" style="text-align: right" title="Outstanding Exercisable Aggregate Intrinsic Value">14,040,120</td><td style="text-align: left"> </td></tr> </table>

2515200

0.96

P9Y7M6D

2501040000

250000

0.84

P9Y7M6D

29200

17.34

2736000

0.78

P9Y

14040120000

2736000

0.78

P9Y

14040120000

5.76

1076015

498445 655863

450820

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzLnGrTG40y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the nine months ended September 30, 2025, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted: SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assumption</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Weighted average grant date fair value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDHt4jHNgFu4" title="Derivative liability">0.80</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z1sKhKftfMn3" title="Derivative liability">122.43</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1KXfGilH25e" title="Derivative liability">4.32</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zl8pn7EUXXJf" title="Derivative liability">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeTermOfContract_dtY_c20250101__20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zSL53aLjuyyd" title="Derivative liability, measurement input, expected life">10.0</td><td style="text-align: left"> </td></tr> </table>

0.80

122.43

4.32

0.00

P10Y

<p id="xdx_892_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_zWrghcwcDW02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of September 30, 2025: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zO56bI8EQoif" style="width: 30%; text-align: right" title="Exercise price">0.3000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zJGF5rCHORGg" style="width: 30%; text-align: right" title="Number Outstanding">11,982</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_989_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_z7pzl1puXCjf" style="width: 32%; text-align: center; padding-left: 0pt" title="Expiration date">Nov-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zAkvbZOPNeT3" style="text-align: right" title="Exercise price">0.9547</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zISl91NZKu24" style="text-align: right" title="Number Outstanding">665,900</td><td style="text-align: left"> </td><td> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zKuAZ1vMoax" style="text-align: center; padding-left: 0pt" title="Expiration date">Sep-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_zjc140hKvUgd" style="text-align: right" title="Exercise price">1.7800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_zVEHQsRSL8Ze" style="text-align: right" title="Number Outstanding">523,561</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_zfcnNTRm7EGf" style="text-align: center; padding-left: 0pt" title="Expiration date">May-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt23875Member_zVWZ2K7Peoui" style="text-align: right" title="Exercise price">2.3875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt23875Member_zAKObytDKdNk" style="text-align: right" title="Number Outstanding">106,237</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt23875Member_zlcJEXNLCyo3" style="text-align: center; padding-left: 0pt" title="Expiration date">May-29</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zaundhH0sCdd" style="text-align: right" title="Exercise price">3.3640</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zWj5ly9OIOz8" style="text-align: right" title="Number Outstanding">117,828</td><td style="text-align: left"> </td><td> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_z6CJ0DKCIPad" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zRskGC9YaKvl" style="text-align: right" title="Exercise price">4.0660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_z4jJIDIVkRsk" style="text-align: right" title="Number Outstanding">25,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zaRhYD9YdDRg" style="text-align: center; padding-left: 0pt" title="Expiration date">Nov-32</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zGwrelWMOXsb" style="text-align: right" title="Exercise price">4.4550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zM9qkB4dUDJ5" style="text-align: right" title="Number Outstanding">107,483</td><td style="text-align: left"> </td><td> </td> <td id="xdx_982_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zTugMyHN1UDe" style="text-align: center; padding-left: 0pt" title="Expiration date">Jun-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zFjPCcl1nWkb" style="text-align: right" title="Exercise price">4.4660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zxFIVepwqnba" style="text-align: right" title="Number Outstanding">48,980</td><td style="text-align: left"> </td><td> </td> <td id="xdx_980_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_znjnAMCpvkjk" style="text-align: center; padding-left: 0pt" title="Expiration date">Nov-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_z3HkmvQXyDah" style="text-align: right" title="Exercise price">4.6626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zG02gYfz0szl" style="text-align: right" title="Number Outstanding">5,580</td><td style="text-align: left"> </td><td> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zhPZJSVz0fO1" style="text-align: center; padding-left: 0pt" title="Expiration date">Apr-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zGmVWnZawpMf" style="text-align: right" title="Exercise price">4.9252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zERPnZypLkDf" style="text-align: right" title="Number Outstanding">49,550</td><td style="text-align: left"> </td><td> </td> <td id="xdx_989_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zwGoyf8mVusd" style="text-align: center; padding-left: 0pt" title="Expiration date">Mar-29</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zqcOKzaDjYK1" style="text-align: right" title="Exercise price">4.9290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zDHFNWpsjb3e" style="text-align: right" title="Number Outstanding">71,593</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zZMxUR7bkS33" style="text-align: center; padding-left: 0pt" title="Expiration date">Mar-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zsZntc7uOkX6" style="text-align: right" title="Exercise price">5.1358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zYtPxHs3Izgb" style="text-align: right" title="Number Outstanding">99,243</td><td style="text-align: left"> </td><td> </td> <td id="xdx_987_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zGFt4ZX5V676" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zGqi3vY0DxQh" style="text-align: right" title="Exercise price">7.1810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zOO7DPz8P5v6" style="text-align: right" title="Number Outstanding">83,270</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zfFrk5hpA073" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_z9vO2KoGJSj" style="text-align: right" title="Exercise price">7.5020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zcTT2SBcGrA3" style="text-align: right" title="Number Outstanding">9,846</td><td style="text-align: left"> </td><td> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zX4guVcJJMjg" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zJCsBuj1f1Ih" style="text-align: right" title="Exercise price">7.9630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zbfgzbkVJqNb" style="text-align: right" title="Number Outstanding">21,369</td><td style="text-align: left"> </td><td> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_ziORY5TRQ9Sf" style="text-align: center; padding-left: 0pt" title="Expiration date">Aug-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zvmECEOd3J8c" style="text-align: right" title="Exercise price">9.0000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zguQ2IoXXjZf" style="text-align: right" title="Number Outstanding">21,709</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zRPyLJHr8fzd" style="text-align: center; padding-left: 0pt" title="Expiration date">Jun-27</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_z12BomgLPtr8" style="text-align: right" title="Exercise price">9.5960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zeMc6x43r84j" style="text-align: right" title="Number Outstanding">84,390</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98C_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zCBcGxZK2ZN5" style="text-align: center; padding-left: 0pt" title="Expiration date">Jan-29</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zzHktr3QNqZ2" style="text-align: right" title="Exercise price">10.0992</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zgj4IrjWR62c" style="text-align: right" title="Number Outstanding">19,118</td><td style="text-align: left"> </td><td> </td> <td id="xdx_986_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zHYhteUpzfdl" style="text-align: center; padding-left: 0pt" title="Expiration date">Aug-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zTylGPqg6cu2" style="text-align: right" title="Exercise price">10.2600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zkN8Fe8NrIg4" style="text-align: right" title="Number Outstanding">51,705</td><td style="text-align: left"> </td><td> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zWpdw2DcM3Ca" style="text-align: center; padding-left: 0pt" title="Expiration date">Sep-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_z2zNI2zEch0k" style="text-align: right" title="Exercise price">10.4678</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zT1GvHRFCQ9" style="text-align: right" title="Number Outstanding">84,296</td><td style="text-align: left"> </td><td> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zPxcEZ8Sb6Z6" style="text-align: center; padding-left: 0pt" title="Expiration date">Sep-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zpDOcVdA4A3g" style="text-align: right" title="Exercise price">11.3000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zBV65b2A1Sbb" style="text-align: right" title="Number Outstanding">40,417</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98D_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zfNGpFguQY9d" style="text-align: center; padding-left: 0pt" title="Expiration date">Oct-28</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zmnX0WLTvS66" style="text-align: right" title="Exercise price">13.2800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zWS4XdCDMfya" style="text-align: right" title="Number Outstanding">96,198</td><td style="text-align: left"> </td><td> </td> <td id="xdx_986_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zD62lvvcE32c" style="text-align: center; padding-left: 0pt" title="Expiration date">Nov-28</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zBGvlKV3NCTc" style="text-align: right" title="Exercise price">48.0000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zNjNeTRzIXWg" style="text-align: right" title="Number Outstanding">12,500</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98B_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zbyrz74Wicoe" style="text-align: center; padding-left: 0pt" title="Expiration date">Jul-26</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_z977ZdxrB7L2" style="padding-bottom: 1pt; text-align: right" title="Exercise price">61.6000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zQzKpeMIH1Qg" style="border-bottom: Black 1pt solid; text-align: right" title="Number Outstanding">56,892</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zCLVkuVXygy4" style="text-align: center; padding-bottom: 1pt; padding-left: 0pt" title="Expiration date">Nov-27</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zRHwf9Ookvbd" style="text-align: right" title="Number outstanding">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="padding-left: 0pt"> </td></tr> </table>

0.3000

11982

Nov-29

0.9547

665900

Sep-28

1.7800

523561

May-29

2.3875

106237

May-29

3.3640

117828

Jul-29

4.0660

25000

Nov-32

4.4550

107483

Jun-28

4.4660

48980

Nov-28

4.6626

5580

Apr-29

4.9252

49550

Mar-29

4.9290

71593

Mar-29

5.1358

99243

Jul-28

7.1810

83270

Jul-28

7.5020

9846

Jul-28

7.9630

21369

Aug-28

9.0000

21709

Jun-27

9.5960

84390

Jan-29

10.0992

19118

Aug-28

10.2600

51705

Sep-28

10.4678

84296

Sep-28

11.3000

40417

Oct-28

13.2800

96198

Nov-28

48.0000

12500

Jul-26

61.6000

56892

Nov-27

2414647

758514

0.9547

1644743

2357377

A summary of the warrant activity for nine months ended September 30, 2025 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Remaining Contractual Term</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20250101__20250930_z66w5wUaI9G9" style="width: 12%; text-align: right" title="Outstanding shares">4,899,716</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20250101__20250930_zQU93NuwhI2c" style="width: 12%; text-align: right" title="Weighted-Average Exercise Price,beginning">4.88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> 3.5</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightsOutstandingIntrinsicValue_iS_c20250101__20250930_zooOrGrJxzik" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value">405,018</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantsOrRightIssued_pid_c20250101__20250930_zHksGGBUu58" style="text-align: right" title="Issued">758,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_pid_uUSDPShares_c20250101__20250930_z83lZ6Kjlrjj" style="text-align: right" title="Weighted-Average Exercise Price Issued">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantsOrRightForfeited_iN_pid_di_c20250101__20250930_zzAraWgrToP3" style="text-align: right" title="Forfeited/expired">(886,206</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20250101__20250930_zTQ54fXam302" style="text-align: right" title="Weighted Average Exercise Price Forfeited/expired">41.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredIntrinsicValue_c20250101__20250930_zWdyhNlK32Ul" style="text-align: right" title="Outstanding Aggregate Intrinsic Value, Forfeited/expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantsOrRightExpried_pid_c20250101__20250930_zHkLAhfTkDNl" style="border-bottom: Black 1pt solid; text-align: right" title="Exercised">(2,357,377</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_pid_uUSDPShares_c20250101__20250930_zFYymc1uEqW2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Expired">2.41</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue_c20250101__20250930_zeGt7Juan3Da" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding Aggregate Intrinsic Value, Exercised">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20250101__20250930_zZw95xKxQhA3" style="text-align: right" title="Outstanding shares">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,404,542</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightsVestedAndExpectedToVestOutstanding_iE_pid_c20250101__20250930_zecUf0QoUQd3" style="text-align: right" title="Warrants Vested and expected to vest, Shares">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding_iE_pid_uUSDPShares_c20250101__20250930_zoKBxKa2qV2c" style="text-align: right" title="Weighted-Average Exercise Price Vested and expected to vest">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930_ztehXGauDhBl" title="Weighted-Average Remaining Contractual Term Vested and expected to ves">3.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightsVestedAndExpectedToVestOutstandingIntrinsicValue_iI_c20250930_zuShBAysSdWe" style="text-align: right" title="Warrants Vested and expected to vest, Aggregate Intrinsic Value">6,404,542</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightsExercisable_iE_pid_c20250101__20250930_zb3bcrdoAVCb" style="text-align: right" title="Warrants Exercisable, Shares">2,414,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable_iE_pid_uUSDPShares_c20250101__20250930_z4PmjgRkjKV" style="text-align: right" title="Weighted-Average Exercise Price Exercisable">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightsExercisableIntrinsicValue_iI_c20250930_zzQn1XTWn7d" style="text-align: right" title="Warrants Exercisable, Aggregate Intrinsic Value">6,404,542</td><td style="text-align: left"> </td></tr> </table>

4899716

4.88

P3Y6M 405018000 758514 0.95 P2Y7M6D 886206

41.32

-2357377 2.41

2414647

5.57 P3Y2M12D 6404542000 2414647 5.57 P3Y2M12D 6404542000 2414647 5.57 P3Y2M12D 6404542000

5.76

The following table summarizes the restricted stock activity for the nine months ended September 30, 2025: SCHEDULE OF RESTRICTED STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Restricted shares issued as of January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzf0dxvEfYU7" style="width: 16%; text-align: right" title="Restricted shares issued, beginning balance">1,385,839</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmuAYevFCZ09" style="text-align: right" title="Granted">7,515,267</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxvlVYCEU5ob" style="text-align: right" title="Vested and issued">(7,836,943</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWwu40Ia1wlf" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">(64,163</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbHYujNCPGd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested restricted shares, ending balance">1,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested restricted shares as of September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5yRBAHt3wzd" style="text-align: right" title="Vested restricted shares">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Unvested restricted shares as of September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1OLphmdh3Ii" style="text-align: right" title="Unvested restricted shares">1,000,000</td><td style="text-align: left"> </td></tr> </table>

1385839

7515267

7836943

64163

1000000

7380267

1000000

5000000.0

155000

125000

135000

200000

14660000

4590000

870000

1020000.00

4030000.00

P1Y2M19D

2915071

<p id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zhacXJP4cC5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the warrant activity for nine months ended September 30, 2025 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zZgXUKocqBYb" style="width: 12%; text-align: right" title="Outstanding shares">480,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zRez5gA8NO36" style="width: 12%; text-align: right" title="Weighted-Average Exercise Price,beginning">5.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z4b0KQ7r8J3f" style="width: 12%; text-align: right" title="Weighted-Average Remaining Contractual Term, Outstanding">2.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited/expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantsOrRightForfeited_iN_pid_di_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zLTdavE0Ei85" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited/expired">(6,575</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExpired_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zit5vraR65d4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited/expired">10.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zdiWWEQC9qjl" style="text-align: right" title="Outstanding shares">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding_iE_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z5R348bqgSX8" title="Weighted-Average Exercise Price ending">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zFZMzepnz5Rj" title="Weighted-Average Remaining Contractual Term, Outstanding">2.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightsExercisable_iE_pid_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zRwh3EpsX4nh" style="text-align: right" title="Warrants Exercisable, Shares">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable_iE_pid_uUSDPShares_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zzCLp5ZT7E67" style="text-align: right" title="Weighted-Average Exercise Price Exercisable">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--WarrantsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zKgNXlXZ8Qal" title="Weighted-Average Remaining Contractual Term Exercisable">2.1</td><td style="text-align: left"> </td></tr> </table>

480347

5.07

P2Y10M24D 6575 10.00

473772

5.00 P2Y1M6D 473772 5.00 P2Y1M6D <p id="xdx_896_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zsHUEgzFHahh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information related to warrants (ViralClear) at September 30, 2025: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__us-gaap--AwardTypeAxis__custom--RangeOneMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zN5X8hzRBHVa" style="width: 30%; text-align: right" title="Exercise price">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__custom--RangeOneMember_z6dcmdh42L7" style="width: 30%; text-align: right" title="Number Outstanding">473,772</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_c20250101__20250930__us-gaap--AwardTypeAxis__custom--RangeOneMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zK1H3pyDgggd" style="width: 32%; text-align: center" title="Expiration date">November 2027</td></tr> </table>

5.00

473772

November 2027

<p id="xdx_897_eus-gaap--NonvestedRestrictedStockSharesActivityTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zNhOHwyyCvK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the restricted stock activity for the nine months ended September 30, 2025: SCHEDULE OF RESTRICTED STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%">Restricted shares outstanding at January 1, 2025:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zG2vnkOIcTWl" style="width: 12%; text-align: right" title="Restricted shares issued, beginning balance">678,679</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zbeFbusdlvla" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total restricted shares outstanding at September 30, 2025:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zCyLdimZFVw1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted shares issued, ending balance">678,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested restricted shares as of September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zHvbyyhtGqe8" style="text-align: right" title="Vested restricted shares">678,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Unvested restricted shares as of September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zihQFXmvzyVg" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested restricted shares">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnvestedNumberOfShares_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zhZnoobhKkY6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">678,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

678679

678679 678679 <p id="xdx_891_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--BioSigAISciencesIncMember_zGzRQZtapVr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at September 30, 2025: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zQmpUgZStKH8" style="width: 30%; text-align: right" title="Exercise price">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zzNwjgxFYjYh" style="width: 30%; text-align: right" title="Number Outstanding">130,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_988_ecustom--WarrantsExpirationDateDescription_c20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zBAFbXK7BB9k" style="width: 32%; text-align: right" title="Expiration date">June-July 2028</td></tr> </table>

1.00

130500

June-July 2028

NOTE 11 – NON-CONTROLLING INTEREST As of September 30, 2025 and December 31, 2024, the Company had a majority interest in ViralClear of <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ViralClearPharmaceuticalsIncMember_zgo9GlD3W64f" title="Majority interest">69.74% and <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ViralClearPharmaceuticalsIncMember_zbS9GiPv4cSh" title="Majority interest">69.08%, respectively. As of September 30, 2025 and December 31, 2024, the Company had a majority interest in of BioSig AI of <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioSigAIMember_ztQDKVG9THg9" title="Majority interest"><span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioSigAIMember_z5hHy4R1CDdc" title="Majority interest">84.5% for both periods. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) A reconciliation of ViralClear Pharmaceuticals, Inc. and BioSig AI Sciences, Inc. non-controlling loss attributable to the Company: Net loss attributable to the non-controlling interest for the three months ended September 30, 2025 (000’s): SCHEDULE OF NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_493_20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zDCPo3WxdBnd" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49D_20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zcqIuqt9mlt5" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49F_20250701__20250930_zsg911Y0fqLk" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zOBHyYiU9qK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_ztwG9BSWSlE3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">30</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_906_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_z1AW8AZYlQo6" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_901_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_fKg_____z9SG0jLbovTa" title="Net loss attributable to non-controlling interest">-*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 4%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 96%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Less than $0.5 thousand</td></tr> </table> Net loss attributable to the non-controlling interest for the three months ended September 30, 2024 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_z062O8V2HcN4" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_490_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zbhO26sroDlb" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49C_20240701__20240930_z69iwIw5i478" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_z3Mq7AAuFGWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income (loss)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_zHUDxWPYi1z7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of profit/losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">32</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">15</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income (loss) attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90C_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zFfAGqfLLT8h" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zKaHn6GpoRTi" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> Net loss attributable to the non-controlling interest for the nine months ended September 30, 2025 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_494_20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zEmRdRhj1Age" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_496_20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_z4rJ7XKnm6p3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_493_20250101__20250930_zZWojVMTi757" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_z5A7ACQkows" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 95</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 95</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_zIuDMO8Avjxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">30</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_909_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zlNqHwFZTLse" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_902_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zadjWWz66L51" title="Net loss attributable to non-controlling interest">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> Net loss attributable to the non-controlling interest for the nine months ended September 30, 2024 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zKVvOFp3Thp" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zPve0BgmTDZ1" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_490_20240101__20240930_zhqmJk3HpIaa" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zKw8nlfdWQk9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income (loss)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (41</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 24</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_zd8XaduidxA4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of profit/losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">32</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">52</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income (loss) attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zCjR2iy4zbxj" title="Net loss attributable to non-controlling interest">(13</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zPHUfw48Dmzk" title="Net loss attributable to non-controlling interest">4</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(9</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> </table> <p id="xdx_890_eus-gaap--ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_zmsrF9b7hW7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2025 (000’s): SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B8_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zjT9AfvBXmV1" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zzCZGlUx8nAc" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B3_zJ2H1RFlbBz1" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_43B_c20250101__20250930_eus-gaap--MinorityInterest_iS_pn3n3_zVdoCIwKYNI5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Balance, January 1, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 188</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_z9TFFMBON8ke" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_43B_c20250101__20250930_eus-gaap--MinorityInterest_iE_pn3n3_z3aocYjH2eUg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance, September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">204</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">33</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table> The following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2024 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B8_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zyCbJ0CBAx52" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zUqpawyRjUJg" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B3_zS1dhZlU7Mba" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_433_c20240101__20240930_eus-gaap--MinorityInterest_iS_pn3n3_znsnQIUp6CB2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Balance, January 1, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (158</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 184</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_432_c20240101__20240930_eus-gaap--MinorityInterest_iS_pn3n3_zB5E8z6DCNN9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (158</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 184</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zWrmgAUiOvYe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income (loss) attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(13</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">4</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(9</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr id="xdx_435_c20240101__20240930_eus-gaap--MinorityInterest_iE_pn3n3_zVr6rshm21Tl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance, September 30, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">188</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_431_c20240101__20240930_eus-gaap--MinorityInterest_iE_pn3n3_zfJ0nUTC7C6k" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">188</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

0.6974

0.6908

0.845

Net loss attributable to the non-controlling interest for the three months ended September 30, 2025 (000’s): SCHEDULE OF NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_493_20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zDCPo3WxdBnd" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49D_20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zcqIuqt9mlt5" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49F_20250701__20250930_zsg911Y0fqLk" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zOBHyYiU9qK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_ztwG9BSWSlE3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">30</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_906_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_z1AW8AZYlQo6" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_901_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250701__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_fKg_____z9SG0jLbovTa" title="Net loss attributable to non-controlling interest">-*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 4%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 96%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Less than $0.5 thousand</td></tr> </table> Net loss attributable to the non-controlling interest for the three months ended September 30, 2024 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_z062O8V2HcN4" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_490_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zbhO26sroDlb" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49C_20240701__20240930_z69iwIw5i478" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_z3Mq7AAuFGWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income (loss)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_zHUDxWPYi1z7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of profit/losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">32</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">15</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income (loss) attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90C_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zFfAGqfLLT8h" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zKaHn6GpoRTi" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> Net loss attributable to the non-controlling interest for the nine months ended September 30, 2025 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_494_20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zEmRdRhj1Age" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_496_20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_z4rJ7XKnm6p3" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_493_20250101__20250930_zZWojVMTi757" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_z5A7ACQkows" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> -</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 95</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 95</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_zIuDMO8Avjxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">30</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_909_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zlNqHwFZTLse" title="Net loss attributable to non-controlling interest">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_902_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zadjWWz66L51" title="Net loss attributable to non-controlling interest">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> </table> Net loss attributable to the non-controlling interest for the nine months ended September 30, 2024 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zKVvOFp3Thp" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zPve0BgmTDZ1" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_490_20240101__20240930_zhqmJk3HpIaa" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: center; padding-right: 0pt"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zKw8nlfdWQk9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Net income (loss)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (41</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 24</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td></tr> <tr id="xdx_408_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_zd8XaduidxA4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Average Non-Controlling interest percentage of profit/losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">32</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">52</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income (loss) attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_zCjR2iy4zbxj" title="Net loss attributable to non-controlling interest">(13</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zPHUfw48Dmzk" title="Net loss attributable to non-controlling interest">4</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(9</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> </table> -3000 -3000 0.30 0.16 0.16 0.32 0.16 0.15 95000 95000 0.30 0.16 0.16

16000

-41000 24000 -17000 0.32 0.16 0.52

-13000

4000

-9000

<p id="xdx_890_eus-gaap--ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_zmsrF9b7hW7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2025 (000’s): SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B8_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zjT9AfvBXmV1" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zzCZGlUx8nAc" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B3_zJ2H1RFlbBz1" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_43B_c20250101__20250930_eus-gaap--MinorityInterest_iS_pn3n3_zVdoCIwKYNI5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Balance, January 1, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 188</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_z9TFFMBON8ke" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">16</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_43B_c20250101__20250930_eus-gaap--MinorityInterest_iE_pn3n3_z3aocYjH2eUg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance, September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">204</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">33</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table> The following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2024 (000’s): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B8_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zyCbJ0CBAx52" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">ViralClear</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zUqpawyRjUJg" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">BioSig AI</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" id="xdx_4B3_zS1dhZlU7Mba" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Pharmaceuticals, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Sciences, Inc.</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">(000’s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_433_c20240101__20240930_eus-gaap--MinorityInterest_iS_pn3n3_znsnQIUp6CB2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 49%; padding-right: 0pt; padding-bottom: 0pt">Balance, January 1, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (158</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 184</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 13%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_432_c20240101__20240930_eus-gaap--MinorityInterest_iS_pn3n3_zB5E8z6DCNN9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> (158</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 184</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"> 26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zWrmgAUiOvYe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">Net income (loss) attributable to non-controlling interest</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(13</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">4</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(9</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt">)</td></tr> <tr id="xdx_435_c20240101__20240930_eus-gaap--MinorityInterest_iE_pn3n3_zVr6rshm21Tl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance, September 30, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">188</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_431_c20240101__20240930_eus-gaap--MinorityInterest_iE_pn3n3_zfJ0nUTC7C6k" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">(171</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">188</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">17</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table>

-171000

188000

17000

16000

-171000

204000

33000

-158000

184000

26000

-158000

184000

26000

-13000

4000

-9000

-171000

188000

17000

-171000

188000

17000

NOTE 12 — COMMITMENTS AND CONTINGENCIES 2017 Know-How License Agreement with Mayo Foundation On March 15, 2017, the Company entered into an exclusive license agreement with Mayo Foundation for Medical Education and Research, covering specific know-how and patent applications in signal processing and electrophysiology. The agreement has a ten-year term. The Company is obligated to pay royalties of <span id="xdx_908_ecustom--RoyaltyPercentageOfNetSales_pid_dp_uPure_c20170315__20170315__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentySeventeenKnowHowLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zING236jQJqh" title="Royalty percentage of net sales">1% or <span id="xdx_905_ecustom--RoyaltyPercentageOfNetSales_pid_dp_uPure_c20170315__20170315__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentySeventeenKnowHowLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zZGBNDKHd0md" title="Royalty percentage of net sales">2% on net sales of licensed products. As of September 30, 2025 and December 31, 2024, accounts payable under this agreement was $<span id="xdx_908_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentySeventeenKnowHowLicenseAgreementMember_zcgWZKBsxu8g" title="Accounts payable due"><span id="xdx_90C_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentySeventeenKnowHowLicenseAgreementMember_z7swKSR75K5c" title="Accounts payable due">4. EP Software License Agreement (2019) On November 20, 2019, the Company entered into an exclusive worldwide license agreement with Mayo for electrophysiology software and related patent rights. The agreement includes earned royalty payments and milestone payments up to $625,000. It expires upon the later of the patent rights’ expiration or the 10th anniversary of the first commercial sale. As of September 30, 2025 and December 31, 2024, accounts payable under this agreement was $0. Tools License Agreement (2019) Also on November 20, 2019, the Company entered into an amended and restated license agreement with Mayo for electrophysiology systems. The Company paid an upfront fee of $100,000 and agreed to milestone payments up to $550,000. In June 2021, a $75,000 milestone payment was made upon the issuance of patent rights. As of September 30, 2025 and December 31, 2024, accounts payable under this agreement was $0. ViralClear License Agreement (2019) On November 20, 2019, the Company’s majority-owned subsidiary, ViralClear, entered into an exclusive license agreement with Mayo for technologies related to stimulation and electroporation for various medical treatments. The agreement includes earned royalty payments and milestone payments up to $700,000. In June 2021, a $75,000 milestone payment was made upon the issuance of patent rights. As of September 30, 2025 and December 31, 2024, accounts payable under this agreement was $0. Trek Therapeutics Agreement On March 24, 2020, ViralClear agreed to pay Trek Therapeutics, PBC, 10% of any consideration received from sublicensing, sale, transfer, or similar transactions. Additionally, ViralClear received rights from Trek involving certain formulas and compounds, with milestone payments of $<span id="xdx_907_eus-gaap--PaymentsForRoyalties_pn6n6_c20200324__20200324__us-gaap--TypeOfArrangementAxis__custom--TrekTherapeuticsMember__us-gaap--AwardTypeAxis__custom--FirstCountryMember_zhI8LyHkXP0g" title="Payments for royalties">10 million and $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_pn6n6_c20200324__20200324__us-gaap--TypeOfArrangementAxis__custom--TrekTherapeuticsMember__us-gaap--AwardTypeAxis__custom--SecondCountryMember_zQARogsSleI4" title="Payments for royalties">5 million upon marketing authorization in the first and second countries, respectively, and 6% royalty payments. As of September 30, 2025 and December 31, 2024, accounts payable under this agreement was $0. Tokenized Yield Partnership Agreement Overview On September 8, 2025, the Company entered into a Tokenized Yield Partnership Agreement (the “Token Agreement”) with Monetary Metals & Co. (“MM”), a Delaware corporation. The Token Agreement establishes an exclusive, multi-year strategic partnership to design, launch, and distribute blockchain-based financial products that tokenize the yield generated from MM’s precious-metal lease and bond programs. The Token Agreement commenced on September 8, 2025 and continues for an initial term of three years, subject to automatic one-year renewal periods unless terminated in accordance with its terms. As of September 30, 2025, there was no activity under this arrangement, and no amounts have been recognized in the Company’s financial statements. Exclusivity and Performance Conditions For at least three years, MM agreed not to engage with any other party to tokenize the yield or other financial attributes of its precious-metal lease or bond products, and the Company agreed not to partner with any third party to tokenize yield derived from precious-metal leases, in each case subject to specified volume-based performance conditions. To maintain exclusivity, the Company must supply at least 10% of the total leased ounces presented by MM each quarter that meet defined criteria, including minimum insurance standards, a net yield of at least 3% per annum after origination fees, and compliance with restrictions on counterparties and jurisdictions. Failure to meet these thresholds, after a 90-day cure period, results in loss of exclusivity but does not obligate the Company to commit capital or continue participation. Economic Terms MM will provide the Company with a discounted fee and quarterly cash rebate on Company gold purchases based on a tiered schedule ranging from <span id="xdx_901_ecustom--DiscountedFeePercentage_pid_dp_c20250101__20250930__dei--LegalEntityAxis__custom--MonetaryMetalsAndCoMember__srt--RangeAxis__srt--MaximumMember_z2C1csH1KeYk" title="Discounted fee percentage">0.75% to <span id="xdx_904_ecustom--DiscountedFeePercentage_pid_dp_c20250101__20250930__dei--LegalEntityAxis__custom--MonetaryMetalsAndCoMember__srt--RangeAxis__srt--MinimumMember_zCWf2m7kFoH9" title="Discounted fee percentage">0.20% of aggregate quarterly purchase volume. MM will also pay the Company a quarterly revenue share on Company-supplied gold deployed in qualifying leases, ranging from <span id="xdx_906_ecustom--RevenueSharePercentage_pid_dp_c20250101__20250930__dei--LegalEntityAxis__custom--MonetaryMetalsAndCoMember__srt--RangeAxis__srt--MinimumMember_zBNoNTt7Tqri" title="Revenue share percentage">0.35% to <span id="xdx_904_ecustom--RevenueSharePercentage_pid_dp_c20250101__20250930__dei--LegalEntityAxis__custom--MonetaryMetalsAndCoMember__srt--RangeAxis__srt--MaximumMember_zyP3inNbEIEb" title="Revenue share percentage">0.50%, depending on total kilograms leased. All intellectual property arising from the design and development of tokenized yield products will be owned exclusively by the Company, while MM retains ownership of intellectual property related to its lease and bond products. Termination Either party may terminate the Token Agreement for convenience on six months’ notice or for customary breach and insolvency events. Certain exclusivity obligations survive for a minimum of three years. TriView Capital Ltd. On June 1, 2025, the Company entered into an agreement with TriView Capital Ltd. (“TriView”) to acquire <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250601__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriViewCapitalLtdMember_zyvtyZQEUjoi" title="Ownership percentage">9.9% of TriView’s issued and outstanding shares for a total purchase price of CAD $198,000 (approximately USD $146,843), payable in four equal monthly installments from June through September 2025. The Company completed all installment payments during the quarter ended September 30, 2025 and expects to receive the shares representing its <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250601__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriViewCapitalLtdMember_ztWDPjZGg87h" title="Ownership percentage">9.9% ownership interest. Under the agreement, the Company also holds an option to acquire the remaining <span id="xdx_90B_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_pid_dp_uPure_c20250601__us-gaap--BusinessAcquisitionAxis__custom--TriViewCapitalLtdMember_zEx992WH6F2l" title="Option acquire remaining percentage">90.1% of TriView’s outstanding shares for CAD $<span id="xdx_90E_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn5n6_uCAD_c20250601__20250601__us-gaap--BusinessAcquisitionAxis__custom--TriViewCapitalLtdMember_zvvaUeLYoWfd" title="Outstanding shares additional amount">1.8 million (approximately USD $<span id="xdx_908_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn5n6_c20250601__20250601__us-gaap--BusinessAcquisitionAxis__custom--TriViewCapitalLtdMember_zI5JyiNbrGq3" title="Outstanding shares additional amount">1.3 million) at any time prior to December 12, 2025. This option has not been exercised as of September 30, 2025 and is disclosed as a commitment. TriView retains the right to cancel the agreement prior to issuance of shares, in which case amounts paid would be refunded; management believes the likelihood of cancellation is remote. See Note 15 – Investment in TriView Capital Ltd. for additional details. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Senior Secured Convertible Debenture and Equity Agreements On July 7, 2025, the Company entered into a secured convertible debenture purchase agreement with YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville”), pursuant to which Yorkville will purchase senior secured convertible debentures in the aggregate principal amount of USD$100,000,000 (the “Convertible Debentures”), which will be convertible into shares of the Company’s common stock, par value $0.001 per share. On August 13, 2025, the Company amended the agreement to revise the structure of the transaction. Under the amended terms, Yorkville will purchase two secured convertible debentures: one in the principal amount of $25 million and another in the principal amount of $25 million. Additional secured convertible debentures totaling up to $50 million may be issued upon mutual agreement of the parties, at their sole discretion. <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription_c20250707__20250707__us-gaap--DebtInstrumentAxis__custom--TwoSecuredConvertibleDebenturesMember_zBuTjj8ZsXGe" title="Convertible debt description">The purchase price for each debenture remains 96% of its face value. The Convertible Debentures are convertible into shares of the Company’s common stock, subject to shareholder approval and customary closing conditions. The amendment also sets a floor price for conversions at 20% of the Nasdaq Official Closing Price immediately prior to the original agreement date. Yorkville’s obligation to purchase is limited to the initial $50 million (two closings) upon satisfaction of closing conditions. Additional issuances beyond the initial $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20250707__us-gaap--DebtInstrumentAxis__custom--TwoSecuredConvertibleDebenturesMember_zO03dCKKvKV3" title="Debt maximum capacity">50 million are discretionary and require mutual consent. The agreement does not contain a specified termination date; however, it remains in effect until all obligations are satisfied or terminated by mutual agreement. Standby Equity Purchase Agreement On July 7, 2025, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with Yorkville. Under the SEPA, the Company has the right, but not the obligation, to issue and sell to Yorkville up to $<span id="xdx_906_eus-gaap--EquityMethodInvestmentDeferredGainOnSale_c20250707__20250707__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z7NXbqt029Hc" title="Sale of stock issued, vale">1,000,000,000 of its Common Stock, from time to time during a 36-month commitment period, subject to certain terms, limitations, and conditions. The Company controls the timing and amount of any sales of Common Stock to the Yorkville under the SEPA at its discretion. The Company may deliver an advance notice (“Advance Notice”) to Yorkville specifying the number of shares it elects to sell, but may not deliver an Advance Notice until any issued Convertible Debenture(s) has been repaid and/or converted in full, except with Yorkville’s prior written consent. <span id="xdx_90F_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20250707__20250707__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zq80cwwDu92a" title="Variable weighted average percentage, description">Each Advance Notice will be priced at 97% of the lowest VWAP of the Common Stock during the three consecutive trading days commencing on the date the Advance Notice is received by Yorkville, subject to certain adjustments if the daily VWAP is below a minimum acceptable price specified by the Company. No Advance Notice may cause Yorkville’s beneficial ownership to exceed <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250707__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvestorsMember_zriI5OPgrPfg" title="Ownership percentage">4.99% of the Company’s outstanding Common Stock. The Company may not deliver Advance Notices that would cause the aggregate number of shares issued under the SEPA to exceed the Exchange Cap (representing <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250707__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvestorsMember_zFRqEVV5Kn5" title="Ownership percentage">19.99% of the Common Stock outstanding as of the effective date of the SEPA), unless (a) approval of the Company’s stockholders is obtained or (b) the average price of all sales of Common Stock under the SEPA equals or exceeds $9.414, as defined in the agreement. The Company is required file a registration statement with the SEC to register for resale the Common Stock issuable under the SEPA and is required agree to maintain its effectiveness during the term of the SEPA. Yorkville’s obligation to purchase Common Stock under the SEPA is subject to customary closing conditions, including the effectiveness of the registration statement. As consideration for Yorkville’s commitment under the SEPA, the Company agreed to pay a commitment fee equal to 1.0% of the commitment amount, with the initial payment due concurrently with the first closing of a sale under the SEPA, and the balance payable in equal quarterly installments within fifteen days after the end of the applicable calendar quarter, in either cash or shares of Common Stock, at Yorkville’s discretion. The SEPA contains customary representations, warranties, covenants, conditions, and indemnification obligations of the parties. The SEPA will terminate automatically on the earliest of (i) 36 months after the date of execution, or (ii) the date Yorkville has purchased the full commitment amount of Common Stock. The Company may also terminate the SEPA at any time without fee or penalty upon five business days’ written notice to Yorkville, provided there are no pending Advance Notices. Both agreements are subject to customary closing conditions, including stockholder approval and, in the case of the SEPA, the effectiveness of a registration statement. The Company may not access proceeds under the SEPA until any issued debentures have been repaid or converted, unless waived by Yorkville. Equity Line of Credit On February 28, 2025 (the “Effective Date”), the Company entered into a Equity Subscription Agreement (the “Subscription Agreement”) with Lind Global Fund III, LP (the “Investor”). Pursuant to the Subscription Agreement, the Company has the right, but not the obligation, to sell to the Investor from time to time (each such occurrence, an “Advance”) up to $5.0 million (the “Commitment Amount”) of the Company’s common stock, $0.001 par value per share (“Common Stock”), during the 36 months following the execution of the Subscription Agreement, subject to (a) an overall cap of 10,000,000 shares and (b) the restrictions and satisfaction of the conditions set forth in the Subscription Agreement. The Company is under no obligation to sell any of its Common Stock to the Investor under the Subscription Agreement. At the Company’s option, the shares of Common Stock would be purchased by the Investor from time to time at a price (the “Market Price”) equal to 95% of the lowest of the daily VWAPs (as hereinafter defined) during a five (or such other period as the Company and the Investor may agree) consecutive trading day period commencing on the date that the Company delivers a notice to the Investor (an “Advance Notice”) that the Company is requiring the Investor to purchase a specified number of shares of Common Stock (the “Advance Shares”). The Company may also specify a minimum acceptable price per share in each Advance. “VWAP” means, for any trading day, the daily volume weighted average price of the Company’s Common Stock for such trading day on the Nasdaq Stock Market as reported by Bloomberg L.P. <span id="xdx_90C_ecustom--InvestorPurchaseOfSharesPercentageDescription_c20250228__20250228__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zYjMl1AshYT4" title="Investor purchase of shares percentage description">The maximum number of shares of Common Stock that the Company may require the Investor to purchase in any Advance is an number equal to 66.667% of the average daily volume of the Common Stock on the Nasdaq Stock Market during the five consecutive trading days immediately preceding the date of the Advance Notice; provided that notwithstanding the foregoing limitation, in any period of 30 consecutive days, the total number of Advance Shares that the Company may sell to the Investor may be up to 0.5% of the quotient of the number of shares of Common Stock outstanding on the date of the Advance divided by the Market Price determined for such Advance. As consideration for the Investor’s irrevocable commitment (subject to the conditions set forth in the Subscription Agreement) to purchase the Company’s Common Stock up to the Commitment Amount, the Company issued <span id="xdx_90D_ecustom--PurchaseOfCommonStockSharesUpToCommitmentAmount_c20250228__20250228__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zEJrlvPQBEMg" title="Purchase of common stock up to the commitment amount">108,542 shares of Common Stock (the “Commitment Shares”) to the Investor with a grant date fair value of $100,000. The Company had previously advanced to the Investor $10,000 to cover certain expenses related to the Subscription Agreement. The Investor’s obligation to purchase the Company’s shares of Common Stock pursuant to the Subscription Agreement is subject to a number of conditions, including that the Company file a registration statement on Form S-1 or Form S-3 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”), registering the issuance and sale of the Commitment Shares and the Advance Shares to be issued and sold pursuant to an Advance under the Securities Act of 1933, as amended (the “Securities Act”), and that the Registration Statement be declared effective by the SEC. The Company has not filed a registration statement on a Form S-1 or Form S-3 as of September 30, 2025. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Finder Agreements Related to Streamex Exchange Transaction On May 27, 2025, the Company and Streamex Exchange entered into separate Finder Agreements with three unaffiliated third parties (each, a “Finder”) in connection with the transactions contemplated by the Share Purchase Agreement dated May 23, 2025, among the Company, Streamex Exchange, and related parties. Under the terms of the Finder Agreements, the Finders facilitated introductions between Streamex Exchange and Company management. As compensation for these introductory services, the Company agreed to issue to the Finders, in aggregate, shares of its common stock representing 3.75% of the Company’s outstanding shares immediately prior to the closing of the Share Purchase Agreement (the “Closing”). The shares are to be issued no later than two business days following shareholder approval of certain matters set forth in the Share Purchase Agreement (the “Parent Stockholder Matters”). The Streamex transaction successfully closed on May 28, 2025. Although the issuance of shares to the Finders remains contingent upon shareholder approval of the Parent Stockholder Matters, the Company determined that the obligation to compensate the Finders was probable upon the Closing. Accordingly, the Company recognized expense and recorded an accrual of approximately $6,025,880 in connection with the Finder Agreements during the nine months ended September 30, 2025. The expense is reflected in general and administrative expenses in the unaudited condensed consolidated statements of operations. On November 4, 2025, the Company obtained shareholder approval of the Parent Stockholder Matters. As a result, the share issuance obligation under the Finder Agreements became effective, and the Company expects to issue the shares in accordance with the terms of the agreements. Letter of Intent with Simplify On September 14, 2025, the Company entered into a non-binding Letter of Intent with Simplify Asset Management Inc. to explore a potential strategic partnership focused on developing tokenized exchange-traded products (ETPs) and ETFs incorporating Streamex’s Gold Yield Token. The LOI outlines preliminary terms for product co-development, revenue sharing, and regulatory cooperation; however, it does not create any binding obligation to consummate a transaction. The LOI includes customary confidentiality and other provisions and will expire 90 days from execution unless extended by mutual agreement. There can be no assurance that definitive agreements will be executed or that any transaction will occur. Share Purchase Agreement with Streamex Exchange On May 23, 2025, the Company entered into a Share Purchase Agreement with Streamex Exchange Corporation and related parties. The transaction closed on May 28, 2025, at which time the Company, through a wholly owned subsidiary, acquired all issued and outstanding shares of Streamex Exchange in exchange for <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_znuBPMVeggEc" title="Exchangeable shares">109,070,079 Exchangeable Shares. These Exchangeable Shares are convertible into shares of the Company’s common stock on a one-for-one basis, subject to certain conditions and shareholder approvals. In accordance with Nasdaq listing rules, the Exchangeable Shares are initially limited to 19.9% of the Company’s pre-transaction common stock outstanding. The Company is seeking shareholder approval of certain matters outlined in the Share Purchase Agreement (the “Parent Stockholder Matters”), which would authorize sufficient common stock and remove the conversion cap. Upon approval, Streamex Exchange shareholders would be entitled to convert their Exchangeable Shares into the Company’s common stock up to a total of 75% of the Company’s fully diluted common stock. No additional shares are issued—rather, the approval enables full conversion of shares already held. If such approval is not obtained by November 28, 2025, the exchange ratio will adjust from 1.0 to 1.25, increasing the number of common stock issuable upon conversion of each Exchangeable Share. As of September 30, 2025, shareholder approval of the Parent Stockholder Matters had not been obtained, and the Exchangeable Shares remain subject to the initial conversion limitations. On November 4, 2025 the Company received shareholder approval. As a result, the conversion cap was removed, and Streamex Exchange shareholders may now convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. Litigation On February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from alleged unlawful actions taken by the Company and its board of directors. The claimant contends that he and others have sustained losses totaling approximately $1,440,000. On March 22, 2024, September 3, 2024, September 27, 2024 and December 6, 2024, the claimant sent additional letters to the Company referencing the previous letters and requesting several documents. On September 19, 2024, the Company sent the claimant a cease and desist and litigation hold notice which threatened legal action against the claimant if the conduct continued. On March 24, 2025, the Company entered into a settlement agreement with the claimant and accrued $0 and $494,000 as of September 30, 2025 and December 31, 2024, respectively. The settlement was paid on April 24, 2025. We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. Stock-based compensation The Company takes some tax positions, including the reporting of stock-based compensation, that may not be accepted by the Internal Revenue Service upon an examination, and we may be subject to penalties for underreporting of recipient’s income. The result of any such examination is uncertain, and any such penalties could be material to our financial position and results of operations given our current limited cash and revenues. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

0.01 0.02

625000

100000

550000

75000

700000

75000

10000000

5000000

0.06

0.0075 0.0020 0.0035 0.0050

0.099

198000

146843

0.099

0.901

1800000

1300000

100000000

0.001

25000000

50000000

The purchase price for each debenture remains 96% of its face value. The Convertible Debentures are convertible into shares of the Company’s common stock, subject to shareholder approval and customary closing conditions. The amendment also sets a floor price for conversions at 20% of the Nasdaq Official Closing Price immediately prior to the original agreement date.

50000000

1000000000

Each Advance Notice will be priced at 97% of the lowest VWAP of the Common Stock during the three consecutive trading days commencing on the date the Advance Notice is received by Yorkville, subject to certain adjustments if the daily VWAP is below a minimum acceptable price specified by the Company.

0.0499

0.1999

9.414

Company agreed to pay a commitment fee equal to 1.0% of the commitment amount, with the initial payment due concurrently with the first closing of a sale under the SEPA

5000000.0

0.001

10000000

The maximum number of shares of Common Stock that the Company may require the Investor to purchase in any Advance is an number equal to 66.667% of the average daily volume of the Common Stock on the Nasdaq Stock Market during the five consecutive trading days immediately preceding the date of the Advance Notice; provided that notwithstanding the foregoing limitation, in any period of 30 consecutive days, the total number of Advance Shares that the Company may sell to the Investor may be up to 0.5% of the quotient of the number of shares of Common Stock outstanding on the date of the Advance divided by the Market Price determined for such Advance. 108542

100000

10000

0.0375

6025880

109070079

1440000

0 494000

NOTE 13 – BUSINESS ACQUISITION Streamex Exchange Corporation Transaction Overview On <span id="xdx_906_eus-gaap--BusinessAcquisitionDateOfAcquisitionAgreement1_dd_c20250528__20250528__us-gaap--BusinessAcquisitionAxis__custom--StreamexExchangeCorporationMember_zGCdr6slz1Va" title="Business acquisition, date">May 28, 2025, the Company completed the acquisition of Streamex Exchange, a software development company based in Vancouver, British Columbia, specializing in digital tools for commodity trading and finance. The acquisition was effected pursuant to a Share Purchase Agreement dated May 23, 2025, as amended on May 27, 2025 (collectively, the “Agreement”), by and among the Company, its wholly-owned subsidiaries ExchangeCo and Callco, the Stream Exchange Shareholders, and 1540873 B.C. Ltd., as trustee under the Exchange Rights Agreement. Under the terms of the Agreement, ExchangeCo acquired all of the issued and outstanding shares of Streamex Exchange (the “Purchased Shares”) in exchange for <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250528__20250528__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zbwvLy3lbpi5" title="Exchangeable shares">109,070,079 Exchangeable Shares of ExchangeCo, issued at a ratio of 2.046862 Exchangeable Shares per Purchased Share. The Exchangeable Shares are exchangeable on a one-for-one basis for shares of the Company’s common stock, subject to certain adjustments and conditions described below. The purpose of the Acquisition is to enhance shareholder value by combining with a privately held operating company and positioning the combined entity for future growth with expansion into digital commodity trading and blockchain-based financial technologies. The acquisition is expected to enhance the Company’s product offerings, accelerate blockchain integration, and provide access to Streamex Exchange engineering talent and regulatory infrastructure. Shareholder Approval and Contingent Features Initially, the Exchangeable Shares are not exchangeable into more than 19.99% of the Company’s outstanding common stock on a pre-transaction basis, in accordance with Nasdaq listing rules. Following the closing, the Company intended to seek stockholder approval to the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">A)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Approve the issuance of our shares of common stock exchangeable for Exchangeable Shares and one share of Special Voting Preferred Stock in connection with the Agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">B)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Approve the issuance of shares of our common stock underlying the Convertible Debentures to Yorkville.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">C)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Approve the increase in the total number of shares of our common stock authorized for issuance under our 2023 Long-Term Incentive Plan by <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250527__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zl5AoRJj8zMk" title="Number of common stock authorized for issuance">10,359,211 shares to a total of <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250528__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zG1QB2rRKLea" title="Number of common stock authorized for issuance">14,735,806 shares.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">D)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Approve the potential issuance of 19.99% or more of our issued and outstanding common stock pursuant to the SEPA with Yorkville.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">E)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 500,000,000.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">F)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Approve of an amendment to our Amended and Restated Certificate of Incorporation to classify our board of directors into three staggered classes.</td></tr> </table> At the special meeting of stockholders held on September 5, 2025, Proposals B—F were approved. Proposal A was adjourned to November 4, 2025. Upon stockholder approval of Proposal A, the holders of Exchangeable Shares are entitled to receive, in total, shares representing 75% of the Company’s fully diluted common stock as of the Agreement date. Consideration Transferred The preliminary fair value of the consideration transferred was $105.7 million, consisting of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">$105.5 million in Exchangeable Shares issued by ExchangeCo; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">$0.2 million in assumed liabilities.</td></tr> </table> Due to the lack of an active market for the Exchangeable Shares and the contingent nature of their conversion, a fundamentals-based valuation approach was used to estimate the fair value of the consideration. The contingent consideration related to the potential adjustment of the Exchange Ratio from 1.0 to 1.25—triggered if shareholder approval is not obtained within six months following the closing date—is not included in the preliminary purchase consideration as of May 28, 2025. Management believes it is probable that shareholder approval will be obtained within the specified period, and therefore, the contingency is not considered to represent a currently estimable obligation under ASC 805. In connection with the acquisition of Streamex Exchange, the Company incurred total acquisition-related costs of $<span id="xdx_90D_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20250101__20250930__us-gaap--BusinessAcquisitionAxis__custom--StreamexExchangeCorporationMember_zrYhrXma1qth" title="Acquisition related costs">7,116,411 during the nine months ended September 30, 2025. These costs primarily consisted of legal, accounting, and consulting fees directly attributable to the transaction. Included in this amount was the issuance of 200,000 shares of the Company’s common stock to a third-party consultant, valued at $1,010,000 based on the grant-date fair value and the expected issuance of 1,030,065 shares of the Company’s common stock to third party consultants in connection with a finders fee, valued at $6,025,880. These costs were expensed as incurred and are reflected in general and administrative expenses in the unaudited condensed consolidated statements of operations. Purchase Price Allocation The Company has applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired and liabilities assumed at their fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. As the Company finalizes the estimation of the fair value of the assets acquired and liabilities assumed, additional adjustments may be recorded during the measurement period (a period not to exceed 12 months from the acquisition date). STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) <p id="xdx_898_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zBiwCK4ImkB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recorded all tangible and identifiable intangible assets acquired and liabilities assumed at their preliminary estimated fair values as of the acquisition date. The preliminary allocation is as follows: SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preliminary Amount Recognized as of the Acquisition Date (In Thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250528_zXI01QDd1d2f" style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAzypu_zfdxJGeSzzv5" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">366</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromRelatedParty_iI_pn3n3_maBCRIAzypu_z0smDVjQJAhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Due from related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSalesTaxReceivable_iI_pn3n3_maBCRIAzypu_zdGuhNCX3DO" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Sales tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pn3n3_maBCRIAzypu_z7BNyriEVSp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName_iI_pn3n3_maBCRIAzypu_zx4LA1BxyQ8g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopedTechnology_iI_pn3n3_maBCRIAzypu_zjBJP13PlZ1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLegalAndComplianceFramework_iI_pn3n3_maBCRIAzypu_z8I8svh93Beh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_maBCRIAzypu_zyoHqYagOho" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70,435</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAzypu_maBCRIAzqkD_ziiBtWdHd34a" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total assets acquired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">118,348</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_iNI_di_maBCRIAzdzv_zNtNcGzmmTv3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts payable and accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(262</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_maBCRIAzdzv_zlq0f4Evidkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Deferred tax liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,588</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_mtBCRIAzdzv_msBCRIAzqkD_z66OndRc3sjj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,850</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzqkD_zzWQOb0Ajznd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: justify">Net assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">105,498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred tax liability In connection with the acquisition of Streamex Exchange, the transaction was structured as a stock acquisition for both U.S. and Canadian tax purposes. No election was made under IRC §338(g); therefore, no step-up in the tax basis of the acquired assets was obtained in either jurisdiction. The purchase price allocation created taxable temporary differences related to identifiable intangible assets, resulting in a deferred tax liability of approximately $12.6 million, measured using the enacted combined Canadian federal and provincial rate of 26.5%. Because these deferred tax liabilities arise in a separate foreign jurisdiction, they cannot offset deferred tax assets of the U.S. parent. The corresponding increase in goodwill was recognized as part of purchase accounting. Intangible Assets The Company identified the following finite-lived intangible assets: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Trade Name: Valued at $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn5n6_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zRRATG1zbtSi" title="Finite lived intangible assets">5.1 million using the relief-from-royalty method, applying a 1.0% royalty rate and a 40.5% discount rate. The trade name is expected to be utilized over a <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zN3FrAlQc3f8" title="Estimated useful lives">10-year period and is amortized accordingly.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Developed Technology</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Comprised of two distinct components, both valued using the multi-period excess earnings method (MPEEM) and amortized over <span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zcuxufUD4oMl" title="Estimated useful lives">8 years:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 72px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Securitization Platform: Valued at $<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn5n6_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SecuritizationPlatformMember_zVKPQXFB634b" title="Finite lived intangible assets">31.1 million, representing proprietary protocols and infrastructure enabling the tokenization of real-world assets and integration with decentralized finance platforms.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Blockchain Integration: Valued at $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn5n6_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BlockchainIntegrationMember_zWKG4wUFqD7j" title="Finite lived intangible assets">8.9 million, reflecting proprietary systems facilitating token creation and secondary market trading through blockchain-based platforms.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Legal and Compliance Framework: Valued at $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn5n6_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zLVYsNY1PR74" title="Finite lived intangible assets">2.4 million using the cost approach, based on the estimated cost to recreate the regulatory and legal infrastructure necessary for operations. The asset has a useful life of 7 years and is amortized accordingly. The legal and compliance framework is expected to contribute to future revenue generation by enabling the Company to operate in regulated jurisdictions, supporting onboarding of clients who require robust compliance infrastructure, enhancing credibility with partners, regulators and investors and reducing legal and regulatory risk exposure.</td></tr> </table> Goodwill Goodwill of $70.4 million represents the excess of the purchase consideration over the fair value of net assets acquired. Goodwill of $70.4 million was recognized in connection with the acquisition. None of the goodwill is expected to be deductible for tax purposes. The goodwill is assigned to the consolidated reporting unit, as the Company operates as a single segment. The goodwill primarily represents expected synergies, assembled workforce, and future growth potential. No goodwill arose from step acquisitions or noncontrolling interests. Measurement Period During the three months ended September 30, 2025, the Company recorded a measurement period adjustment related to the acquisition of Streamex Exchange. The adjustment resulted in the recognition of a deferred tax liability of approximately $12.6 million, primarily related to permanent differences arising from the fair value of identifiable intangible assets acquired in the transaction. This adjustment was recorded as an increase to deferred tax liabilities and a corresponding increase to goodwill. The adjustment was identified based on additional information obtained about facts and circumstances that existed as of the acquisition date and was accounted for retrospectively as a measurement period adjustment. As such, the adjustment was reflected as if it had been recorded at the acquisition date and did not impact the Company’s consolidated statements of operations or cash flows for the three and nine months ended September 30, 2025. The Acquisition was recorded as a business combination on a preliminary valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). We expect to complete our purchase price allocation, as well as our fair value estimate of the purchase price consideration as soon as reasonably possible, not to exceed one year from the acquisition date. Adjustments to the preliminary purchase price allocation could be material. Goodwill represent the excess of the purchase price consideration over the preliminary valuation of the net assets acquired. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) As of September 30, 2025, the purchase price allocation remains preliminary. The Company is continuing to assess the fair values of certain identifiable intangible assets and contingent liabilities, including the potential adjustment to Exchangeable Shares in the event shareholder approval is not obtained. As the shareholder vote had not occurred as of September 30, 2025, the related contingency remains unresolved and subject to final valuation. On November 4, 2025 the Company received shareholder approval for the issuance of our shares of common stock exchangeable for Exchangeable Shares and one share of Special Voting Preferred Stock in connection with the Agreement. As a result, the conversion cap was removed, and Streamex Exchange shareholders may now convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. Pro-Forma Financial Information (Unaudited) The following unaudited pro forma information presents the consolidated results of Streamex Exchange included in the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2025, as if the acquisition was made on January 1, 2025, and operations for the three and nine months ended September 30, 2024, as if the Acquisition had occurred on April 5, 2024, the date of inception of Streamex Exchange. The unaudited pro forma information is presented for illustrative purposes only. It is not necessarily indicative of the results of operations of future periods, or the results of operations that actually would have been realized had the entities been a single company during the periods presented or the results that the combined company will experience after the acquisition. The unaudited pro forma information does not give effect to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost savings that may be associated with the acquisition. The unaudited pro forma information also does not include any integration costs or remaining future transaction costs that the companies may incur related to the acquisition as part of combining the operations of the companies. The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisition had occurred on January 1, 2025, is as follows: SCHEDULE OF UNAUDITED PRO FORMA CONSOLIDATED RESULTS OF REVENUE AND NET LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250930_zb5CaSCYW00d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessAcquisitionsProFormaRevenue_z5JtXYoEaBa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify; padding-bottom: 1pt; padding-left: 0pt">Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">200</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zBkUr7KCqMF8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(42,098</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisitions had occurred on April 1, 2024, the date of inception of Streamex Exchange, is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20240701__20240930_zxZELcUyXzD8" style="font-weight: bold; text-align: center">For the Three Months Ended September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20240101__20240930_zbaI4O3gdAp5" style="font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessAcquisitionsProFormaRevenue_z8lmwdrKCVKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt; padding-left: 0pt">Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">27</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_z18GHLSO9Pil" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,038</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(20,753</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The unaudited pro forma results for the nine months ended September 30, 2025, include material nonrecurring adjustments of $2,297 related to the amortization of intangible assets acquired in connection with the Streamex Exchange acquisition, and $609 related to income tax benefit recognized from the deferred tax liability acquired in connection with the Streamex Exchange acquisition. The unaudited pro forma results for the three months ended September 30, 2024, include material nonrecurring adjustments of $1,477 related to the amortization of intangible assets acquired in connection with the Streamex Exchange acquisition, and $391 related to income tax benefit recognized from the deferred tax liability acquired in connection with the Streamex Exchange acquisition. The unaudited pro forma results for the nine months ended September 30, 2024, include material nonrecurring adjustments of $2,963 related to the amortization of intangible assets acquired in connection with the Streamex Exchange acquisition, $785 related to income tax benefit recognized from the deferred tax liability acquired in connection with the Streamex Exchange acquisition, $6,026 related to the finders fees incurred and earned upon closing of the transaction, $400 of severance expense related to the resignation of the Company’s former CEO following the acquisition, and $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20240101__20240930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT71LYvDbwMe">1,010 related to the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20240101__20240930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHoB6aACo8b">200,000 shares of the Company’s common stock to a consultant in lieu of cash compensation in connection with the acquisition. For the nine months ended September 30, 2025, the operating activities of Streamex Exchange included in the Company’s unaudited condensed consolidated statement of operations and comprehensive loss were insignificant to the Company’s financial results. For the three months ended September 30, 2025 the operating activities of Streamex Exchange are fully reflected in the Company’s unaudited condensed consolidated statement of operations and comprehensive loss.

2025-05-28

109070079

2.046862

10359211

14735806

200000000

500000000

105700000

105500000

200000

7116411

200000

1010000

1030065

6025880

<p id="xdx_898_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zBiwCK4ImkB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recorded all tangible and identifiable intangible assets acquired and liabilities assumed at their preliminary estimated fair values as of the acquisition date. The preliminary allocation is as follows: SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preliminary Amount Recognized as of the Acquisition Date (In Thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250528_zXI01QDd1d2f" style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAzypu_zfdxJGeSzzv5" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">366</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromRelatedParty_iI_pn3n3_maBCRIAzypu_z0smDVjQJAhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Due from related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSalesTaxReceivable_iI_pn3n3_maBCRIAzypu_zdGuhNCX3DO" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Sales tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pn3n3_maBCRIAzypu_z7BNyriEVSp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName_iI_pn3n3_maBCRIAzypu_zx4LA1BxyQ8g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopedTechnology_iI_pn3n3_maBCRIAzypu_zjBJP13PlZ1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLegalAndComplianceFramework_iI_pn3n3_maBCRIAzypu_z8I8svh93Beh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_maBCRIAzypu_zyoHqYagOho" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70,435</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAzypu_maBCRIAzqkD_ziiBtWdHd34a" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total assets acquired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">118,348</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_iNI_di_maBCRIAzdzv_zNtNcGzmmTv3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts payable and accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(262</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_maBCRIAzdzv_zlq0f4Evidkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Deferred tax liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,588</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_mtBCRIAzdzv_msBCRIAzqkD_z66OndRc3sjj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,850</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzqkD_zzWQOb0Ajznd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: justify">Net assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">105,498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

366000

11000 14000

22000

5100000 40000000 2400000 70435000

118348000

262000

12588000

12850000

105498000

12600000

5100000

0.010 0.405

P10Y

P8Y

31100000

8900000

2400000

70400000

12600000

The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisition had occurred on January 1, 2025, is as follows: SCHEDULE OF UNAUDITED PRO FORMA CONSOLIDATED RESULTS OF REVENUE AND NET LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250930_zb5CaSCYW00d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessAcquisitionsProFormaRevenue_z5JtXYoEaBa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify; padding-bottom: 1pt; padding-left: 0pt">Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">200</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zBkUr7KCqMF8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(42,098</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisitions had occurred on April 1, 2024, the date of inception of Streamex Exchange, is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20240701__20240930_zxZELcUyXzD8" style="font-weight: bold; text-align: center">For the Three Months Ended September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20240101__20240930_zbaI4O3gdAp5" style="font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessAcquisitionsProFormaRevenue_z8lmwdrKCVKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt; padding-left: 0pt">Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">27</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_z18GHLSO9Pil" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,038</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(20,753</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

200000

-42098000

27000

-4038000

-20753000

1477

391

2963

785

6026

400

1010

200000

NOTE 14 – FAIR VALUE MEASUREMENTS The Company measures certain financial instruments at fair value on a recurring basis in accordance with ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in impairments and other charges, net in the consolidated statements of operations. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows: SUMMARY OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250528__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zaUYFUzYhSBe" style="border-bottom: Black 1pt solid; text-align: center">May 28, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ziosHX4G0NIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Trade name</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedTechnologyMember_zCGlqmrmRV95" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zetonKJ5cq62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_znZHxPFhrRd3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of intangible assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GoodwillFairValueDisclosure_iI_zxB014D5poCf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">70,435</td><td style="text-align: left"> </td></tr> </table> All these assets were measured at the acquisition dates in conjunction with the Streamex Exchange acquisition. <p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zxVbq5dEbf78" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The significant unobservable inputs used in our level 3 fair value measurements during the nine months ended September 30, 2025 are as follows: SUMMARY OF UNOBSERVABLE INPUTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Areas</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Valuation Techniques</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Unobservable Inputs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Range (Weighted Average)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 22%; padding-right: 0pt; padding-bottom: 0pt">Trade name</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24%; padding-right: 0pt; padding-bottom: 0pt">Relief-from-Royalty Method</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 28%; padding-right: 0pt; padding-bottom: 0pt">Royality Rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 18%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90C_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RoyaltyRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNn9692fCcu" title="Range (Weighted Average)">1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Revenue Growth Rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90D_ecustom--RevenueGrowthRateDescription_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRAzcUs6ILH1" title="Revenue growth rate description">53% average through FY2030, 3% thereafter</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Discount rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_903_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--DiscountRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zww2bOng1F91" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Income tax rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_906_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--IncomeTaxRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7pZjrFCnhZa" title="Range (Weighted Average)">26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Tax amortization period</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_909_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_dtY_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--TaxAmortizationPeriodMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2csDXOYgr55" title="Tax amortization period">20 yrs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Developed technology</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Multi-Period Excess Earnings Method (MPEEM)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Royalty rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_902_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RoyaltyRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdhRITIQtUS2" title="Range (Weighted Average)">1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Revenue Growth Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90F_ecustom--RevenueGrowthRateDescription_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1ybW2gZtFN6" title="Revenue growth rate description">53% average through FY2030, 3% thereafter</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Expense Growth Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRatesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zA8EtQaXexY9" title="Range (Weighted Average)">16% - <span id="xdx_901_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRatesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_z5aHfJmFh8pj" title="Range (Weighted Average)">26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Contributory Assets’ Charge</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_900_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--ContributoryAssetsChargeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_z8hcqNGVntJ" title="Range (Weighted Average)">17.1% - <span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--ContributoryAssetsChargeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zq7NWakQfqAi" title="Range (Weighted Average)">193.6</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Obsolesce</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">Sigmoid curve over <span id="xdx_909_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_pid_dtY_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--ObsoleceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJkUmjKVILKl" title="Obsolesce">8-year life</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Distributor EBIT margin for customer relationships</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--EBITMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPHNCvxa9uD7" title="Range (Weighted Average)">9</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Discount rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--DiscountRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znij16tudmQ2" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Income tax rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_900_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--IncomeTaxRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqt3cpvz4JQ1" title="Range (Weighted Average)">26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Tax amortization period</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_906_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_dtY_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--TaxAmortizationPeriodMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTDiBDi7FWX1" title="Tax amortization period">20 yrs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Legal and compliance framework</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Cost Approach</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Replacement cost growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_904_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--ReplacementCostGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDjKSL1umg5i" title="Range (Weighted Average)">3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Cap Ex Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_901_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--CapExRatesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhdTSakUAui1" title="Range (Weighted Average)">1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Contributory Assets Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_902_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--ContributoryAssetsChargeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zutzO6jNBg7" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">After tax rate of return</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_908_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--AfterTaxRateOfReturnMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zISmBOZaulGk" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Useful life</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90F_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_pid_dtY_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--UsefulLifeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCr4LqzbTB5" title="Tax amortization period">7 yrs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table> In connection with the acquisition of Streamex Exchange Corporation on May 28, 2025, Streamex Corp. issued <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250528__20250528__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zxxRfsCFkrKk" title="Exchangeable shares">109,070,079 Exchangeable Shares through its wholly-owned subsidiary, ExchangeCo, as purchase consideration. The Exchangeable Shares are convertible into the Company’s common stock on a 1:1 basis, subject to a 1.25:1 adjustment if shareholder approval is not obtained within six months. As of the acquisition date, the Exchangeable Shares were not exchangeable into more than 19.9% of the Company’s outstanding common stock, pending shareholder approval. Due to the lack of an active market and the contingent nature of conversion, the Exchangeable Shares were classified as a Level 3 instrument under ASC 820. The fair value of the derivative liability was estimated using a discounted cash flow method and a market capitalization reconciliation. The following table summarizes the significant unobservable inputs used in the valuation: Initial Recognition – May 28, 2025 The valuation incorporated: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">● </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Valuation technique: Discounted Cash Flow (DCF) method and a market capitalization reconciliation</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">● </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Key unobservable inputs:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 48px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Discount rate: <span id="xdx_906_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--DiscountRateMember_z7pBjiOxyfB6" title="Range (Weighted Average)">40.0%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Terminal growth rate: <span id="xdx_900_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--TerminalGrowthRateMember_zAIeYQfuJZt3" title="Range (Weighted Average)">3.0%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Capitalization rate: <span id="xdx_903_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--CapitalizationRateMember_zj4HknWwTdE1" title="Range (Weighted Average)">37.0%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Revenue growth rate: <span id="xdx_90A_ecustom--RevenueGrowthRateDescription_c20250528__20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRateMember_z4UcgptrJJ1e" title="Revenue growth rate description">53% average annual growth through FY2030, 3% thereafter</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Expense rate: ~<span id="xdx_90E_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--ExpenseRateMember__srt--RangeAxis__srt--MinimumMember_z8LeMrMqEGSd" title="Range (Weighted Average)">16% to ~<span id="xdx_906_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--ExpenseRateMember__srt--RangeAxis__srt--MaximumMember_z2TJpbYPs5We" title="Range (Weighted Average)">26% of tokenization revenue over the forecast period</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Capital expenditure rate: <span id="xdx_902_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--CapitalExpenditureRateMember_zFcyWVFa8Rbg" title="Range (Weighted Average)">1% of revenue annually</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Income tax rate: <span id="xdx_905_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250528__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--IncomeTaxRateMember_zsEa39TYjjMi" title="Range (Weighted Average)">26%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">● </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Fair value conclusion: $105.5 million (USD in 000s)</td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) This valuation was used to determine the total preliminary purchase consideration for the acquisition. Remeasurement – September 30, 2025 As of September 30, 2025, the Exchangeable Shares remained unlisted and subject to shareholder approval for full conversion. No observable market transactions occurred during the period. The Company reassessed the fair value using updated inputs, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">● </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Valuation technique: Discounted Cash Flow (DCF) method and a market capitalization reconciliation</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">● </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Key unobservable inputs:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 48px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Discount rate: <span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--DiscountRateMember_zgPEOcaGAgVg" title="Range (Weighted Average)">40.0%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Terminal growth rate: <span id="xdx_900_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--TerminalGrowthRateMember_zlYDLFxEg4Wi" title="Range (Weighted Average)">3.0%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Capitalization rate: <span id="xdx_90D_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--CapitalizationRateMember_zlFS4FcN4L64" title="Range (Weighted Average)">37.0%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Revenue growth rate: ~<span id="xdx_901_ecustom--RevenueGrowthRateDescription_c20250101__20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRateMember_zZZ7pCuglIJb" title="Revenue growth rate description">106% average annual growth through FY2032, 3% thereafter</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Expense rate: ~<span id="xdx_907_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--ExpenseRateMember__srt--RangeAxis__srt--MinimumMember_z5gUyQ8GXFRi" title="Range (Weighted Average)">16% to ~<span id="xdx_904_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--ExpenseRateMember__srt--RangeAxis__srt--MaximumMember_z0pfjm0ylo3d" title="Range (Weighted Average)">26% of tokenization revenue over the forecast period</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Capital expenditure rate: <span id="xdx_90C_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--CapitalExpenditureRateMember_zMaJ1D5mNUe7" title="Range (Weighted Average)">1% of revenue annually</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">○ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Income tax rate: <span id="xdx_90F_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__us-gaap--MeasurementInputTypeAxis__custom--IncomeTaxRateMember_zCAnGd2GjG4h" title="Range (Weighted Average)">26%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">● </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Fair value conclusion: $115.7 million (USD in 000s)</td></tr> </table> As a result, the fair value of the Exchangeable Shares remained was $115.7 million as of September 30, 2025. The instrument continues to be classified as Level 3 due to the absence of observable market inputs and the contingent nature of conversion. <p id="xdx_894_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zH9krtuRipG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Rollforward of Level 3 Fair Value Measurements: SUMMARY OF FAIR VALUE MEASUREMENTS DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" id="xdx_491_20250528__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWhH4D3BbdDi" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Amount ($000s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zvkA1T2Ze4Df" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 76%; padding-right: 0pt; padding-bottom: 0pt">Initial recognition (May 28, 2025)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 21%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">105,498</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfDerivativeLiability_zu3tsO60uvLa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Change in fair value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">10,214</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_407_ecustom--SettlementsExchangeToCommonStock_zJzhPT0v1Nh5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Settlements (Exchange to Common Stock)*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zx8vKqXW3b3j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance as of September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">115,712</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 20px; padding-bottom: 0pt; text-align: right; padding-right: 0pt">*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Represents the reduction in derivative liability for Exchangeable Shares exchanged for common stock upon shareholder approval. No exchanges occurred during the period ended September 30, 2025.</td></tr> </table> There were no transfers into or out of Level 3 during the period. Any future exchanges of Exchangeable Shares for common stock will be reflected as settlements in the rollforward table. The Company’s valuation process for Level 3 fair value measurements involves consultation with independent valuation specialists and review by management. The process includes regular reassessment of key assumptions and inputs. The fair value of the Exchangeable Shares is sensitive to changes in key unobservable inputs, particularly the discount rate and projected cash flows. An increase in the discount rate or a decrease in projected cash flows would result in a lower fair value measurement. These inputs are interrelated, as higher perceived risk (reflected in the discount rate) may also impact management’s cash flow expectations. Due to the venture-stage nature of Streamex Exchange and the contingent conversion feature, the valuation remains highly sensitive to these assumptions.

Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows: SUMMARY OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250528__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zaUYFUzYhSBe" style="border-bottom: Black 1pt solid; text-align: center">May 28, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ziosHX4G0NIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Trade name</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedTechnologyMember_zCGlqmrmRV95" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zetonKJ5cq62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_znZHxPFhrRd3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of intangible assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GoodwillFairValueDisclosure_iI_zxB014D5poCf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">70,435</td><td style="text-align: left"> </td></tr> </table>

5100000

40000000

2400000

70435000

<p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zxVbq5dEbf78" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The significant unobservable inputs used in our level 3 fair value measurements during the nine months ended September 30, 2025 are as follows: SUMMARY OF UNOBSERVABLE INPUTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Areas</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Valuation Techniques</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Unobservable Inputs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Range (Weighted Average)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 22%; padding-right: 0pt; padding-bottom: 0pt">Trade name</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24%; padding-right: 0pt; padding-bottom: 0pt">Relief-from-Royalty Method</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 28%; padding-right: 0pt; padding-bottom: 0pt">Royality Rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 18%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90C_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RoyaltyRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNn9692fCcu" title="Range (Weighted Average)">1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Revenue Growth Rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90D_ecustom--RevenueGrowthRateDescription_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRAzcUs6ILH1" title="Revenue growth rate description">53% average through FY2030, 3% thereafter</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Discount rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_903_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--DiscountRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zww2bOng1F91" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Income tax rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_906_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--IncomeTaxRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7pZjrFCnhZa" title="Range (Weighted Average)">26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Tax amortization period</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_909_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_dtY_c20250930__us-gaap--FinancialInstrumentAxis__custom--TradeNameMember__us-gaap--ValuationTechniqueAxis__custom--ReliefFromRoyaltyMethodMember__us-gaap--MeasurementInputTypeAxis__custom--TaxAmortizationPeriodMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2csDXOYgr55" title="Tax amortization period">20 yrs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Developed technology</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Multi-Period Excess Earnings Method (MPEEM)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Royalty rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_902_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RoyaltyRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdhRITIQtUS2" title="Range (Weighted Average)">1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Revenue Growth Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90F_ecustom--RevenueGrowthRateDescription_c20250101__20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1ybW2gZtFN6" title="Revenue growth rate description">53% average through FY2030, 3% thereafter</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Expense Growth Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRatesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zA8EtQaXexY9" title="Range (Weighted Average)">16% - <span id="xdx_901_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--RevenueGrowthRatesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_z5aHfJmFh8pj" title="Range (Weighted Average)">26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Contributory Assets’ Charge</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_900_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--ContributoryAssetsChargeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_z8hcqNGVntJ" title="Range (Weighted Average)">17.1% - <span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--ContributoryAssetsChargeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zq7NWakQfqAi" title="Range (Weighted Average)">193.6</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Obsolesce</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">Sigmoid curve over <span id="xdx_909_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_pid_dtY_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--ObsoleceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJkUmjKVILKl" title="Obsolesce">8-year life</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Distributor EBIT margin for customer relationships</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--EBITMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPHNCvxa9uD7" title="Range (Weighted Average)">9</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Discount rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90A_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--DiscountRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znij16tudmQ2" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Income tax rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_900_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--IncomeTaxRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqt3cpvz4JQ1" title="Range (Weighted Average)">26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Tax amortization period</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_906_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_dtY_c20250930__us-gaap--FinancialInstrumentAxis__custom--DevelopedTechnologyMember__us-gaap--ValuationTechniqueAxis__custom--MultiPeriodExcessEarningsMethodMember__us-gaap--MeasurementInputTypeAxis__custom--TaxAmortizationPeriodMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTDiBDi7FWX1" title="Tax amortization period">20 yrs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Legal and compliance framework</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Cost Approach</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Replacement cost growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_904_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--ReplacementCostGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDjKSL1umg5i" title="Range (Weighted Average)">3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Cap Ex Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_901_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--CapExRatesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhdTSakUAui1" title="Range (Weighted Average)">1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Contributory Assets Rates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_902_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--ContributoryAssetsChargeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zutzO6jNBg7" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">After tax rate of return</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_908_eus-gaap--InvestmentCompanyInvestmentOwnedFairValueMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--AfterTaxRateOfReturnMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zISmBOZaulGk" title="Range (Weighted Average)">40</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Useful life</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_90F_eus-gaap--RegulatoryLiabilityAmortizationPeriod_iI_pid_dtY_uPure_c20250930__us-gaap--FinancialInstrumentAxis__custom--LegalAndComplianceFrameWorkMember__us-gaap--ValuationTechniqueAxis__custom--CostApproachMember__us-gaap--MeasurementInputTypeAxis__custom--UsefulLifeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCr4LqzbTB5" title="Tax amortization period">7 yrs</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table>

53% average through FY2030, 3% thereafter

P20Y

53% average through FY2030, 3% thereafter

17.1

193.6

P8Y

P20Y

P7Y

109070079

The Exchangeable Shares are convertible into the Company’s common stock on a 1:1 basis, subject to a 1.25:1 adjustment if shareholder approval is not obtained within six months. As of the acquisition date, the Exchangeable Shares were not exchangeable into more than 19.9% of the Company’s outstanding common stock, pending shareholder approval.

40.0

3.0

37.0

53% average annual growth through FY2030, 3% thereafter

105500000

40.0

3.0

37.0

106% average annual growth through FY2032, 3% thereafter

115700000

<p id="xdx_894_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zH9krtuRipG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Rollforward of Level 3 Fair Value Measurements: SUMMARY OF FAIR VALUE MEASUREMENTS DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td> <td colspan="2" id="xdx_491_20250528__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWhH4D3BbdDi" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt">Amount ($000s)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zvkA1T2Ze4Df" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 76%; padding-right: 0pt; padding-bottom: 0pt">Initial recognition (May 28, 2025)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 21%; text-align: right; padding-right: 0pt; padding-bottom: 0pt">105,498</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfDerivativeLiability_zu3tsO60uvLa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Change in fair value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">10,214</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_407_ecustom--SettlementsExchangeToCommonStock_zJzhPT0v1Nh5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Settlements (Exchange to Common Stock)*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zx8vKqXW3b3j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">Balance as of September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">$</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt">115,712</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 20px; padding-bottom: 0pt; text-align: right; padding-right: 0pt">*</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt">Represents the reduction in derivative liability for Exchangeable Shares exchanged for common stock upon shareholder approval. No exchanges occurred during the period ended September 30, 2025.</td></tr> </table>

105498000

10214000

115712000

NOTE 15 – INVESTMENT IN TRIVIEW CAPITAL LTD. On June 1, 2025, the Company entered into an agreement with TriView Capital Ltd. (“TriView”) to acquire <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250601__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriViewCapitalLtdMember_zH9u5FMvrH94" title="Ownership percentage">9.9% of TriView’s issued and outstanding shares for a total purchase price of CAD $198,000 (approximately USD $146,843), payable in four equal monthly installments from June through September 2025. The Company completed all installment payments during the quarter ended September 30, 2025 and expects to receive the shares representing its <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20250930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriViewCapitalLtdMember_z8JgPZJkqY2k" title="Ownership percentage">9.9% ownership interest. The investment is accounted for under ASC 321, Investments – Equity Securities, and is recorded at cost as a non-marketable equity security. As of September 30, 2025, the carrying amount of the investment was approximately USD $142,000, based on the cumulative USD equivalent of CAD $198,000 translated at payment dates. The Company will evaluate the investment for impairment and adjust for observable price changes in orderly transactions for identical or similar securities, if any. Under the agreement, the Company also holds an option to acquire the remaining <span id="xdx_90B_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_pid_dp_uPure_c20250601__us-gaap--BusinessAcquisitionAxis__custom--TriViewCapitalLtdMember_zwhuSziUQO7j" title="Option acquire remaining percentage">90.1% of TriView’s outstanding shares for CAD $<span id="xdx_904_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn5n6_uCAD_c20250601__20250601__us-gaap--BusinessAcquisitionAxis__custom--TriViewCapitalLtdMember_z54nxmXmjLff" title="Outstanding shares additional amount">1.8 million (approximately USD $<span id="xdx_908_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn5n6_c20250601__20250601__us-gaap--BusinessAcquisitionAxis__custom--TriViewCapitalLtdMember_zTgaLqwCz1Rf" title="Outstanding shares additional amount">1.3 million) at any time prior to December 12, 2025. This option has not been exercised as of September 30, 2025 and is disclosed as a commitment. TriView retains the right to cancel the agreement prior to issuance of shares, in which case amounts paid would be refunded; management believes the likelihood of cancellation is remote.

0.099

198000

146843

0.099

142000

198000

0.901

1800000

1300000

NOTE 16 – SEGMENT REPORTING Chief Operating Decision Maker (CODM) and Segment Evaluation On May 28, 2025, in connection with the acquisition of Streamex Exchange, the Company appointed Henry McPhie, former co-founder and CEO of Streamex Exchange, as its new Chief Executive Officer and Board of Directors. As a result of this leadership change, Mr. McPhie was designated as the Company’s new Chief Operating Decision Maker (“CODM”), replacing Anthony Amato, the Company’s former CEO and director. Following this change, the Company re-evaluated its operating and reportable segments based on the internal financial information reviewed by the CODM for purposes of performance assessment and resource allocation. Although the acquisition of Streamex Exchange introduced a new line of business focused on digital asset infrastructure, the CODM has not yet begun reviewing Streamex Exchange’s operating results separately for purposes of performance assessment or resource allocation. As of September 30, 2025, the CODM continues to evaluate the Company’s financial performance on a consolidated basis, and the internal reporting structure has not been modified to reflect discrete segment-level financial information. Management believes that a transitional period is appropriate given the timing of the acquisition, the pre-revenue status of Streamex Exchange, and the pending financing and shareholder approvals necessary to operationalize the Streamex Exchange platform. Accordingly, the Company has concluded that no change in reportable segments has occurred as of September 30, 2025. The Company will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at the segment level. STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) In accordance with ASC 280-10-50-34, if a change in reportable segments occurs in a future period, the Company will recast prior-period segment disclosures retrospectively to reflect the new segment structure. Basis of Segmentation The Company’s CODM evaluates financial performance and allocates resources on a consolidated basis. The Company manages its operations as one integrated business, and the CODM does not receive or review separate financial information for Streamex Exchange or any other business unit. This approach reflects the manner in which the CODM: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Assesses performance against budgeted targets;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Forecasts future financial results;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Makes strategic and operational decisions;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">●</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Allocates resources across the organization.</td></tr> </table> Accordingly, the Company has determined that it operates as one reportable and operating segment as of September 30, 2025 Management continues to evaluate whether the Streamex Exchange business may become a separate reportable segment in future periods, depending on the scale and financial significance, and the CODM’s review of discrete operating results. Segment Performance Measures The primary measure used by the CODM to assess performance is consolidated net loss, which is reviewed in conjunction with other consolidated financial metrics. The CODM also evaluates actual results against budgeted amounts and considers consolidated operating results in making decisions about research and development investments and other strategic initiatives. Segment assets are not separately reported to or reviewed by the CODM. Therefore, the Company does not disclose segment asset information. All assets are managed on a consolidated basis and are reported in the Company’s unaudited condensed consolidated balance sheets. The Company does not currently disclose geographic revenue or customer concentration by segment, as such information is not reviewed by the CODM. However, this will be reassessed as operations evolve. Revenue and Expense Information Information concerning the operations of the Company’s reportable segments is as follows: SCHEDULE OF SEGMENT REPORTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zeKr8zx5n294" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_ziZzR5rHS7a2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zYal1i1wzuH7" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zz9JKaQ9yeh8" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_msOEzBsm_zgcTtzgQCiYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 36%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Segment expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzBsm_zYwMO95gn4ic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ResearchAndDevelopmentStockbasedCompensationExpenses_i01_pn3n3_maOEzBsm_zqkBPm0fZkZi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">Research and development - stock-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEzBsm_zZCIYJboM2Ai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,624</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--GeneralAndAdministrativeStockbasedCompensationExpenses_i01_pn3n3_maOEzBsm_zdl6ol6zyAHh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">General and administrative - stock-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,935</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_i01_pn3n3_maOEzBsm_zuLDucw02Ik6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Impairment of long term assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_i01_pn3n3_maOEzBsm_zgCW7r3Zzywa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,488</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,065</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">158</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01NT_pn3n3_di_mtOEzBsm_msPLznqt_zzRtLwLqFFB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total operating and segment expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,113</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,950</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,461</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,679</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestIncomeExpenseNet_pn3n3_maNIEznkC_z66ChSL65RV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Interest income (expense)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ChangeInFairValuesOfDerivativeLiability_pn3n3_maNIEznkC_z9rGpP7YeSwf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">Change in fair value of derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,214</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,214</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_maNIEznkC_ziI2pkadoYf3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Gain on settlement and extinguishment of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">196</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,409</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_maNIEznkC_zxU12S2FvNn8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other income (expense)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(40</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_mtNIEznkC_maPLznqt_zZwAmIqm1e17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total other income (expense)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,236</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,036</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,055</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,439</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01_pn3n3_maOEzBsm_zz28OqusnJdb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Income taxes (benefit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(765</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(765</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ProfitLoss_iT_pn3n3_mtPLznqt_maNILz0fJ_z7ZdsLeVE7al" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Segment Net Loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(15,584</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,914</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(38,751</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(9,240</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_msNILz0fJ_z3PL2RdnM2Q1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz0fJ_z65fK5abCJAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss attributable to Streamex Corp.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,584</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,914</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(38,767</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,231</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> STREAMEX CORP. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited)

Information concerning the operations of the Company’s reportable segments is as follows: SCHEDULE OF SEGMENT REPORTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zeKr8zx5n294" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_ziZzR5rHS7a2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zYal1i1wzuH7" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zz9JKaQ9yeh8" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000’s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_msOEzBsm_zgcTtzgQCiYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 36%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Segment expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzBsm_zYwMO95gn4ic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ResearchAndDevelopmentStockbasedCompensationExpenses_i01_pn3n3_maOEzBsm_zqkBPm0fZkZi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">Research and development - stock-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEzBsm_zZCIYJboM2Ai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,624</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--GeneralAndAdministrativeStockbasedCompensationExpenses_i01_pn3n3_maOEzBsm_zdl6ol6zyAHh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">General and administrative - stock-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,935</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_i01_pn3n3_maOEzBsm_zuLDucw02Ik6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Impairment of long term assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_i01_pn3n3_maOEzBsm_zgCW7r3Zzywa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,488</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,065</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">158</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01NT_pn3n3_di_mtOEzBsm_msPLznqt_zzRtLwLqFFB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total operating and segment expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,113</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,950</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,461</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,679</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestIncomeExpenseNet_pn3n3_maNIEznkC_z66ChSL65RV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Interest income (expense)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ChangeInFairValuesOfDerivativeLiability_pn3n3_maNIEznkC_z9rGpP7YeSwf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">Change in fair value of derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,214</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,214</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_maNIEznkC_ziI2pkadoYf3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Gain on settlement and extinguishment of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">196</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,409</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_maNIEznkC_zxU12S2FvNn8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other income (expense)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(40</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_mtNIEznkC_maPLznqt_zZwAmIqm1e17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total other income (expense)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,236</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,036</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,055</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,439</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01_pn3n3_maOEzBsm_zz28OqusnJdb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Income taxes (benefit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(765</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(765</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ProfitLoss_iT_pn3n3_mtPLznqt_maNILz0fJ_z7ZdsLeVE7al" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Segment Net Loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(15,584</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,914</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(38,751</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(9,240</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_msNILz0fJ_z3PL2RdnM2Q1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz0fJ_z65fK5abCJAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss attributable to Streamex Corp.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,584</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,914</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(38,767</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,231</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

27000

6000

23000

31000

661000

133000 75000

3747000

1246000

11805000

3624000

872000 1517000 15560000 6935000

253000

1488000

31000

2065000

158000

6113000

2950000

29461000

11679000

-10000

3000

-8000

-10214000 -10214000

1021000

196000

2409000

-12000

15000

-40000

38000

-10236000

1036000

-10055000

2439000

-765000

-15584000

-1914000

-38751000

-9240000

16000

-9000

-15584000

-1914000

-38767000

-9231000

NOTE 17 – RELATED PARTY TRANSACTIONS Accounts payable and accrued expenses as of September 30, 2025 include approximately $499 thousand due to related parties, compared to $19 thousand as of December 31, 2024. These amounts primarily relate to executives and board compensation, severance, and reimbursements. Included in the due from related party balance as of September 30, 2025 is $<span id="xdx_90A_eus-gaap--OtherReceivables_iI_pn3n3_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--HenryMcPhieMember_zlWV9ahszPAd" title="Due from related parties">11 thousand due from Henry McPhie, the Company’s new Chief Executive Officer and Board of Directors. During the nine months ended September 30, 2025, the Company issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zmRFAcUNfAek" title="Shares issued">235,000 shares of its common stock to Mr. Groenewald, the Interim Chief Financial Officer, with a total grant-date fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zWDudh1FgXmd" title="Shares issued, value">0.95 million During the nine months ended September 30, 2025, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__srt--TitleOfIndividualAxis__custom--MrAmatoMember_zxy7Kr7xT8x7" title="Number of shares issued">2,198,345 shares of its common stock to Mr. Amato, the Chief Executive Officer, with an aggregate grant date fair value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20250101__20250930__srt--TitleOfIndividualAxis__custom--MrAmatoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z5E86nFuAnf2" title="Common shares issued">5.9 million. The issuances were primarily made in connection with Mr. Amato’s resignation pursuant to the terms of the Purchase Agreement dated May 23, 2025, and the First Amendment to his Executive Employment Agreement. Under the amendment, all previously granted equity awards — including vested and unvested stock options, RSUs, PSUs, and other equity-based awards — were accelerated and deemed fully vested and nonforfeitable as of the Effective Date of the transaction. This treatment was contractually agreed upon as part of the severance provisions associated with Mr. Amato’s resignation in connection with the Company’s acquisition of Streamex Exchange Corporation.

499000

19000

11000

235000

950000

2198345

5900000

NOTE 18 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date on which these unaudited condensed financial statements were issued. Other than as described in the notes above, the Company did not have any material subsequent events that impacted its unaudited condensed financial statements or disclosures. Amendments and First Closing to Senior Secured Convertible Debenture On October 28, 2025, Streamex Corp. entered into Amendment No. 2 to the Secured Convertible Debenture Purchase Agreement with Yorkville. The amendment revised certain terms of the original agreement, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt">●</td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Requiring that $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251024__20251024__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrrYvXfx8ei8" title="Proceeds from senior debt">25.1 million of aggregate proceeds from the first and second closings be allocated to purchase Allocated Vaulted Gold Bullion as collateral, consisting of: </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.75in; padding-right: 0pt; padding-bottom: 0pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt">◌</td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">$<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251024__20251024__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--AwardTypeAxis__custom--FirstClosingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaanO3wWJ2ja" title="Proceeds from senior debt">12.6 million at the first closing, and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.75in; padding-right: 0pt; padding-bottom: 0pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt">◌</td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">$<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251024__20251024__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--AwardTypeAxis__custom--SecondClosingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3sLjKbDAIRe" title="Proceeds from senior debt">12.5 million at the second closing.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt">●</td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Confirming formation of special purpose entities for collateral arrangements.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt">●</td><td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt">Updating closing conditions and related security documentation requirements.</td></tr></table> The amendment did not change the aggregate commitment of up to $<span id="xdx_906_eus-gaap--OtherCommitment_iI_pn6n6_c20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIgy7UIXN4Fg" title="Aggregate commitment on secured convertible debentures">100 million in secured convertible debentures but modified certain mechanics for funding and collateral compliance. On November 4, 2025, the Company entered into Amendment No. 3 to its Secured Convertible Debenture Purchase Agreement with Yorkville, further updating closing conditions and related documentation requirements. No material economic terms were amended. On the same date (the “First Closing Date”), the Company issued a secured convertible debenture to Yorkville in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrXcQ4NDp2rc">25,000,000 (the “First Convertible Debenture”). The First Convertible Debenture matures on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20251104__20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4Ri0Q0B7HWe">November 4, 2027, accrues interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztzxpWpF3hI3">4.00% per annum (increasing to 18.00% upon an event of default), and is payable in cash at maturity or earlier upon acceleration or conversion. Interest may be paid in cash or, at the Company’s election, in kind through the issuance of common stock upon conversion. The conversion price is the lower of (i) $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJRSdChbEez3" title="Conversion price">6.016 per share (125% of the VWAP on November 3, 2025), subject to a one-time downward-only reset based on the average VWAP over the 30 trading days following effectiveness of the resale registration statement, and (ii) 97.0% of the lowest daily VWAP during the three trading days prior to conversion, subject to a floor price of $<span id="xdx_909_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfqvJI5zuD86" title="Floor price">4.00 per share. The debenture includes customary anti-dilution adjustments. Gross proceeds from the First Convertible Debenture were approximately $<span id="xdx_908_ecustom--ProceedsFromDebentures_pid_c20251104__20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhpsrFmBq3gb" title="Proceeds">24,000,000, representing 96.0% of the principal amount. The Company allocated $<span id="xdx_90C_eus-gaap--PaymentsForPurchaseOfOtherAssets1_pn5n6_c20251104__20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUuA7ZaIO6Aa" title="Payments for purchase of assets">12.6 million of the proceeds toward the purchase of Allocated Vaulted Gold Bullion as collateral, in accordance with Amendment No. 2 to the agreement. The Company may prepay the First Convertible Debenture prior to maturity, subject to a 10% premium and a ten-trading-day notice period during which the holder retains conversion rights. The debenture includes customary covenants, default provisions, and rights of the holder, including restrictions on beneficial ownership exceeding 4.99% of outstanding common stock post-conversion. Yorkville may purchase a second $<span id="xdx_90C_ecustom--ProceedsFromSecondDebenture_pid_c20251104__20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLRwNkMzpbY8" title="Proceeds">25,000,000 debenture upon satisfaction of specified conditions and may purchase additional debentures up to $<span id="xdx_90E_ecustom--ProceedsFromAdditionalDebentures_pid_c20251104__20251104__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebenturesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8VIL5V27vf2" title="Proceeds for additional debentures">50,000,000 upon mutual agreement. In connection with the first closing on November 4, 2025, the company also entered into a U.S. guaranty agreement, a Canadian guarantee, and a registration rights agreement with Yorkville. Pursuant to the registration rights agreement, the company agreed to register for resale, under the Securities Act of 1933, as amended, the shares of common stock issuable upon conversion of the first convertible debenture. Shareholder Approval for Streamex Exchange Proposal On November 4, 2025, the Company reconvened its Special Meeting of stockholders, which had been partially adjourned solely with respect to Proposal 1 (the “Acquisition Proposal”). Stockholders approved the issuance of approximately <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--StreamexExchangeProposalMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTGhpkNLtmh3" title="Shares issued">109,070,079 shares of Common Stock, subject to adjustment, and one share of Special Voting Preferred Stock pursuant to the Share Purchase Agreement dated May 23, 2025, as amended, among the Company, its subsidiaries, Streamex Exchange, and its shareholders. As a result, the conversion cap on the Exchangeable Shares issued in connection with the acquisition was removed, enabling holders to convert into Common Stock. The related derivative liability was reclassified to permanent equity as of the approval date. Following this reclassification, the Company’s stockholders’ equity increased above the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Equity transactions In October 2025, the Company granted an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zJ2u8HT70To7" title="Number of shares issued">2,428,399 shares of its common stock in lieu of cash for services to key consultants under the Company’s 2023 Long Term Incentive Plan at a value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zdjs0ap2EuC9" title="Number of shares issued, value">13,234,823. In November 2025, the Company granted <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251101__20251130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantsOneMember_zmeaGyzLxKEh" title="Number of shares issued">425,000 shares of its common stock in lieu of cash for services to a key consultant under the Company’s 2023 Long Term Incentive Plan at a value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251001__20251031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantsOneMember_zHCdpLDoAN2b" title="Number of shares issued, value">2,014,500. On October 6, 2025, the Company granted <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuALCXM660i6" title="Number of stock units granted">2,500,000 restricted stock units to a key consultant under the Company’s 2023 Long Term Incentive Plan in lieu of cash for services. Of these units, 50% (<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znWx7FhVCKc4" title="Number of stock units vested">1,125,000) vested on the grant date, and the remaining 50% (<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251206__20251206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmKlsAnn5mJj" title="Number of stock units vested">1,125,000) are scheduled to vest two months from the grant date. The <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEeV2dRILuOf" title="Number of stock units vested">1,125,000 granted on October 6, 2025 had a value of $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJuc1zi0Ao8l" title="Number of stock units vested, value">7,098,750. On October 6, 2025, the Company granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsTwoMember_zN8ShmaOb48g" title="Number of stock units granted">200,000 restricted stock units to a key consultant under the Company’s 2023 Long Term Incentive Plan in lieu of cash for services. Of these units, 50% (<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsTwoMember_zWkg7VegRyxa" title="Number of stock units vested">100,000) vested on the grant date, and the remaining 50% (<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251206__20251206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsTwoMember_zg5kgADrUMye" title="Number of stock units vested">100,000) are scheduled to vest three months from the grant date. The <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsTwoMember_zljoxwZM5XB6" title="Number of stock units vested">100,000 granted on October 6, 2025 had a value of $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20251006__20251006__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsTwoMember_zPPJFHeuYhG1" title="Number of stock units vested, value">631,000. On October 1, 2025, the Company granted an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20251001__20251001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantsFourMember_z34CjvtCCwsf" title="Number of restricted shares issued">937,500 restricted stock units vesting over three years from the date of grant in equal quarterly installments in lieu of cash for services to key consultants under the Company’s 2023 Long Term Incentive Plan.

25100000

12600000

12500000

100000000

25000000

2027-11-04

0.0400

6.016

4.00

24000000

12600000

25000000 50000000

109070079

2428399

13234823

425000

2014500

2500000

1125000

7098750

200000

100000

631000

937500

- less than $1 Related to the acquisition of the Streamex Exchange. See Note 13 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss. Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment. On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172,622, of which $544,242 was paid as a down payment and $1,628,380 was financed. The agreement includes a finance charge of $51,172, resulting in total payments of $1,679,552, payable in nine monthly installments of $186,617 through May 2026 at an annual percentage rate of 7.48%. Less than $0.5 thousand Represents the reduction in derivative liability for Exchangeable Shares exchanged for common stock upon shareholder approval. No exchanges occurred during the period ended September 30, 2025.